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Abstract 10
Abstract
Brain–specific proteins (BSP) are each relatively specific for particular cell–
types within the nervous system. The BSP studied were glial fibrillary
acidic protein (GFAP) and S100B for the astrocyte, ferritin for microglia and
neurofilaments (Nf) for the axon. BSP are released into the extracellular
fluid (ECF) following cellular destruction and during phases of high cellular
activity such as astrocytic or microglial activation. ECF BSP equilibrate
with those in the cerebrospinal fluid (CSF). This allows us to quantify BSP
from the CSF and estimate the overall average of axonal damage (CSF Nf),
astrocytic and microglia activation (respectively CSF S100B, CSF ferritin)
and astrogliosis (CSF GFAP).
New enzyme linked immunoabsorbant assays (ELISA) have been devel-
oped for measuring Nf and GFAP in the CSF. Previously established ELISAs
have been used to measure S100B and ferritin.
It has been shown that spinal cord atrophy in a mouse model of autoim-
mune encephalomyelitis (EAE) was paralleled by a decrease of Nf indicating
loss of axons, and an increase in GFAP indicating astrogliosis. These findings
have been confirmed and extended in a human post–mortem study where
BSP levels were quantified in multiple sclerosis (MS) lesions of different age
and activity. S100B and Nf were associated with acute lesions, ferritin was
elevated in all lesion types, while GFAP was increased in both acute and
chronic lesions.
CSF BSP levels were then quantified in a cross–sectional study of MS
patients with the aim of distinguishing clinical subgroups, such as relapsing
remitting (RR), primary progressive (PP) and secondary progressive (SP)
disease. In addition an attempt was made to relate CSF BSP levels to
grades of disability using clinical scales including Kurtzke’s EDSS, an am-
bulation index (AI) and the 9–hole PEG test (9HPT). It was shown that
CSF S100B was higher in RR MS while CSF ferritin was elevated in PP
MS patients. The S100B:ferritin ratio emphasised the distinction between
the MS subtypes. CSF GFAP was higher in poorly ambulating (AI) and
severely disabled (EDSS) patients. CSF GFAP correlated with the EDSS
in SP MS patients. This suggests that gliosis is an important feature in SP
MS.
CSF Nf levels were quantified in a longitudinal study at baseline and at
3–year follow–up. It was shown that more SP/PP than RR MS patients
experienced an increase in CSF Nf levels over this time, suggesting cumu-
lative axonal damage in this subgroup. RR MS patients who had elevated
CSF Nf levels at baseline had a worse clinical course, suggesting that initial
high CSF Nf levels in RR MS patients are a poor prognostic sign. CSF Nf
levels at follow–up correlated with the EDSS, AI and 9HPT suggesting that
axonal pathology in MS is a dynamic process possibly balancing features of
de- and regenerative activities.
Acknowledgement 11
Acknowledgement
I am grateful to my supervisors Ed Thompson and Louise Cuzner who with
invaluable academic experience guided my thirst for knowledge. I am deeply
indebted to Gordon Plant who with great care nourished my clinical skills.
I feel humble towards the knowledge and personal skills of Geoff Keir.
I thank all those who have to whatever degree enriched the discussions,
challenged and exchanged hypotheses and contributed to the work.
Glossary
2
2,5-HD 2,5-hexandione: a neurotoxic substance which induces dying
back neuropathy.
9
9HPT Nine–hole PEG test: a clinical scale which measures upper limb
function.
A
ABI Acute brain injury.
AD Alzheimer’s disease.
ADEM Acute demyelinating encephalomyelitis.
AI Ambulation index.
AL Acute lesion.
Alb Albumin.
ANOVA Analysis of variance.
APC Antigen presenting cell.
APP amyloid precursor protein.
B
BIH Benign intracranial hypertension.
BSA Bovine serum albumin.
BSP Brain–specific proteins.
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C
C2 Complement factor 2.
C3 Complement factor 3.
C9 Complement factor 9.
C9neo Activated terminal complement component.
CANTAB Cambridge Neuropsychological Test Automated Battery.
CD Cluster differentiation. The abbreviation CD is used to cate-
gorise the proteins on cell surfaces. These proteins are num-
bered.
CD3 A set of cell surface antigens which are regarded as a pan T–cell
marker. They are part of the TCR complex and are necessary
for signal transduction from the cell membrane to the cytoplasm
once an antigen occupies the antigen–binding site of the TCR.
CD4 A cell surface protein present on a subset of T–cells. The CD4
protein binds to class II MHC proteins.
CD8 A cell surface protein present on a subset of T–cells which are
usually cytotoxic. CD8 interacts with class I MHC proteins.
CI Confidence interval.
CJD Creutzfeldt–Jakob disease.
CMH The Mantel–Haenzel trend analysis.
CNS Central nervous system.
CRP C–reactive protein.
CTRL Control group.
CV Coefficient of variation.
D
DEM Dementia.
DM Demyelinating disease.
DNA Deoxyribonucleic acid.
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E
ECF Extracellular fluid.
ECM Extracellular matrix.
EDSS Extended disability status scale: a clinical scale developed by
Kurtzke which measures disability.
ELISA Enzyme–linked immuno–assay.
F
FTH Ferritin heavy chain. Predominantly expressed in heart tissue.
FTL Ferritin light chain. Predominantly expressed in liver.
G
GBS Guillain–Barre´ Syndrome.
G-CSF a colony stimulating factor (CSF) which acts upon granulocytes.
Gd Gadolinium: an element of the periodic table (No. 64) which
belongs to the group of lanthanoids and has a molecular mass
of 298 K. Because of its paramagnetic properties Gd is used as
a contrast medium in MRI.
GDC granular disintegration of the cytoskeleton. A stage of Wallerian
degeneration.
GFAP Glial fibrillary acidic protein. A structural protein of the cy-
toskeleton of the astrocyte. The soluble form has a molecular
mass of about 41 kDa.
GLM General linear model. A two–way unbalanced ANOVA.
GM-CSF a colony stimulating factor (CSF) which acts upon granulocytes
and macrophages.
H
HAD The National Hospital anxiety and depression scale.
HD Headache.
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I
IFN Interferon.
Ig Immunoglobulin.
IgG Immunoglobulin G.
IL Interleukin.
index The ratio of quotients.
iNOS Inducible NO synthetase.
IQ Intelligence quotient.
K
KSP Repeats of the aminoacid sequence: Lys-Ser-Pro. KSP repeats
are particularly abundant in Nf and determine the phosphory-
lation sites of the protein.
M
M Molar.
MAG Myelin associated glycoprotein.
MAP microtubules associated protein.
MBP Myelin basic protein.
M-CSF a colony stimulating factor (CSF) which acts upon macrophages.
MDEM Multiphasic disseminated encephalomyelitis.
E
EAE Experimental autoimmune encephalomyelitis.
M
M-H χ2 see CMH.
MHC major histocompatibility complex.
Monoclonal A single band in the gamma region of the electrophoresis pat-
tern indicating the secretion of a homogeneous protein.
MRC Medical Research Council.
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MRI Magnetic resonance imaging.
MRS Magnetic resonance spectroscopy.
MSFC Multiple Sclerosis Functional Composite.
MSGM MS grey matter.
MSWM MS white matter.
N
N/A Not applicable.
NAGM Normal appearing grey matter.
NART National Adult Reading Test.
NAWM Normal appearing white matter.
N.D. Not determined.
Nf Neurofilament protein: an obligate heteropolymer of the inter-
mediate filament group. The normal human Nf consists of 3
subunits (NfL, NfM, NfH). Intermediate filaments have a diam-
eter of about 8–10 nm, which is between the large diameter of
the myosin filaments of the muscle cell and the small diameter
of actin filaments (microfilaments).
NfH Neurofilament heavy chain. The 190-210 kDa Nf subunit.
NfL Neurofilament light chain. The 68 kDa Nf subunit.
NfM Neurofilament medium chain. The 150 kDa Nf subunit.
nm nanometer: meter * 10−9.
NO Nitric oxide.
NO2 Nitrate.
NO3 Nitrite.
NSE Neuron specific enolase.
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O
OCB Oligoclonal bands.
OD Optical density.
Oligoclonal A limited number of bands in the gamma region of the elec-
trophoresis pattern indicating the secretion of a few proteins
suggestive of a yet restricted antigen response.
ON Optic neuritis.
OPD O–phenylenediamine.
P
p The significance of a statistical test is indicated by the p–value.
PAGE Polyacrylamide gel electrophoresis.
PASAT Paced auditory serial addition test.
PBS Phosphate buffered saline.
P.M. Post mortem.
PNS peripheral nervous system.
Polyclonal Many bands in the gamma region of the electrophoresis pat-
tern indicating the secretion of a heterogeneous population of
proteins.
PPMS Primary progressive multiple sclerosis.
PPWM Periplaque white matter.
Q
Quotient A calculation between different fluid compartments on the same
substance, of the form: substanceACSFsubstanceBserum .
R
R The strength of a correlation is indicated by the R–value.
Ratio A calculation within the same fluid compartment of the form:
substanceACSF
substanceBCSF
.
RRMS Relapsing remitting multiple sclerosis.
RT Room temperature.
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S
S100B The S100B protein. A member of a multigenic family of calcium-
modulated S100 proteins of the EF-hand type with intracellular
and extracellular functional roles.
SAH Subarachnoid haemorrhage.
SAL Subacute lesion.
SAS A statistical package provided by the SAS Institute Inc., Cary,
NC, USA.
SD Standard deviation.
SDS Sodium dodecyl sulfate.
SMI Sternberger Monoclonal Incorporated. A company providing
the monoclonal antibodies. Due to the extensive work of Nancy
and Ludwig Sternberger the label ’SMI’ became an acronym for
many antibodies used in immunocytochemistry. In this thesis
the name of the clone for a particular antibody has been cho-
sen to describe the antigen recognised by this SMI clone. Hence
the terminology NfH-SMI32, which describes the neurofilament
heavy chain which is recognised by Sternberger’s monoclonal
clone No. 32.
The terminology Sternberger refers to in his publications is dif-
ferent to the label of the commercially available antibodies (SMI).
SMI32 was 02–135, SMI33 was 02–40, SMI34 was 07–5, SMI35
was 03–44, SMI 37 was 06–32, SMI38 was 10–1, SMI310 was
04–7.
SO Space occupying lesion.
SPMS Secondary progressive multiple sclerosis.
T
TCR T–cell antigen receptor.
Th-1 (T cytotoxic cells): a population of T cells which can be stim-
ulated to secrete cytokines such as IL-2, IFγ or TNFβ. Th1
cells are involved in many delayed–type hypersensitivity reac-
tions. Th1 cells have an important role in the pathogenesis of
autoimmune diseases such as MS and EAE.
Th-2 (T helper cells): a population of T cells which can be stimulated
to secrete cytokines such as IL-2, IL-4, IL-5, etc. Th2 cells
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support the differentiation of B cells and thereby modulate the
specific humoral immuneresponse. Most cytokines secreted by
Th2-cells have antagonistic properties to Th1–cell cytokines.
TNF Tumor necrosis factor.
TNFα Tumor necrosis factor α.
TNFR2 The tumor necrosis factor receptor 2 (TNFR2) is expressed on
specific progenitor cells and promotes the differentiation into
mature and functional oligodendrocytes.
TWT The timed walk test.
U
UK United Kingdom.
W
WHO World Health Organisation.
w/v weight per volume.
Y
yrs Years.
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Chapter 1
Multiple sclerosis
Although multiple sclerosis (MS) has been recognised for over 160 years58,61,76,325
its aetiology remains unknown.298 There is epidemiological evidence that in-
fectious or nutritional factors can contribute.207,210,440 Additional disease
susceptibility factors have been considered on the basis of genetic studies
and twin studies,89,90,326 with the strongest link to the Human Leukocyte
Antigen system. This is all consistent with the notion that disease progres-
sion is predominantly driven by autoimmunity.
The pathological hallmarks of MS are inflammation, demyelination, glio-
sis and to a lesser extent, axonal loss.258,315 The classical MS plaque has
a clear demarcation line, is hypocellular, has axons which are relatively
well preserved and has a histological picture dominated by an astrogliotic
scar–tissue.101 The formation of such a lesion is thought to be triggered by
inflammation and is expressed clinically as a relapse. The symptoms to the
patient depend on the anatomical site of the lesion.
The diagnosis of MS remains clinical, despite ever–increasing experimen-
21
CHAPTER 1. MULTIPLE SCLEROSIS 22
tal knowledge. The clinical diagnosis is based on established international
consensus criteria which require that lesions of the central nervous system
are separated by time and space.257,311 The introduction of the McDonald
criteria increased the sensitivity of diagnosis of MS.79 The number of pa-
tients diagnosed with early MS can therefore be expected to increase in the
coming years. These patients are an important target for emerging treat-
ment strategies.
The treatment of MS is based on (1) diet and lifestyle, (2) pharmaco-
logical and/ or (3) interventional procedures.38,298 There are currently no
established measures other then magnetic resonance imaging markers which
allow for either good prognostic estimates or monitoring of disease progres-
sion on a subclinical level. Surrogate markers are therefore needed in order
to refine future strategies for the treatment of MS.
1.1 Disease heterogeneity
Multiple sclerosis is a heterogeneous disease. This includes the clinical pic-
ture,213 the pathological appearance238 and the magnetic resonance imaging
findings.50,217 This has implications for the selection of treatment strate-
gies.39
Clinical heterogeneity The dynamics of clinical symptoms in MS are
used to determine the clinical subtypes.236 The classical patterns for devel-
opment of disability are outlined in Figure 1.1. These are:
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benign MS
RR MS
RR −> SP MS
PP MS
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Figure 1.1: Disease progression in multiple sclerosis. The dynamics of dis-
ability over time are shown for benign MS, relapsing–remitting MS (RR
MS), the conversion from relapsing–remitting to secondary progressive MS
(RR→SP MS) and primary progressive MS. A relapse is indicated by a tri-
angle and disease progression by the slope of the curve (dashed for RR and
closed for SP/PP MS). Adapted from Lublin236 et al. (1996).
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1. Relapsing–remitting MS (RR MS). This pattern shows the most re-
markable changes of disability over time. The triangular peaks in
Figure 1.1 describe what is clinically observed as a relapse. The onset
of functional loss is acute and recovers within 2-4 months. As indi-
cated by the dotted line there is however increasing evidence that the
irreversible deficit increases over time.
2. Secondary progressive MS (SP MS). This pattern frequently starts
in similar fashion to that observed in RR MS. A crucial moment is
reached when RR MS converts to SP MS. From this point on the
progression of the disease is clinically irreversible. The occurrence of
relapses during this phase is possible but not necessary for the classi-
fication.70,190
3. Primary progressive MS (PP MS). This pattern has a subacute onset,
but loss of function seems to be irreversible and progressive.
4. A heterogeneous group of acute–onset demyelinating diseases are char-
acterised by their clinical picture:
• Optic neuritis (ON): localised demyelination of the optic nerve
.330,342,344
• Transverse myelitis: localised demyelination of the spinal cord.12
• Neuromyelitis optica or Devic’s syndrome 84: the strict defini-
tion includes only patients with monophasic ON and complete
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transverse myelitis, frequently found after infections.427 The case
reported by Devic was a 45 year old woman who suffered from gas-
trointestinal problems and a disturbed sleep pattern, and subse-
quently developed headaches. She was diagnosed having neuras-
thenia, but continued to develop ON with a severely swollen disc
and retinal hemorrhages. Subsequently she became paraplegic
and died within 35 days. The autopsy confirmed bilateral ON
and acute demyelination of the lumbar spinal cord.84
• Balo’s disease30: autopsy30,444 and MRI findings184 demonstrate
concentric lamellae of demyelination affecting the cerebral hemi-
spheres. Presentation acute and mortality is high. Balo reported
a 23 year old patient who suffered from acute onset right hemi-
paresis, aphasia and papilloedema. The patient died within 8
months ∗. Autopsy showed concentric lamellae of demyelination
and partially myelinated axons.30
• Acute disseminated encephalomyelitis (ADEM): a monophasic
inflammatory/ demyelinating disease, more frequently seen in
children than in adults.78,187 In cases with relapses, the term
“multiphasic disseminated encephalomyelitis” (MDEM) is used.78,310
∗This case is frequently cited as an example for the high mortality of Balo’s disease.
However, the patient of Balo died from an autopsy confirmed subdural haematoma after
exploratory neurosurgery. Neurosurgery was done because a brain tumor was suspected
as primary aetiology for the clinical presentation. This could not be confirmed, the wound
was closed and the patient died on the following day.
CHAPTER 1. MULTIPLE SCLEROSIS 26
• Marburg’s variant 247: a rapidly progressive, non–remitting dis-
ease with very high mortality, involving the cerebral hemispheres,
brainstem and optic nerve.427 The case reported by Marburg was
a 30–year old woman in a confusional state with headaches, vom-
iting and unsteady gait. She developed a left hemiparesis and
died within 26 days. The autopsy confirmed white matter de-
myelination.247
5. Benign MS. The patient remains fully functional in all neurological
systems 15 years after disease onset.236
Given the clinical heterogeneity it is worthwhile remembering that the
definition of categories (1) to (3) was not unanimously accepted by the
members of the committee responsible for this task:
“Informal discussions among clinicians and clinical researchers
and consensus developed among investigators attending a 1994
MS clinical trials design workshop13 revealed that there was no
unanimous agreement on definitions for the various clinical sub-
types of MS [236, p.907, 3rd paragraph, 1st line].”
It was suggested that this could possibly be overcome if the additional
information derived by biological markers was used in order to distinguish
subtypes of MS .236 Such markers will be discussed in section 1.3 (page 40).
Furthermore the definition of these categories was based on a survey with
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an initial population of 215 patients but with a drop out of 42%, so that
only 125 questionnaires were available for analysis.
Pathological heterogeneity The classical MS plaque, as already de-
scribed in the 19th century,58,59,76,325 is characterised by selective destruc-
tion of myelin with relative preservation of axons.215
Lesions which are actively demyelinating in contrast show many dif-
ferent structural and immunological features. The activation of glia and
macrophages,48,52,225,372,407 the presence of free radicals,25,374 cytokines154,352
and the interaction of specific antibodies with activated complement have
been studied in detail.112,116,312,382 The systematic analysis of demyeli-
nation in active lesions revealed a high degree of inter–individual hetero-
geneity.237,238 On the basis of this finding a classification of demyelination
into 2 main categories was proposed: (1) those with close similarity to au-
toimmune encephalomyelitis (EAE), i.e. inflammation and (2) those with
predominantly oligodendrocyte dystrophy. Each category features 2 typical
immunohistological patterns adding up to 4 patterns altogether237 (Table
1.1).
CHAPTER 1. MULTIPLE SCLEROSIS 28
Table 1.1: Pathological heterogeneity in MS. Patterns of demyelination according to
the dominant associated pathology. The values represent cells per mm2. AL = active
lesion, PPWM = periplaque white matter. Adapted from Lucchinetti237 et al. (2000).
Inflammation Degeneration
Feature Pattern I Pattern II Pattern III Pattern IV
Inflammation
CD3 T cells 197±68 133±18 145±23 134±71
Plasma cells 5.9±1.9 9.3±2.1 5.4±1.6 3.8±
Macrophages 1158±105 931±71 842±91 1650±30
C9neo — ++ — —
Oligodendrocytes
DNA fragmentation ± ± ++ in AL ++ in PPWM
Apoptosis — — 14–37% —
Myelin protein loss Even Even MAGÀothers Even
The first 2 patterns dominate in acute lesions (pattern 1) or RR MS (pat-
tern 2). These 2 patterns are characterised by large demyelinated plaques,
have a high number of CD3 T–cells, plasma cells and macrophages. Re-
myelination as demonstrated by shadow plaques is present and the number
of oligodendrocytes in the plaque is about 5 times higher compared to pat-
terns 3 and 4, which in turn showed no signs of remyelination. Pattern 2 can
be distinguished from pattern 1 by the high concentration of the activated
terminal complement component, C9neo.382 The presence of C9neo suggests
that antibodies are likely to play an important pathological role.112,312,382
In pattern 1 these antibodies were present to a much lesser degree suggesting
that other pathological features such as tumor necrosis factor–α (TNF-α)
154,352,355 and cytokines 154,352 contribute to the destructive process. Pat-
tern 1 and 2 resemble the structural hallmarks of MS lesions as described
by Charcot ,59 Rindfleisch325 and Dawson.81 They are consistent with a
delayed–type hypersensitivity reaction215 which is T–cell mediated. These
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2 patterns are consistent with the notion that MS is mainly a Th-1 T–cell–
driven disease.155,156
Pattern 3 dominates in patients with monophasic disease or who died
from acute disease within 1 year.237 This pattern showed an ill–defined lesion
edge, a high rate of DNA fragmentation and apoptosis of oligodendrocytes.
There is a marked decrease of myelin–associated glycoprotein compared to
the three other patterns.
Pattern 4 had the highest content of macrophages and lowest content
of plasma cells. Pattern 4 was only observed in lesions from 3 MS patients
having a primary progressive course. In these patients cerebellar, brainstem
and cognitive symptoms dominated.237
Taking these findings together it appears that pathological heterogene-
ity is a feature particularly of early MS. Different pathological mechanisms
are likely to account for demyelination in subgroups of MS patients. How
the histopathological differences relate to the phenotype, the genotype or
differences in the disease–inducing trigger remains to be clarified.215,216
Although axonal pathology is not the most striking feature in MS brain
tissue it is possibly the one with the highest impact for the patient.43,256,398,400,424,438
Historically axonal loss in MS has been been associated with the “burnt–
out” phase of the disease .130,313 Using immunohistology Ferguson et al.
(1997) were able to demonstrate axonal pathology in active MS lesions .106
Extensive staining for amyloid precursor protein (APP) was observed and
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the APP positive structures resembled terminal ends of transected axons. A
three dimensional reconstruction of these axonal ovoids using confocal mi-
croscopy confirmed the presence of transected axons in acute MS lesions.398
An accumulation of neurofilament protein was observed in these end–bulbs.
An additional relationship between the frequency of axonal transections and
active inflammation was described.398
The concept of axonal loss in MS is not new,20,58,59,76,80,106,252,255,261,286,325,398
but the important new insight is that a high number of transected axons
is already present in acute lesions106,398 and in patients with a short clin-
ical course.398 This finding might have important prognostic implications
for individual MS patients. Secondly the concept of axonal loss provides
a testable hypothesis which could explain the conversion of RR MS to SP
MS255,261 (Figure 1.1). However axonal injury is a dynamic process and
quantification of axonal loss in histological material is complicated by tissue
oedema, the presence of inflammatory cells and the problem of establishing
a relationship with the number of healthy axons.399
Morphology and dynamics of axonal injury The first systematic de-
scription of axonal injury in humans was done 1850 by Waller,415 hence the
eponym “Wallerian degeneration”.
Wallerian degeneration is a complex process which describes the degen-
eration of the distal axonal stump after axonal transection from the neuron.
CHAPTER 1. MULTIPLE SCLEROSIS 31
Wallerian degeneration begins with the enzymatic proteolysis of the axonal
cytoskeleton ,117 but proceeds outside the axon causing changes in the en-
sheathing glial cells, alterations in the adjacent blood–tissue barriers and
responses of cells of macrophage lineage. In mammalian nerves Wallerian
degeneration becomes macroscopically visible 24-36 hours post injury .66,235
The dynamics of Wallerian degeneration are, however, broad and rapid Wal-
lerian degeneration has been distinguished from slow Wallerian degeneration
which can last for up to 3 weeks.66 It was hypothesised that one function of
Wallerian degeneration is to prepare a pathway for potential axonal regen-
eration. The cellular events of Wallerian degeneration following axonotomy
are considered to be sequential and a classification into 5 stages has been
proposed131 (Figure 1.2 A - E):
(A) Survival of the disconnected distal stump: the distal segment ad-
jacent to transection progressively accumulates neurofilaments (Nf)
and intra–axonal organelles,423,445 histologically observed as “axonal
bulbs”.398 This phenomenon originates from the continuity of retro-
grade axonal transport .317
(B) Granular disintegration of the axoplasm and axonal breakdown: Gran-
ular disintegration of the cytoskeleton (GDC) is defined as the abrupt
conversion of the axoplasm into fine particulate and amorphous debris.
This is considered to be an extremely rapid process of disintegration
of the axonal cytoskeleton along the entire length of the axon.118,239
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GDC correlates with the cleavage of Nf into lower molecular weight
products347,348 recognised by anti–Nf antibodies.401
(C) Early responses of non-neuronal cells involve the blood–tissue bar-
rier and glial cells. Local breakdown of the blood–tissue barrier oc-
curs 24 to 48 hours after axonal injury and leads to early endoneurial
oedema.47 The glial cell reaction is divided into (1) astrocytic activa-
tion , (2) microglial and macrophage activation and (3) oligodendro-
cyte response .24,199 The relative timing of these cellular events differs
considerably between the central nervous system (CNS) and periph-
eral nervous system (PNS) .24,131 In general terms the CNS response
is much slower and most macrophages are recruited by differentiation
of microglia, rather recruitment from the circulation.117,380,381
(D) Mature glial and macrophage lineage cell responses: These represent
a continuum from the previous stage and describe the clearance of
cellular debris. Again the time scale of events in the CNS is prolonged
when compared to the PNS.380,381
(E) Late changes: oligodendrocytes progressively disappear,426 endoneurial
fibroblasts remain prominent, endoneurial collagen content increases
and the former nerve tissue is replaced by a fibrillary glial scar 61,118
Wallerian degeneration has to be distinguished from dying back neu-
ropathy, defined as the slow proximal spread of nerve fibre breakdown and
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Figure 1.2: Wallerian degeneration. (A) Transection and transient survival
of the distal stump, (B) granular disintegration, (C) early responses of non–
neuronal cells, (D) mature glial and macrophage lineage response, (E) late
changes, (F) legend.
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ultimate apoptosis of the neuron .371 The term dying back was introduced
to describe the spatio–temporal pattern of central and peripheral nerve fi-
bre pathology in degenerative diseases. Particular experiments with 2,5-
hexanedione (2,5-HD) and acrylamid showed that the initial changes in the
ultrastructure of the axon consisted of Nf accumulation which was accom-
panied by clearly visible focal fibre swelling.309,346 Focal Nf accumulation
started proximal to the Ranvier nodes with subsequent impairment of axonal
transport.412
1.2 Disability
The terms impairment (i.e. “loss or abnormality. . . of structure of function),
disability (i.e. “a restriction or lack. . . of ability to perform an activity in
the manner of within the range considered normal for a human being”) and
handicap (i.e. “the disadvantage for an individual. . . that prevents or limits
the performance of a role that is normal. . . for that individual”) are used ac-
cording to the recommendations of the system adopted by the World Health
Organisation (WHO).300 Handicap represents the effects of impairments or
disabilities in a wide social context and may be heavily influenced by culture.
It will therefore not be used for any type of classification in this thesis.
Clinical scales Impairment or loss of function300 is quantified by clinical
scales. The paradox between clinical examination and each clinical scale is
that normal functioning is tested, but loss of function is quantified. Because
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of the potential of CNS regeneration and plasticity the clinical appearance
of disability is a dynamic process. This has been illustrated in Figure 1.1
and forms the basis on which MS patients are classified.
A range of validated clinical scales is now in use. For MS the most widely
applied scale is the extended disability status scale (EDSS) for multiple
sclerosis developed by Kurtzke in 1983.206 The EDSS combines a disability
status scale203 with functional systems.204,205,208,209 A simple assessment of
lower limb function is provided by the ambulation index (AI) or the timed
walk test.177 Motor function of the upper limbs is quantified by the 9 hole
peg test (9HPT) .177
Psychometry is tested by the paced auditory serial addition test (PASAT)
.133 The National Adult Reading Test (NART) is used to give an esti-
mate of the premorbid IQ .287 Current intellectual function is assessed by
the Advance Progressive Matrices, Set 1 (Ravens). Memory is assessed by
recognition of words and faces.419 The paired associated learning test es-
timates learning abilities. Attention is quantified by the speed of letter
counting.437 Tests of executive function include the Wisconsin Card sort-
ing test (Nelson) and the Cambridge Neuropsychological Test Automated
Battery (CANTAB) .287,343 Fatigue is commonly estimated by Krupp’s Fa-
tigue Rating Scale .200 Anxiety and depression have been measured using
the National Hospital anxiety and depression scale (HAD) .449 There is an
emerging range of scales measuring quality of life and measures for outcome
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of neuro–rehabilitation.393
Recently the timed walk test (TWT), 9 hole peg test (9HPT) and Paced
Auditory Serial Addition Test (PASAT) have been combined mathematically
to give the Multiple Sclerosis Functional Composite (MSFC) .77,158 The
MSFC has the potential to provide a more reliable measure of changes of
function in MS than the EDSS, which is non–linear and biased towards
locomotion.31
It has been argued that the rate of progression of sustained disability is
relapse–independent.68–70 This hypothesis is based on the epidemiological
evidence that the rate of progression remains “linear” during pregnancy de-
spite a significant reduction in the relapse rate68 (Figure 1.3 A). Additional
evidence comes from an epidemiological study on a cohort of 1844 MS pa-
tients. The progression of sustained disability from an EDSS of 4 to a score
of 6 or 7 was unaffected by the number of relapses prior to the progressive
phase70 (Figure 1.3 B).
Is MS a two–phase disease? The epidemiological findings raise the
question whether the pathological process which drives disease progression
in MS falls into one of two phases375: (1) “inflammatory” and (2) “degen-
erative” 69,367,400 (Figure 1.4 A). On the basis of clinical and pathological
disease heterogeneity, particularly in the early or acute phase of the disease
one could speculate that heterogeneity decreases while disability accumu-
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Figure 1.3: Progression of sustained disability in MS is relapse–independent.
(A) During pregnancy the relapse rate decreases significantly, but this does
not halt progression of irreversible deficit. (B) The rate of progression of
EDSS from 4 to 6 and from 6 to 7 is not affected by the presence or absence
of relapses during the relapsing–remitting phase. This also holds true for
the presence or absence of relapses superimposed on the progressive phase
of either PP or SP MS. Modified from Confavreux68,70 et al. (1998, 2000).
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Figure 1.4: MS as a two–phase disease. (A) the earlier “inflammatory” phase
progresses into a “degenerative” phase with accumulation of impairment. A
critical threshold (circle) describes the conversion from RR to SP MS. (B)
Disease heterogeneity is high during the early “inflammatory” phase of the
disease and decreases with emerging degeneration.
lates (Figure 1.4 B).
The clinical heterogeneity in the early phase of MS is likely to be trig-
gered by a range of factors, further complicating the formulation of a single
unifying hypothesis of the aetiology of MS. Simplification is also hampered
by the notion that inflammation, particularly the innate arm of the im-
mune response, has beneficial/ neuroprotective roles .291,324 Macrophages
are required for effective remyelination,196 astrocytes and immune cells po-
tentially provide neurotrophic factors186,291 and autoimmune T–cells protect
neurons from secondary degeneration after experimental trauma .277 TNF–
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α contributes to the apoptosis of immune cells244 and binds to TNFR2
on the surface of specific progenitor cells to promote their differentiation
into mature and functional oligodendrocytes .291 The wide range of inter–
individual heterogeneity during the “inflammatory” phase of the disease is
thus not surprising. It is therefore interesting that the heterogeneous group
of MS subtypes (item 4 on page 24) have all been linked to inflammation
and acute onset.12,30,78,84,187,247,330,342,344,427,444
The “degenerative” phase of the disease seems to be characterised by
an inexorable loss of function (Figure 1.4). The pathological mechanisms
accounting for this are few: conduction block, demyelination and axonal
loss.105,182,259,320,365,366,398 Among these only axonal loss is irreversible.
Plasticity of the CNS might transiently overcome the reduced operational
abilities of many functional systems. However some systems such as the optic
nerve, tract and radiation have no capacity for plasticity whatsoever.178–181
In these cases only partial recovery is possible by adaptive changes of higher
cortical centres following the reduced input.167
Once a critical threshold is reached, the inexorable loss of axons and
neurons integrated into the functional CNS network will surpass the poten-
tial for plasticity. This phase is possibly reflected by the epidemiological
finding that once an EDSS of about 4 is reached, the disease continues to
progress inexorably.70
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1.3 Surrogate markers
A surrogate is a substitute or deputy. With regard to MS a surrogate marker
is a substitute for the clinical observation. As yet there are no biological
markers available which allow for either a clear–cut distinction between the
various subgroups of MS or a correlation with disability.236,399,431
Biomarkers can be attributed to 3 categories with regard to specificity
and sensitivity.
• Metabolic biomarkers
• Inflammatory/immunological biomarkers
• Cell–type specific biomarkers
Metabolic biomarkers The main advantage of using metabolic biomark-
ers is based on the analytical experience. Very small samples can be anal-
ysed and results can be obtained within minutes to hours. Because the basic
metabolic pathways are shared by all cell types, the specificity is low. The
main problem is that the analysis of serum or urine does not permit the dif-
ferentiation between the CNS and the systemic compartments. Metabolic
biomarkers are therefore unlikely to gain widespread acceptance as surrogate
markers in MS.
Inflammatory biomarker Monitoring the CNS inflammatory response
is of particular interest because pathology in MS is triggered by inflam-
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mation and is largely autoimmune driven. However, the balance between
detrimental and beneficial factors remains to be elucidated.291,324
Some inflammatory biomarkers have gained particular interest for MS:
• Acute phase proteins. In inflammation a marked increase is observed
for C–reactive protein (CRP) and a mannose–binding protein which
fixes complement and opsonises, the transport protein α1–acid glyco-
protein and serum amyloid P component. Only moderately increased
levels are observed for α1–proteinase inhibitors, α1–antichymotrypsin,
C3, C9 , factor B, ceruloplasmin, fibrinogen, angiotensin, haptoglobin
and fibronectin.331 Of these, C–reactive protein has been associated
with Gd–enhanced MRI activity in MS .88,122
• Cytokines describe a class of low molecular weight (15–25 kDa) protein
mediators which include molecules known as lymphokines, monokines,
interleukines and interferons (IFN).
– Interleukins (IL–1 to IL–18). In MS raised levels of the IL-1,32
IL-2,64 IL-10,64,176,384 IL-17229 and IL-18233 were observed com-
pared to controls. IL-4 increased after intravenous prednisolone
treatment in MS,176 as did IL-12 after interferon beta treat-
ment.26,232 IL-6 levels were reported to be either increased64,229,271
or decreased.32 No difference between controls and MS patients
was observed for IL-8.67 Out of these IL-1, IL-2, IL-4 and IL-6
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have been associated with acute relapses.
– Colony stimulating factors: GM–CSF, G–CSF, M–CSF and steel
factor.331 No differences between MS and neurological control
patients were found for GM–CSF in the stable phase of the dis-
ease,57,221 whilst GM–CSF levels were elevated in the active phase.57
A treatment trial with G–CSF in MS patients increased disease
activity and resulted in one fatality.299
– Tumor necrosis factors: TNFα was found to be increased in MS
patients and to correlate with progression of disability 249,355,356
and disease activity as assessed by MRI .53 This finding was not
confirmed by another group who also measured TNFβ.197 TNFα
was also found to rise prior to clinical relapse .35,323
– The interferons, α, β and γ all exhibit anti–viral properties. Al-
though the long–term effects remain unknown, IFNβ has been
accepted as a treatment strategy in MS .298
– Chemokines exhibit strong chemotactic properties. The α–chemo-
kine CXCL10 was increased in MS patients when compared to
neurological controls.245 CXCL10 levels could be associated with
acute relapse.245 The βchemokine MCP-1 was decreased245,345,362
or increased162,265,408 in MS patients when compared to neuro-
logical controls. Comparing active and stable MS patients lower
MCP-1 levels were found in the active group,109 but the speci-
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ficity remains a matter of discussion.192 RANTES was increased
in MS patients.362
• Free radicals: the nitric oxide metabolites NO2 and NO3 have been
found to be elevated in MS patients when compared to controls.121
In summary there is evidence that inflammatory markers have an impor-
tant role as surrogate markers for the “inflammatory” arm of the disease.
They may have additional value for monitoring anti-inflammatory effects
of new immunomodulatory treatment strategies. However they have proved
less reliable for measuring disease progression and disability.
Cell–type specific biomarker Each cell is characterised by its morphol-
ogy and function, both of which are programmed genetically and mate-
rialised by the interaction of proteins, sugars and lipids. The process of
post–translational modification leads to complex protein structures, which
can be cell–type specific. The lipid membrane of the cell is not an absolute
barrier and soluble proteins diffuse into the extracellular space .104 Soluble
glial and neuro–axonal proteins are regularly found in the cerebral extracel-
lular space. The extracellular fluid (ECF) concentration is relatively high,
because there is no lymphatic drainage from the brain and all proteins equi-
librate with the cerebrospinal fluid (CSF) or diffuse into the blood. These
“brain–specific proteins” (BSP) 395 can be measured in the CSF and other
body fluids.
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The quantification of cell–type specific markers allows us to draw rel-
atively specific conclusions on the type of cell involved in a pathological
process. Whether this involvement means cellular destruction and release of
cell–type specific proteins into the ECF following disintegration of the cel-
lular lipid membrane, or an increase which parallels upregulation of cellular
metabolism is difficult if not impossible to distinguish by the measurement
of a single marker.
The two main cellular populations of the brain are either of glial or
neuronal origin. Specific glial markers are summarised in Table 1.2.
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Table 1.2: Glial biomarkers in the cerebrospinal fluid. All values are given as
mean±SD unless indicated otherwise. GFAP = glial fibrillary acidic protein.
Surrogate CTRL MS Heterogeneity Disability
S100B278 0.33±0.09 ng/mL (n=18) Acute 1.1 (n=1)
stationary 0.36, 0.52 (n=2)
(+) N/A
S100B129 0.2±0.08 ng/mL (n=13) 0.18±0.09 ng/mL (n>20) N/A N/A
S100B363 N/A Not detectable in MS (n=5) N/A N/A
S100B212 Extrapyramidal disorder:
82 (median) µg/L (n=26)
MS all: 92 µg/L (n=87)
progressive: 93 µg/L (n=41)
relapsing: 93 µg/L (n=29)
— N/A
S100B172 0.7–2.0 µg/L RR (n=18) 1.5 µg/L
SP (n=16) 1.2 µg/L
— ∗ N/A
S100B270 < 6 ng/mL
detection limit
acute phase:
> 6 ng/mL in 14/17
stationary:
> 6 ng/mL in 4/9
(+) † N/A
S100B251 < 5 ng/mL
detection limit
Time from relapse: numbers
with “high” values
1–7 days: 6/7
8–14 days: 5/5
15–21 days: 7/7
2–28 days: 4/6
29–35 days: 1/4
+ ‡ N/A
GFAP 5 4.3±0.7 ng/ml Acute (n=25): <10 ng/mL
progressive (n=7): <10 ng/mL
— N/A
GFAP 336 142±26 pg/ml 386±169 pg/ml N/A +
The glial marker S100B was detectable in the CSF of patients with MS
∗No single marker can be used to distinguish RR from SP MS. The authors use a
“composite score” combining the measurements of CSF
serum
albumin ratio, mononuclear cell
count, CD4+, CD8+, B1+ subsets, CD4+:CD8+ ratio, IgG, IgG index, IgM, IgM index,
complement components C3 and C4, C3 and C4 indices, myelin basic protein, neuron
specific enolase, S100 and lactate in order to distinguish between RR and SP MS patients.
†The following post–hoc categorical analysis can be done on the presented data, using
the 100% cumulative frequency of the stationary MS patients (≈8 ng/mL) as cut–off for
defining “high” S100B levels, 0% (0/9) of the stationary and 65% (11/17) of the acute
phase MS patients have “high” S100B levels (p=0.002, Fisher’s exact test). Using the
assay sensitivity (6.0 ng/mL) as cut–off does not separate the 2 groups (numbers as given
in the table, p=0.06).
‡The same assay as for270 is used. In Figure 1 in251 a cut–off of 8 ng/mL (100%
cumulative frequency of MS patients 29–35 days after relapse) seems more reasonable
than using the assay sensitivity. The 100% cumulative frequency for CSF S100B of the
stationary MS patients was 8 ng/mL in 1980,270 which equals the top value found 29–35
days after relapse in the present study. Taking 8 ng/mL as cut–off, the numbers of patients
with high CSF S100B values are on day 1–7: 6/7 (86%), day 8–14: 4/5 (80%), day 15–21:
5/7 (71%), day 22–28: 1/6 (17%) and day 29–35: 0/4 (0%). Using these numbers the
hypothesis that there is a trend for decreasing CSF S100B levels with time from relapse
can be tested. This is highly significant for a cut–off of 8 ng/mL (M-Hχ2=10.8, p<0.001),
and also significant for a cut–off of 6 ng/mL (M-Hχ2=5.37, p=0.02). For description of
trend-analysis using the Mantel-Haenzel χ2 test, see paragraph 7.2 on page 155
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in some129,172,212,251,270,278 but not all363 studies. There is evidence that
CSF S100B is higher in patients with MS when compared to control pa-
tients.251,270,278 None of the studies performed a statistical analysis to de-
termine whether CSF S100B could be used to separate RR from SP or PP
MS patients. The data given in two studies from the same group251,270 were
sufficient detailed to perform a post–hoc analyses (see footnotes to Table
1.2). These post–hoc analysis showed (1) that CSF S100B is significantly
elevated in acute disease (p=0.002) and (2) that there is a significant linear
trend for decreasing CSF S100B levels following a relapse (p<0.001). None
of the studies investigated the relation of CSF S100B to disability.
The glial marker GFAP was detectable in the CSF of MS patients in two
studies.5,336 There was evidence that CSF GFAP might relate to disability
in one study,336 but not to disease heterogeneity.5
The neuronal marker, NSE was detectable in the CSF of MS patients
in three studies, but no conclusions could be drawn regarding either disease
heterogeneity or disability (Table 1.3).172,212,278
The axonal marker, neurofilament (Nf) was detectable in two studies
and Nf was related to disability in both (Table 1.3).242,353 The data in the
study by Semra et al. (2002) was presented in sufficient detail for a post–hoc
analysis regarding disease heterogeneity which was not significant for either
RR, SP or PP MS patients.353 The data presented by Lycke et al. (1998)
does not allow for post–hoc analysis, but the mean CSF Nf levels in the first
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two months after relapse are 4–5 times greater compared to levels measured
after four months.
Table 1.3: Neuro–axonal biomarkers in the cerebrospinal fluid. All values are given
as mean±SD if not indicated otherwise. NSE = neuron specific enolase, Nf = neuro-
filament.
Surrogate CTRL MS Heterogeneity Disability
NSE278 4.5±1.2 ng/mL (n=18) acute phase: 3.3 ng/ml (n=1)
stable phase: 3.8, 4.5 (n=2)
N/A N/A
NSE172 2.0–10.0 µg/L RR (n=17) 6.2 µg/L
SP (n=16) 4.9 µg/L
— N/A
NSE212 Extrapyramidal disorder:
94 µg/L (n=26)
median value
MS all: 90 µg/L (n=91)
progressive: 88 µg/L (n=41)
relapsing: 94 µg/L (n=29)
— N/A
Nf242 <125 ng/mL days after relapse:
day 0–49: 1000±250 (n=16) ∗
days 50–99: 780±150 (n=24)
days 100-149: 350±50 (n=16)
days 150–199: 400±70 (n=15)
days 200–299: 200±30 (n=12)
days 300-499: 220±50 (n=13)
> 500 days: 200±30 (n=14)
+ +
Nf 353 ≈100 (60–125)
above cut–off: 0/8 †
RR: ≈170 (70–280)
above cut–off: 10/16
SP/PP: ≈200 (65–380)
above cut–off: 14/19
— +
Myelin basic protein is possibly the best characterised human autoanti-
gen.266 There is clear evidence from a range of studies that CSF MBP,
particular the carboxy end of peptide 45-89, is related to acute disease and
disability (Table 1.4).137,394 It was however not possible to distinguish SP
from RR MS using either CSF MBP212 or urinary MBP–like material.432
∗The SEM is given. Values read from [242, Figure 1].
†Values read from [353, Figure 4]. The cut–off was determined as the mean+2SD of
the control group.
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Table 1.4: Myelin basic protein as a marker for axonal damage. All values are given
as mean±SD if not indicated otherwise. MBP = myelin specific protein, MBP45 89
= MBP peptide as detected by a monoclonal antibody against the 45 89 carboxy
fragment, MBP69 89 = MBP peptide as detected by a monoclonal antibody against
the 69 89 carboxy fragment
Surrogate CTRL MS Heterogeneity Disability
MBP 430 MBP45 89
cut–off: 0.50 ng/mL
above cut–off: 0/6
MBP69 89
cut–off: 0.04 ng/mL
above cut–off: 0/6
acute MS: # above cut–off ∗
MBP 45 89 : 6/0
MBP69 89 : 6/0 chronic
progressive MS:
MBP45 89 : 14/15
MBP 69 89 : 10/15 stable MS:
MBP45 89 : 6/0
MBP 69 89 : 1/6
+ † N/A
MBP394 above cut–off: 11/85
cut–off = assay sensi-
tivity (2 ng/mL)
Time from relapse:
0-2 weeks: 23/26
2-4 weeks: 16/21
4-6 weeks: 7/8
remission: 15/44
+ ‡ + §
MBP137 above cut–off: 13/67 ¶ Time from relapse:
<4 weeks: 8/11
>4 weeks: 8/16
Time or EDSS:
<4wk or EDSS>5: 11/14
>4wk or EDSS<5: 5/13
+ +
MBP172 0.2–1.2 µg/L RR (n=11) 0.6 µg/L
SP (n=16) 0.5 µg/L
— N/A
MBP212 Extrapyramidal
disorder: 94 µg/L
(n=25) ‖
MS all: 215 µg/L (n=91)
progressive: 159 µg/L
(n=41)
relapsing: 263 µg/L (n=29)
+ ∗∗ N/A
∗The cut–off value was determined as the 100% cumulative frequency of the
control group. Significantly more numbers of acute MS patients have high CSF
MBP levels if compared to controls for both MBP peptides in the post–hoc analysis
(p=0.001). Significantly more numbers of chronic progressive MS patients have high
CSF MBP levels if compared to controls for both MBP peptides in the post–hoc
analysis (MBP45 89 p<0.001; MBP69 89 , p<0.01). Significantly more numbers of
stable MS patients have high CSF MBP levels if compared to controls only for
MBP45 89 in the post–hoc analysis (MBP45 89 p=0.001; MBP69 89 , N.S.)
†In the post-hoc analysis MBP69 89 distinguishes significantly between acute and
stable MS (p<0.01).
‡In the post–hoc analysis significantly more MS patients with acute relapse have
levels above cut–off when compared to MS patients in remission (p<0.001). Taking
the numbers of patients with high CSF MBP values at the 4 time–points one can
confirm the hypothesis that there is a trend for decreasing CSF MBP levels with
time from relapse. This is highly significant for a cut–off of 8 ng/mL (M-Hχ2=22.13,
p<0.001)
§There was a correlation between CSF MBP levels and Millars relapse score.272
¶The cut–off for MBP45 89 assay was set to 68 pmol/mL.
‖median value. A critical point regarding this paper is that the authors mention
the control group, but do not show the raw data.
∗∗The following post–hoc analysis is possible on basis of the presented data: 27%
(11/41) of the chronic progressive and 53% (17/32) of the relapsing remitting MS
patients had MBP values above the 95%ile of the control group. This is significant
using two-sided Fisher’s exact test, p=0.02.
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A range of commercial assays are available for the measurement of MBP,
NSE and S100B. NSE did not prove to be relevant in any of the previous
studies. No commercial assays are currently available for GFAP and Nf.
GFAP and Nf are promising candidates as surrogate markers for disability.
S100B and Nf are also likely candidates to help distinguish between MS
subtypes.
An attempt to describe these brain–specific proteins into greater detail
and to relate them to a broader clinical context will be made in the next
chapter.
Chapter 2
Brain–specific proteins
Proteins are called brain–specific if they are predominantly expressed in CNS
cells. Measuring brain–specific proteins (BSP) allows us to draw certain
conclusions regarding their role in normal function and pathophysiology in
specific cell types. A list of BSP currently used for diagnostic purposes was
summarised in Tables 1.2 to 1.4.
This study focuses primarily on two astrocytic proteins (GFAP, S100B)
and a family of neuro–axonal proteins (neurofilaments). The microglial–
derived protein ferritin was of some interest during the clinical studies since
it reflected the other cell which played an additional role in the inflammatory
response.
2.1 Neurofilament proteins
2.1.1 Background
The dominant proteins of the axonal cytoskeleton are neurofilaments (Nf).
Nf are obligate heteropolymers composed of 3 subunits and belong to the
class IV–intermediate filaments (IF).110
50
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The Nf light chain (NfL) is coded on chromosome 8p21 and consists
of 543 amino acids. The molecular mass corresponds to 61 kDa, but due
to phosphorylation and glycosylation, migration in sodium dodecyl sulfate
(SDS) polyacrylamide gels (PAGE) is slow, and most authors refer to a
molecular mass of 68 kDa as determined in SDS–PAGE. The Nf medium
chain (NfM) is also coded on chromosome 8p21 and consists of 916 amino
acids. The molecular mass is calculated as 102.5 kDa, and runs at 150 kDa
in SDS gels. The Nf heavy chain (NfH) is coded on chromosome 22q12.2219
and consists of 1020 amino acids. The molecular mass of the amino acids
corresponds to 111 kDa. Most authors however refer to the molecular mass
derived by SDS gels which is also influenced by the charge/weight of bound
phosphate and therefore ranges from 190 to 210 kDa for the various phos-
phoforms (Figure 2.1 A). Each Nf subunit is composed of a highly conserved
α–helical region of approximately 310 amino acids. The core region forms
double–stranded coiled coils flanked by the head (N–terminus) and the hy-
pervariable tail (C–terminus) domains.114
The formation of the typical IF of 10 nm diameter is determined by the
correct assembly of the NfL, NfM and NfH subunits. The assembly of the
three Nf subunits is dependent on the N–terminal head region.120,150,283,359
NfL is known to polymerise on its own, while NfM and NfH cannot. How-
ever, both NfM and NfH can co–assemble with NfL in vitro.115
Cross–linking and interaction of the assembled heteropolymers with other
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cytoskeletal proteins depends upon the C–terminal NfH tail domain (Fig-
ure 2.1 B). This may also play a role in the control of axonal transport.295
Phosphorylation of the C–terminal tail domain is thought to occur at the
side arms protruding from the assembled filaments. The C–terminal tail
domain consists of over 40 KSP (Lys-Ser-Pro) repeats in humans as de-
termined by mass–spectroscopy.36,273,385 Phosphate is coupled with high
affinity to the aminoacid serine within the KSP repeats.36,385 Neurofila-
ments belong to the most extensively phosphorylated proteins of the hu-
man brain. Phosphorylation and dephosphorylation of the neurofilament
proteins is a complex process which is predominately regulated within the
axonal compartment.85,293 Optimal performance of the neuronal network
depends upon the normal functioning of these processes. The N–terminal
domain is phosphorylated by glycogen synthetase kinase-3,135,136 extracellu-
lar signal-regulated kinases328,329 and cyclin-dependent kinase-5.224,293,358
Phosphorylation of the C–terminal domain is regulated by a range of protein
kinases.359–361
About 80% of axonal Nf are highly phosphorylated and integrated by
cross–linking in the axoskeleton, thus constituting the “static pool”.214 Be-
cause phosphorylation alters the charge on the side–arms, it seems likely that
one function of phosphorylation is to increase the charge–based repulsion of
neighbouring filaments, thereby increasing interfilament spacing and conse-
quently increasing axonal calibre.131 However radial axonal growth does not
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(A) Neurofilament Isoforms
(B) Assembled neurofilament triplet protein
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Figure 2.1: (A) The neurofilament protein subunits. The aminoterminal
tail domain is of variable length whilst the central rod and carboxyterminal
head domain remain constant. The calculated molecular weights and the
molecular weights as determined by SDS gel electrophoresis (in brackets)
are shown.
(B) Functional properties of the neurofilament protein such as cross-linking
and protein–protein interactions are controlled locally in the axon by phos-
phorylation and dephosphorylation of the tail domain.
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depend only on mechanisms of NfH phosphorylation318 but also on Nf stoi-
chochemistry as demonstrated by knockout experiments.74,93,168,173,293,436,447
The close relation of axonal diameter and conduction velocity 153,425 is of
physiological relevance. Additionally phosphorylation of NfH changes func-
tional intracellular properties such as mobility and protein-protein interac-
tions.19,175,403,404,435 The remaining 20% of less extensively phosphorylated
Nf constitute the so called “dynamic pool” 214,294and are involved in ante-
and retrograde axonal transport .340 Because of the high amount of hy-
drophobic sides this is likely to be raft–mediated on specific kinin/dynine
motors.124 Axonal transport of Nf is a complex and vulnerable process
involving phases of rapid polymer movements interrupted by prolonged
pauses.1,442,443
Neurofilaments are prone to protease digestion .349,418 Under physio-
logical conditions this is mediated by calmodulin, a Ca2+–dependent pro-
tease.253 Susceptibility of Nf to protease digestion decreases with increase of
phosphorylation.124,378 This has implications for NfH stability in protease–
rich body fluids such as the CSF.
Neurofilament phosphoforms There is no consistent terminology for
naming the different neurofilament phosphoforms. Reference is made com-
monly to non–phosphorylated or hypophosphorylated versus hyperphospho-
rylated or extensively phosphorylated, with phosphorylated being the as-
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sumed normal phosphoform. The use of mass–spectroscopy permits us to
identify the phosphorylation sides within the protein,36,385 but given that
there are over 40 phosphorylation sites, such an approach will be unsuit-
able for clinical laboratory practise. The more practical approach cho-
sen has been to name the NfH phosphoform according to the monoclonal
antibody used either in immunohistology or enzyme–linked immuno–assay
(ELISA). Several monoclonal antibodies have been shown to bind to non–
phosphorylated epitopes of the NfH subunit. If NfH was detected by the
Sternberger monoclonal antibody SMI32 this NfH phosphoform is labelled
NfHSMI32 . Likewise when phosphorylated NfH, was detected by the binding
to a phosphorylated epitope recognised by the Sternberger monoclonal an-
tibody SMI35, this is labelled NfHSMI35 . Extensively phosphorylated NfH
as recognised by the Sternberger monoclonal antibody SMI34, is labelled
NfHSMI34 , and so forth. The advantage of using Sternberger monoclonal
antibodies is that these antibodies have been studied extensively by im-
munohistology376 and are used by most neuropathological laboratories. If
antibodies from other sources are used the name of the clone and the source
are given. This terminology facilitates comparisons with results from other
studies.
2.1.2 Clinical relevance
General Axonal injury causes disintegration of the axonal membrane and
axoskeletal proteins such as Nf are released into the extracellular space
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(ECF). The ECF is continuous with the CSF. A 5–fold increase of the CSF
NfL has been reported after relapse in MS .241 This finding was confirmed by
a different study.353 The CSF NfL levels returned to baseline values within
approximately 3 months241 suggesting the role of NfL as a putative marker
for acute axonal injury. Histological observations provided evidence for the
increase of a different Nf subunit, NfH .398 In injured axons an increase of
the (NfHSMI32 ) NfH phosphoform was observed. Staining for NfHSMI32 has
therefore been used as a immunohistological marker for damaged axons.398
In contrast to MS, an increase of phosphorylated NfH was observed in stroke
proximal/ rostral to the lesion.145 Different NfH phosphoforms could thus
be of clinical relevance in describing axonal injury.
Functional implications of Nf alterations for axonal pathology Nf
subunits are not only constituents of the axoskeleton, but are also actively
involved in the pathogenesis of axonal dysfunctioning and degeneration. The
accumulation of Nf proteins has been observed in amyotrophic lateral sclero-
sis (ALS) ,339 spinal muscular atrophy441 and in giant axonal neuropathy.21
A frameshift, nonsense and missense mutation of Gigaxonin on chromosome
16q24.1 is now recognised to cause disorganisation of the cytoskeletal IFs.46
Mutation close to the NfL rod–domain causes an increase of neuronal
NF-L due to impaired Nf assembly.218 It has been suggested that axonal
transport is “strangulated” .174 In humans a mutation within the NfL rod
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domain has now been associated with the development of the axonal variant
of Charcot–Marie–Tooth disease type 2E .82,240,267 Whether the problem is
primarily due to increased axonal vulnerability, caused by impaired axonal
transport218 or to cytoskeletal instability needs to be clarified.
The role Nf subunits play in axonal pathology has been studied in knock-
out mice models93,168,436:
1. NfL−/− mice: the cellular NfM and NfH cannot form heteropolymers
without NfM resulting in perikaryal accumulation of Nf subunits.436
2. NfM−/− mice: a severe effect on the radial growth of axons was ob-
served.93,168 Unassembled NfL sequestered in the neuronal perikarya
and axonal atrophy was observed.168 It has therefore been suggested
that NfM is needed for transport of NfL from the perikaryon into the
axon.
3. NfH−/− mice: radial growth of axons was reduced to a lesser extend
then in NfM knockout mice.93,168 This was however an inconsistent
finding, suggestive of a range of compensatory changes. Such changes
could include NfL and NfM over expression and increased phosphory-
lation.94,173,447
The observation that Nf accumulates in ALS suggests that alterations
of the expression pattern of Nf subunits could accelerate the degeneration
of pre–damaged axons. This hypothesis led to the development of mice mu-
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tants combining transgenic mice expressing mutants SOD1G93A, SOD1G37R
or SOD1G85R with either Nf subunit knockout or transgenic Nf subunit
overexpression:
1. Double knockout: in SOD1G85R/NfL−/− mice a slight accumulation
of NfH and NfM subunits was observed in the neuronal perikaryon.436
This confirms the hypothesis that NfL is essential for the neuro-axonal
transport of Nf. Interestingly this did not contribute to accelerated dis-
ease progression. Surprisingly the life–span increased by about 15%.436
This has been explained by the neuroprotective effects of the accumu-
lated NfH subunit.174,293,436
2. Triple knockout: in SODG37R mice with NfL+/−/ NfM+/−/ NfH+/−
a stoichochemical balanced reduction of all three Nf subunits by about
40% did not influence the life–span at all.292
3. Nf over-expression:
• Human NfH: despite a substantial reduction of the axonal calibre
the life–span of offspring from SOD1G37R mutant mice mated
with transgenic mice overexpressing human NfH increased by
about 65%. Accumulation of all Nf subunits was observed in
the neuronal perikaryon.74
• Human NfL: the increase of NfL lead to a increase of the ax-
onal calibre of about 50%, but the life–span of the mice was not
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affected.74
• Mouse NfH: the increase of NfH lead to accumulation of Nf sub-
units in the neuronal perikaryon and a substantial reduction of
the axonal calibre. The life–span of the mice increased by 15%.193
• Mouse NfL: a slight increase of Nf subunits was observed in the
neuronal perikaryon and the axonal calibre increased. The life
span of the mice increased by 15%.193
The surprise finding that either NfH overexpression or perikaryal Nf ac-
cumulation in SOD1 mutant mice increases the life–span led to the sugges-
tion that Nf could act as a Ca2+–chelator reducing oxidative damage.173,174
Alternatively it could act as a “phosphorylation–sink” and thus prevent
the phosphorylation–dependent activation of enzymes which finally lead to
apoptosis .293 The finding that NfH has protects from oxidative damage has
been confirmed independently.420
2.2 Glial fibrillary acidic protein
2.2.1 Background
Glial fibrillary acid protein (GFAP) is a non–soluble acidic cytoskeletal pro-
tein. It is the principal intermediate filament of the human astrocyte. GFAP
was first extracted by LF Eng in 1969 from MS plaque tissue96,100 and be-
longs to the class–III intermediate filament proteins. GFAP is coded on
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chromosome 17q21.1-q25 and consists of 432 amino acids.321 The corre-
sponding molecular mass is 49.8 kDa. Cytoskeletal GFAP is tightly packed
into polymers. After break–up of the GFAP polymer a soluble fragment of
GFAP of approximately 41 kDa is released to the adjacent fluid compart-
ments.97 The structure of GFAP has not yet been determined. A schematic
outline of the intracellular organisation of GFAP is shown in Figure 2.2.
2.2.2 Clinical relevance
The astrocyte is a major regulator of brain homeostasis and controls the
molecular and ionic contents of the extracellular space of the CNS. Activa-
tion of astrocytes is a consequence of any insult to the CNS. This includes
in particular trauma, genetic disorders, chemical or immunological chal-
lenge and degeneration. Elevated levels of GFAP have been found in the
CSF of various diseases including MS ,336 dementia,97 normal pressure hy-
drocephalus,7 asphyxiated newborns,44 head injury,276 brain infarction22,148
Lyme–borreliosis87 and trypanosomiasis.220 Astrocytic hypertrophy is ob-
served rapidly after axonal injury322 and increased levels of GFAP become
significant 24 hours post–event in semi–quantitative immunoblotting analy-
sis.392 The motility and shape of astrocytes depends upon the rearrangement
of GFAP, the major cytoskeletal protein.
The term astrocytic activation or reactive astrocytosis is used to de-
scribe the proliferation of astrocytes with hypertrophy of the cell body and
the cytoplasmic processes. Immunohistochemistry at this stage shows ex-
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Figure 2.2: Intracellular organisation of GFAP. The dynamics between the
GFAP monomer and the functional relevant cytoskeletal 8-9 nm intermedi-
ate filament are shown.
CHAPTER 2. BRAIN–SPECIFIC PROTEINS 62
tensive staining for GFAP without increase of the total GFAP content. This
is largely caused by rearrangement of the cytoskeletal GFAP polymer and
unmasking of epitopes.368 Electron microscopy of swollen astrocytes has
demonstrated disrupted and loose bundles of glial filaments contrasting with
the normally observed tight bundles.95 Reactive astrocytosis has been shown
to participate in removal of myelin and neuronal debris in areas where no
activation of microglia was observed and macrophages were absent.98
The term astrogliosis is used to describe the gliotic scar formation after
CNS insult. Astrogliosis walls off areas of the CNS exposed to potentially
hazardous tissue/ substances. The barrier has, however, a pathological role
in itself by preventing remyelination and inhibiting axonal regeneration.97
2.3 S100B protein
2.3.1 Background
Originally isolated from the bovine CNS by Moore in 1965279 the protein
was named S100 because of its solubility in 100% saturated ammonium
sulphate at neutral pH. S100B is now known to belong to a large family
of S100 proteins.86 S100B is coded on chromosome 21q22.3143 whereas the
other 13 members of the family cluster around 1q21. S100B consists of 91
amino acids and its molecular weight corresponds to 10 kDa. S100B is a
water–soluble, cytoplasmic protein and contains 2 EF–hand calcium–binding
domains. The 3D structure of Ca2+-free S100B is compact when compared
to bound S100B (Figure 2.3). The resulting exposure of epitopes hidden by
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Figure 2.3: Structure of the Ca2+–free (left) and Ca2+–loaded (right) S100B
dimer. One S100B monomer is in blue and the other is in green. Helices
are indicated by Roman numerals (I-IV) Binding of Ca2+ to S100B causes
reorientation of helix III relative to all other helices. Note that the Ca2+–
loaded dimer is more extended than the Ca2+–free dimer. The change of
confirmation exposes otherwise hidden epitopes to the solvent†.
the Ca2+–free isoform influences antibody recognition. This is of relevance
when the protein is measured by immunological methods.129,363
The functions of S100B are both intra- and extracellular. Intracellularly
the Ca2+ dependent conformational change of S100B triggers of the phos-
phorylation of enzymes by inhibition of e.g. PKC–mediated phosphoryla-
tion.33,434 Extracellularly S100B protein is involved in neurite extension,
astrocytosis, axonal proliferation and inhibition of microtubule assembly.
This can partly be explained by the Ca2+ dependent interaction with cy-
toskeletal proteins such as the type III IF GFAP, vimentin and desmin.254,370
For the interaction with GFAP it was demonstrated that binding of S100B
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to the N–terminal tail domain hinders GFAP assembly.448
2.3.2 Clinical relevance
S100B has mostly been measured in the CSF and elevated levels were found
in acute and chronic neurological conditions.
It appears from these studies that S100B is possibly of prognostic value in
acute brain injury (ABI) .147,314,338 There was also a suggestion that longer
term outcome measures such as the Glasgow Outcome Score (GOS) or psy-
chometry were related to S100B levels.148,354 Of particular interest were
two reports from the same group where S100B was shown to be elevated in
patients with mild head injury (GCS 13–15).37,163,421 S100B was therefore
considered to be a very sensitive marker of diffuse brain injury. Conse-
quently, it was included in prospective studies investigating cerebral injury
due to cardiac surgery. It is a consistent finding that an increase of serum
S100B levels during surgery is related to a higher rate of complications such
as cerebrovascular accidents (CVA) .10,11,15,45,165,188,202,228,319,327,417,428,429
Consequently the role of S100B in acute neurology is increasing, with par-
ticular reference to stroke.
Few studies have investigated S100B levels in subarachnoid hemorrhage
(SAH) on a systematic basis,278,304,391,433 but levels were generally elevated.
This contrasts with the study by Sindic et al. who found elevated levels
only in 47% (8/17), but did not distinguish between SAH and intracranial
haematoma.363 High CSF levels were associated with a poor Fisher grade391
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or more severe impairment on the Hunt and Hess scale.433
Measurement of S100B increases the sensitivity and specificity of the
differential diagnosis of dementia syndromes with particular reference to
CJD and vCJD.127
On the premise that S100B levels are highly sensitive to changes of the
CNS homeostasis this protein has been investigated as a marker for disease
activity in MS. It appears from 5 studies212,212,250,251,269 that S100B is
increased in the CSF of patients with MS. In particular the longitudinal
study by Michetti et al. (1979) demonstrated an increase of S100B after
relapse with regression to the mean after 29–35 days269 (Table 1.2 on page
45). The results of measuring S100B in MS have however been disappointing
in one cross–sectional study.363 This might have been due to the sensitivity
of the assay using a Particle Counting ImmunoAssay (PACIA) based on
latex agglutination. Importantly, these investigators determined that Ca2+
influenced the sensitivity of the assay, with a concentration of 5 mM being
the optimum for their assay.363
There is also some evidence for elevated S100B levels in epilepsy 212,373
and amyotrophic lateral sclerosis, 278 however systematic investigations
have not yet been performed.
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2.4 Ferritin apoprotein complex
2.4.1 Background
Iron–free ferritin is a nearly spherical apoprotein complex of 450 kDa and
approximately 480 kDa if iron–loaded. The apoprotein shell consist of 24
subunits containing a central cavity with binding capacity for approximately
4,500 iron atoms. There are 2 ferritin subunits: a heavy chain predominantly
expressed in heart tissue (FTH) and a lighter chain expressed in liver (FTL).
FTH is coded on chromosome 11q12-q13, and consists of 182 amino acid
with a molecular mass of 21 kDa. FTH is associated with low iron storage
and high iron utilisation due to its ferroxidase activity.75 FTL is coded on
chromosome 19q13.3-q13.4, consists of 174 amino acids with a molecular
mass of 19.9 kDa.146 FTL is associated with slow uptake and long–term
storage.
CSF ferritin has been shown to be largely non–glycosylated54 in contrast
to serum ferritin. There is evidence for intrathecal ferritin synthesis.185 The
cellular origin of CSF ferritin derives from microglia and oligodendrocytes.
Whereas oligodendrocytes express mainly FTH, microglia are capable of ex-
pressing FTL. Iron is required as a cofactor for cholesterol and lipid biosyn-
thesis in order to produce myelin. Increased endocytotic ferritin uptake
could be demonstrated in oligodendrocyte progenitor cells .71,159 Using
in–situ hybridisation and immunohistochemistry it could be demonstrated
that cellular distribution of ferritin however changes during development
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from predominant expression in microglia to oligodendrocytes. In patholog-
ical conditions however microglia seem to considerably upregulate ferritin
expression. In adult rat brain tissue ferritin is mainly present in oligoden-
drocytes.62 In MS the distribution of ferritin and transferrin binding-sites
undergoes an inversion of the physiological state when compared to normal
controls.160 This suggests a possible role for oligodendroglial ferritin (FTH)
in remyelination.
2.4.2 Clinical relevance
High CSF levels of ferritin have been associated with subarachnoid haemor-
rhage, intraparenchymal cerebrovascular events, miscellaneous central ner-
vous system infections and vasculitis.54,134,140,364
The most characteristic feature of microglial cells is their rapid activa-
tion in response to even minor pathological changes in the CNS. Microglial
activation is a key factor in the defence of the neural parenchyma against
infectious diseases, inflammation, trauma, ischaemia, brain tumours and
neurodegeneration.141,199,262,263,383 Microglial activation occurs as a
graded response in vivo.227,383 The transformation of microglia into poten-
tially cytotoxic cells is under strict control and occurs mainly in response to
neuronal or terminal degeneration, or both.9,305,306,350 Activated microglia
are mainly scavenger cells but also perform various other functions in tissue
repair and neural regeneration. They form a network of immune alert resi-
dent macrophages with a capacity for immune surveillance and control. Ac-
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tivated microglia can destroy invading micro-organisms, remove potentially
deleterious debris and promote tissue repair by secreting growth factors.
An understanding of intercellular signalling pathways for microglial prolif-
eration and activation could form a rational basis for targeted intervention
to injuries in the CNS.199
Chapter 3
Hypothesis
Disease heterogeneity is a feature of early MS and suitable biomarkers might
contribute to improving the subclassification of these patients .236 This
study first aims to test the hypothesis that BSP can help to distinguish
different MS subtypes.
The assessment of the development of disability requires long observa-
tion periods when clinical scales are applied. In addition the inter–observer
variation is high. This study addresses the second question as to whether
BSP can be used as a surrogate for monitoring the development of disability.
Axonal damage is observed early in the disease and is responsible for
irreversible loss of function. Thirdly this study investigates whether BSP can
be used early on as a prognostic marker indicating those patients who suffer
from a high level of axonal injury and thus will develop greater disability.
Taking these together the following hypotheses were formulated:
• Axonal damage is paralleled by release of neurofilament proteins into
69
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the extracellular space, which equilibrates with the adjacent fluid com-
partment (e.g. CSF). Therefore the quantification of neurofilaments
from body fluids should allow to estimate the amount of axonal dam-
age. Because axonal damage is directly related to sustained disability,
the neurofilament levels should be an indirect measure, a surrogate for
disability.
• Astrocytic activation is a direct response to any challenge to brain–
homeostasis. A relapse in MS is such a challenge and therefore S100B,
a surrogate for early astrocytic activation, should be increased in body
fluids. Because relapses are an indicator for disease activity and tend
to be less frequent in progressive than in relapsing disease, the S100B
levels should help to distinguish clinical subgroups of MS.
• Microglial activation, in an analogy to astrocytic activation should be
a direct response to any challenge to brain homeostasis. Therefore the
measurement of CSF ferritin should provide another indirect measure
for disease activity.
• Astrogliosis describes the fibrotic scar tissue replacing any irreversibly
damaged CNS parenchyma and represents therefore the “burnt–out”
phase of the disease. Because these astrogliotic plaques are rich of
GFAP, GFAP levels in body fluids should give a measure of the “total
lesion load” (i.e. with chronic lesions) (CL) which should indirectly
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relate to disability. Additionally GFAP should distinguish progressive
from relapsing disease on the rationale that the total amount of chronic
lesions is higher in the former.
• if the course of MS would be homogeneous then, in theory there should
be a negative relation between GFAP with either S100B or ferritin with
GFAP being higher in progressive/ “burnt–out” MS.
In order to address these questions it was necessary to develop quanti-
tative methods for the assessment of Nf and GFAP. The hypothesis which
claims that BSP are released from MS lesions was tested in animal and
post–mortem studies prior to a cross–sectional and longitudinal approach in
human CSF.
Part II
Methods
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Chapter 4
Development of a
neurofilament ELISA
4.1 Background
Neurofilaments (Nf) are possible candidates for estimating axonal damage
in neurological disorders (Chapter 1.3) and the basic structure of Nf was
reviewed in Chapter 2.1. There are currently no commercial ELISA kits
available for quantification of any of the three Nf subunits. One group
developed a sandwich ELISA technique for the detection of NfL, based on
in–house antibodies. Confirmation of the results derived by this group is
however hampered by the non–availability of the antibodies∗. Another group
tried to develop an ELISA based on commercially available substances but
was not able to obtain satisfactory sensitivity and reproducibility (Dr Eli
Silber, personal communication).
∗In a personal communication Dr Rosengren argued that he preferred not to provide
an external researcher with his antibody on the basis that previously there were problems
with repeating the NfL assay which were related to the expertise of the researcher. Dr
Rosengren was however positive towards a collaborative study where he would be provided
with snap–frozen CSF and perform the NfL assay.
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The aim of this part of the study was to develop an ELISA for the
neurofilament subunits NfL and NfH.
4.2 Materials and methods
4.2.1 Antibodies
Capture (first) antibody
NfH Mouse monoclonal IgG1 anti–NfH antibodies (SMI) were purchased
from Sternberger Monoclonals (Sternberger Monoclonals Incorporated, 10
Burwood Court, Utherville, MD 21093) and Sigma (NE14). The NfH phos-
phoforms were named as discussed (paragraph 2.1.1 on page 54). The pur-
chased antibodies were all provided as ascites fluid and have the following
characteristics †:
NfHSMI32 SMI32 (old notation378: 02–135) is a mouse monoclonal IgG1 which
reacts with a non–phosphorylated epitope in NfH of most mammalian
species. On Western immunoblots two bands (200 and 180 kDa) were
seen for SMI32. On 2D immunoblots these bands merged into a sin-
gle NfH line.123,376 The reaction could be abolished on immunoblots
and immunohistochemistry by phosphorylation. Dephosphorylation
of NfH in contrast lead to increased staining. These findings suggest
that the SMI32 binding–site can be masked and unmasked.123,376,378
NfHSMI32 was present in neuronal cell bodies, dendrites and some
†The information on the antibodies is largely derived through personal commu-
nication with Dr Ludwig Sternberger and his own summary, which is available on:
http://home.att.net/ sternbmonoc/SMIMonoclonalAntibodies.htm
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thick axons of the central and peripheral nervous system. Thin ax-
ons were NfHSMI32 negative. There was no cross–reactivity with ei-
ther tau or with other tissues.18,55,56,152,303,378,422 Treatment with
trypsin abolished the staining for NfHSMI32 ‡. However after incu-
bating the trypsin–treated tissue with alkaline phosphatase, staining
for NfHSMI32 reappeared. NfHSMI32 was now visible in cell bodies,
dendrites , thick and thin axons. This pattern was indistinguish-
able from the one obtained with anti–phospho–neurofilaments such
as NfHSMI35 .378 The interpretation of these results implies that phos-
phorylation protects NfH from digestion and confirms the hypothesis
that phosphorylation masked the NfH binding epitope for SMI32.
A subset of cortical neurons which are lost in pathological conditions
such as Alzheimer’s and Huntington’s disease were NfHSMI32
positive.18,56,152 In primary cell cultures of murine cortex a neuronal
population with enhanced vulnerability to kainate toxicity was also
NfHSMI32 positive. In this model toxicity was related to GABAergic
and kainate–activated Ca2+ uptake.126 In MS, demyelination of axons
and the axon-terminal spheroids of transected axons contain abundant
NfHSMI32 .398 In Alzheimer’s disease unmasking of the SMI32 epitope
by dephosphorylation, revealed that swollen neurites contained a high
concentration of NfHSMI32 suggestive of aberrant NfH phosphoryla-
‡Note that trypsin treatment did not affect the staining for NfHSMI34 .
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tion.379,446 Consequently it has been shown that dephosphorylation
of brain tissue from patients with Alzheimer’s disease had a high num-
ber of NfHSMI32 positive swollen neurites which extended outside the
area positive for tau.387 In a rat model early stages of Alzheimer’s dis-
ease demonstrated axons positive for NfHSMI32 , whilst tau remained
negative.191 It was speculated that projection pathways positive for
NfHSMI32 might be vulnerable152 and that there was a retrograde toxic
effect of the plaque as the primary lesion.386
NfHSMI33 SMI33 (old notation378: 02–04) is a mouse monoclonal IgM which
binds to a non–phosphorylated epitope accessible in both, phospho-
rylated and non–phosphorylated NfH. Some cross–reactivity was ob-
served with NfM. In contrast to other anti–non–phospho-neurofilaments,
reaction with isolated neurofilaments was not intensified by phospho-
rylation with alkaline phosphatase. Immunocytochemically, SMI 33
visualises neuronal cell bodies, dendrites and some thick axons in the
central and peripheral nervous system. SMI33 stained neuronal cell
bodies and processes more abundantly than SMI32. There was some
binding of SMI 33 to non-neuronal elements in peripheral, non-nervous
system tissue, particularly to macrophages. In some pathological con-
ditions, the neuronal cell body showed an increased NfHSMI33 content.
NfHSMI34 SMI34 (old notation378: 07-05) is a mouse monoclonal IgG1 which
CHAPTER 4. DEVELOPMENT OF A NEUROFILAMENT ELISA 77
binds to a phosphorylated epitope of extensively phosphorylated NfH
in mammalian species and chicken. There was some cross–reactivity
with NfM, but not with other cells and tissues. Treatment with al-
kaline phosphatase but not trypsin abolished the NfHSMI34 bands on
Western–blots and NfHSMI34 positivity in immunohistology. In un-
treated tissue sections thick and thin axons and basket cell dendrites
were NfHSMI34 positive. In some pathological conditions neuronal cell
bodies became NfHSMI34 positive. Aberrant phosphorylation of NfH
of the neuronal cell body could be demonstrated in cell cultures after
exposure to agents which induce stress-activated protein kinase.119 In
Alzheimer’s disease indexintraneuronal tangles intraneuronal tangles,
but not extraneuronal (ghost) tangles were NfHSMI34 positive.72,357,379,414,446
NfHSMI35 SMI35 (old notation378: 03–44) is a mouse monoclonal IgG1 which
reacts with high (200 kDa, pI 5.1) to low (170 kDa, pI 6.2) phosphory-
lated NfH phosphoforms.123,376 The latter distinguishes SMI35 from
SMI34 and SMI310. There was some cross–reactivity with NfM in
Western–blots. No cross–reactivity with other tissue was observed.55,72,123,377
In pathological conditions, SMI 35 frequently detected early changes in
neuronal cell body staining. A Golgi-like image of pathological phos-
phorylation in neuronal perikarya and their dendritic arborizations for
NfHSMI35 provided evidence for pre–chromatolytic, retrograde demon-
stration of neuronal connectivities .145 In Alzheimer’s disease intraneu-
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ronal tangles were NfHSMI35 positive, a result which could be amplified
by mild dephosphorylation.
NfHSMI37 SMI37 (old notation378: 06–32) is a mouse monoclonal IgM which
binds to a non–phosphorylated epitope in NfH of most mammalian
species. Immunocytochemically a subpopulation of neuronal cell bod-
ies, dendrites and some thick axons in the central and peripheral ner-
vous systems were NfHSMI37 positive. The pattern was however more
restricted than for NfHSMI32 or NfHSMI38 .
NfHSMI38 SMI38 (old notation378: 10–01) is a mouse monoclonal IgG1 which
binds to a non–phosphorylated epitope in NfH of most mammalian
species. No cross–reactivity was observed towards other cells or tissues.
Immunocytochemically neuronal cell bodies, dendrites and some thick
axons in the central and peripheral nervous systems were NfHSMI38
positive.
NfHSMI310 SMI310 (old notation378: 04–07) is a mouse monoclonal IgG1 which
binds to a phosphorylated epitope in extensively phosphorylated NfH
in most mammals. Phosphorylation of this epitope is essential as
phosphatase–treated tissue sections or Western–blots became NfHSMI310
negative. There was some cross–reactivity with NfM. Immunocyto-
chemically only some axons, but no neurons or dendrites were NfHSMI310
positive. This contrasted with with the staining for all other anti–
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phospho–neurofilaments, e.g. NfHSMI34 or NfHSMI35 .
In pathological conditions neuronal cell bodies became NfHSMI310
positive. In Alzheimer’s diseased extraneuronal (ghost) neurofibrillary
tangles but not intraneuronal tangles were strongly NfHSMI310 positive.
It was therefore speculated that NfHSMI310 could represent an un-
usual and sparsely distributed form of phosphorylated NfH which
might be increased in certain pathologic conditions.414 Staining for
NfHSMI310 distinguished sporadic inclusion–body myositis from hered-
itary inclusion–body myopathies .275
NfHSMI311 SMI311 is a cocktail of a number of monoclonal IgG1 and IgM anti-
bodies to non-phosphorylated NfH. SMI 311 is a convenient marker for
neurons in general and their differentiation from non–neuronal cells.102
In specifically delineating cell bodies and dendrites, SMI311 has been
used to trace the “inside-out gradient” of neuron production and differ-
entiation.405 Pathological conditions, such as under–nutrition, affected
SMI311 visualised soma size and dendritic arborisation.406
NfHNE14 NE14 is derived from the hybridoma produced by the fusion of mouse
myeloma cells and splenocytes from an immunised mouse. Neurofila-
ments purified from pig spinal cord were used as the immunogen. NE14
recognises a phosphorylated epitope on NfH.125 NE14 was purchased
from Sigma.
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NfL Mouse monoclonal IgG1 anti–NfL antibodies (Clone NR4) were pur-
chased from Sigma. This antibody was developed by Debus et al. and
stained specifically for NfL.83 NR4 detected NfL in mammalian and mouse
tissue.243
Detector (second) antibody
Affinity–purified rabbit polyclonal anti–NfH was purchased from Affiniti Re-
search Products, Exeter. Isoelectric focusing and immunoblotting demon-
strated that this antibody reacted against NfH, with some cross–reactivity
against NfL and NfM. Affinity purified rabbit polyclonal anti–NfL was pur-
chased from Affiniti (batch Z01495).
Indicator (third) antibody
Horseradish peroxidase conjugated swine polyclonal anti–rabbit Ig was pur-
chased from Dako (Copenhagen, Denmark). Isoelectric focusing and im-
munoblotting demonstrated that this antibody reacted primarily against
rabbit IgG, with no reactivity against mouse IgG1.
Sodium barbitone, barbitone, ethylene diamine tetra acetic acid dis-
odium salt (EDTA), calcium lactate, 30% hydrogen peroxide, bovine serum
albumin (BSA) were of analytical grade (Sigma). TMB was purchased
from DAKO (Copenhagen, Denmark). Hydrochloric acid was obtained from
Merck (Darmstadt, Germany). Nunc Maxisorb Microtitre plates were ob-
tained from Life Technologies (Paisley, Scotland).
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4.2.2 Working reagents and buffers
Carbonate buffer The stock solution of 0.5 M carbonate buffer con-
tained: Na2CO3 14.85 g, NaHCO3 26.1 g, add H2O to 1 L ⇒ 0.5 M. The
working strength solution (0.05 M) was prepared directly prior to the exper-
iment. The pH was 9.6. Carbonate buffer was used for coating the ELISA
plates with the appropriate antibody.
Phosphate buffered saline (PBS) The 10–fold concentrated stock so-
lution contained: NaCl 80.0 g, KCl 2 g, KH2PO4 2 g, Na2HPO4 11.5 g. The
working–strength solution was prepared directly prior to the experiment.
The pH was 7.4.
Barbitone buffer The working–strength solution contained 13.1 g sodium
barbitone, 2.1 g barbitone in 1 L of purified water. The pH was 8.6.
Washing solution 1 g BSA (0.1%) was dissolved in 1 L of the appropriate
buffer (PBS or barbitone) and 500 µL Tween 20 (0.5%) were added.
Block solution 1 g BSA (1%) was dissolved in 100 mL of the appropriate
buffer (PBS or barbitone).
Antibody diluent 0.1 g BSA (0.1%) in 100 mL of the appropriate buffer
(PBS or barbitone).
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Sample diluent 0.1 g BSA (0.1%) in 100 mL of the appropriate buffer
(PBS or barbitone).
4.2.3 Standards
NfH standards Bovine NfH (200/210 kDa) was obtained from Affiniti
Research Products, Exeter. A range of standards from 0 to 2 ng/mL were
prepared by diluting bovine NfH in barbitone buffer (pH 8.9) containing
0.1% bovine serum albumin, 6 mM EDTA and stored in 1 mL aliquots at
-20◦C.
NfL standards Bovine NfL (68 kDa) was obtained from Affiniti Research
Products, Exeter. A range of standards from 0 to 1.5 ng/mL were prepared
by diluting bovine NfL in barbitone buffer (pH 8.9) containing 0.1% bovine
serum albumin and stored in 1 mL aliquots at -20◦C.
4.2.4 CSF samples and reference population
NfH reference population CSF samples from 463 neurological patients
undergoing a routine diagnostic lumbar puncture were obtained. The se-
lection was randomised from the department’s sample library in order to
obtain a heterogeneous population. Clinical details were only obtained after
analysis. The CSF samples were centrifuged on receipt and stored at 4◦C.
Analysis was performed within 1 week.
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NfL reference population CSF samples from 127 neurological patients
undergoing a routine diagnostic lumbar puncture were obtained. The se-
lection was randomised from the department’s sample library in order to
obtain a heterogeneous population. Clinical details were obtained only after
analysis. The CSF samples were centrifuged on receipt and stored at 4◦C.
Analysis was performed within 1 week.
4.2.5 Analytical procedure
The microtitre plates were coated overnight with capturing antibody (SMI)
diluted 1:5000 in 0.05 M carbonate buffer, 100 µL, pH 9.5. The plate was
washed with barbitone buffer containing 0.1% BSA and 0.05% Tween 20.
Fifty µL of barbitone buffer, 6 mM EDTA. 0.1% BSA were added as sample
diluent to each well. Fifty µL of standard, control or CSF sample were then
added in duplicate to the plate. The plate was incubated at room tempera-
ture (RT) for 1 h. After washing, 100 µL of rabbit anti NfH diluted 1:1000
in barbitone buffer were added to each well and the plate was incubated for
1 h at RT. The microtitre plate was then washed with appropriate wash so-
lution. HRP–labelled swine anti–rabbit antibody diluted 1:1000 was added
and incubated for 1 h at RT. After a final wash, 100 µL of TMB substrate
were added. The plate was incubated for 20 minutes at RT in the dark, the
reaction was stopped by adding 50 µL 1 M HCl and the absorbance was read
at 450 nm with 750 nm as the reference wavelength on a Wallac Victor2.
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4.2.6 Statistical evaluation
Data were managed and analysed as described (Chapter 7, page 151).
4.3 Results
4.3.1 NfH phosphoforms
Standard curves All standard curves were run on the same plate to
minimise the inter-assay variation. The concentration for the first antibody
was 1:10000, for the second and third antibody 1:1000. The standard curves
determined for the NfH capture antibodies were expressed as the percentage
optical density (OD) for each calibrant.
This normalised procedure allows firstly direct comparison of the perfor-
mance of the assay, which was e.g. linear for NfHSMI34 (Figure 4.1) versus
quadratic for NfHSMI35 (Figure 4.2). Secondly, those capturing antibod-
ies which might still be worth using for the further development for an
ELISA specific for one NfH phosphoform can be seen (e.g. SMI34 but not
SMI311). The standard curves for the antibodies binding to phosphorylated
NfH (NfHSMI34 NfHSMI35 NfHSMI310 NfHNE14 ) are shown in Figures 4.1 to
4.4. The standard curves for the antibodies binding to non–phosphorylated
NfH (NfHSMI32 NfHSMI33 NfHSMI37 NfHSMI38 NfHSMI311 ) are shown in Fig-
ures 4.5 to 4.9.
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Figure 4.1: Standard curve for NfHSMI34 . The regression line and 95%
confidence interval curves are shown.
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Figure 4.2: Standard curve for NfHSMI35 . The regression line and 95%
confidence interval curves are shown.
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Figure 4.3: Standard curve for NfHSMI310 . The regression line and 95%
confidence interval curves are shown.
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Figure 4.4: Standard curve for NfHNE14 . The regression line and 95%
confidence interval curves are shown.
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Figure 4.5: Standard curve for NfHSMI32 . The regression line and 95%
confidence interval curves are shown.
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Figure 4.6: Standard curve for NfHSMI33 . The regression line and 95%
confidence interval curves are shown.
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Figure 4.7: Standard curve for NfHSMI37 . The regression line and 95%
confidence interval curves are shown.
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Figure 4.8: Standard curve for NfHSMI38 . The regression line and 95%
confidence interval curves are shown.
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Figure 4.9: Standard curve for NfHSMI311 . The regression line and 95%
confidence interval curves are shown.
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Detection limit and analytical range The detection limit was deter-
mined by the signal–to–noise ratio of the lowest calibrant to the blank (back-
ground), Figure 4.10. An estimate for the analytical range for a particular
antibody combination is the ratio of the highest calibrant to the noise (Fig-
ure 4.11). The signal–to–noise ratio for SMI35 was about 4- to 10–fold and
the analytical range 2- to 10–fold higher than for the other antibody com-
binations. On the basis of these results SMI35 was selected as the capture
antibody for the further development of the NfH ELISA.
Antibody concentration
NfH assay The first antibody was titrated against the second antibody.
Dilutions used for the first antibody were 11000 ,
1
5000 ,
1
10000 and
1
100000 . Di-
lutions used for the second antibody were 1500 ,
1
1000 and
1
5000 . All standard
curves were run in on the same plate. The results are summarised in Figures
4.12 to 4.15.
The signal–to–noise ratio and analytical range were calculated for each
combination. The individual results for the detection limit are shown in
Figure 4.17 and for the analytical range in Figure 4.17. The best result was
received for the combination of SMI35 15000 with polyclonal rabbit anti–NfH
1
10000 (signal–to–noise = 9.1; analytical range = 73) which was therefore
chosen for the further development of the assay.
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Figure 4.10: The detection limit of the NfH assay as determined by the
signal–to–noise ratio (OD of the lowest standard divided by the blank OD)
for different capture antibodies. A signal–to–noise ratio of greater than 1
(reference line) is required in order to obtain a readable signal.
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Figure 4.11: The analytical range as determined by the signal–to–noise ratio
for different capture antibodies for NfH.
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Figure 4.12: Optical density (OD) for different antibody concentrations of
the polyclonal rabbit anti NfH antibody (second antibody) with the first
antibody (SMI35) diluted 11000 .
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Figure 4.13: Optical density (OD) for different antibody concentrations of
the polyclonal rabbit anti NfH antibody (second antibody) with the first
antibody (SMI35) diluted 15000 .
CHAPTER 4. DEVELOPMENT OF A NEUROFILAMENT ELISA 99
Figure 4.14: Optical density (OD) for different antibody concentrations of
the polyclonal rabbit anti NfH antibody (second antibody) with the first
antibody (SMI35) diluted 110000 .
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Figure 4.15: Optical density (OD) for different antibody concentrations of
the polyclonal rabbit anti NfH antibody (second antibody) with the first
antibody (SMI35) diluted 1100000 .
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Figure 4.16: Detection limit as determined by the signal–to–noise ratio for
NfH 0.025 ng/mL. Columns are “colour”–coded (black, grey, white) accord-
ing to the concentration of the second antibody as indicated in the legend.
The absolute value of the signal–to–noise ratio is given for each antibody
combination below the appropriate column.
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Figure 4.17: Analytical range as determined by the signal–to–noise ratio for
NfH 1 ng/mL. Columns are grouped according to the dilution for SMI35
as capture (first). Columns are “colour”–coded (black, grey, white) accord-
ing to the concentration of the second antibody as indicated in the legend.
The absolute value of the signal–to–noise ratio is given for each antibody
combination below the appropriate column.
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NfL assay The antibody concentration for the NfL assay was determined
in a similar way to the NfH assay (data not shown). The optimal com-
bination was found to be 15000 for NR4 and
1
500 for the polyclonal rabbit
anti–NfL.
4.3.2 Reproducibility of the standard curve
Reproducibility of the standard curve was determined by expressing the
optical density (OD) obtained for each calibrant as a percentage of the
optical density. Twenty consecutive standard curves were normalised and
the results averaged. The resulting regression for NfL is shown in Figure
4.18 and forNfHSMI35 in Figure 4.19.
4.3.3 Precision
CSF samples (neat and spiked with either NfH or NfL) were used to calculate
the within- and between-batch precision and recovery.
NfH Within–batch and between–batch precision was determined for high
and low concentrations. The within–batch precision was 5.6% for 2 ng/mL,
6.6% for 0.4 ng/mL and 19.8% for 0.2 ng/mL. The between–batch precision
was 15% for 1.3 ng/mL and 31% for 0.16 ng/mL. The detection limit was 0.1
ng/mL. The sensitivity was calculated as the mean + 3 standard deviations
of the blank signal. The sensitivity was 0.2 ng/mL. The recovery of NfH in
CSF was 121% for pool 1 and 116% for pool 2, averaging at 119%.
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Figure 4.18: Standard–curve for the NfL assay. Reproducibility of twenty
consecutive normalised calibration lines. The graph shows the mean values
(dots) ± standard deviation (bars), quadratic regression line, 5% and 95%
confidence interval curves.
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Figure 4.19: Standard–curve for the NfHSMI35 assay. Reproducibility of
twenty consecutive normalised calibration lines. The graph shows the mean
values (dots) ± standard deviation (bars), quadratic regression line, 5% and
95% confidence interval curves.
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NfL The within–batch precision was 27% for 0.25 ng/mL. The between–
batch precision was over 50%. The sensitivity was 0.25 ng/mL. The recovery
of NfH in CSF was 60% for pool 1 and 66% for pool 2, averaging at 63%.
4.3.4 Parallelism
Parallelism between calibrant and CSF was studied by quantifying recipro-
cal dilutions of buffer spiked with NfH and CSF samples with known high
NfHSMI35 concentrations. The obtained OD for each series of dilutions was
normalised to the highest value within this series (100%). Because of the
vertical displacement the top value is not shown. The parallel relationship
was shown and suggested the absence of endogenous binding between CSF
NfHSMI35 and other CSF substrates (Figure 4.20).
4.3.5 Stability of CSF samples
NfHSMI35 Stability was tested at room temperature (RT), 4◦C and -70◦C.
CSF samples spiked with NfH were frozen in duplicate at -70◦C, thawed on
subsequent days and stored at 4◦C and RT (Figure 4.21). Linear regression
analysis of the 7–day observation period demonstrated no significant de-
crease in NfHSMI35 at -70◦C and 4◦C. At RT there was however a significant
(p<0.05) decrease in the measured NfHSMI35 concentration.
NfL Stability was tested at room temperature (RT) and 4◦C. CSF samples
spiked with NfL were frozen in duplicate at -70◦C, thawed on subsequent
days and stored at 4◦C and RT (Figure 4.22). Linear regression analysis of
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Figure 4.20: Parallelism for NfHSMI35 between calibrant (open, grey circles)
and CSF (closed, black circles). The linear regression, mean (circles) and
standard deviation (horizontal bars) are shown.
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the 3–day observation period demonstrated significant decreases in NfL at
4◦C and RT.
4.3.6 Stability of reagents
No problems were found with stability of antibodies. To minimise any prob-
lems with cumulative contamination, the antibodies were stored in 100 µL
aliquots and used within 4 weeks. All buffers were stored at 4◦C and used
within 1 week.
4.3.7 Cell–type specificity
Abundant neurofilament levels were found in neuronal cell culture and iso-
lated synaptosomes from rat brain tissue and human cerebral and spinal
cord tissue homogenate. In cultures of primary astrocytes an average of 63
fg/mg protein were detected. No NfH was detected in primary microglial
cultures.
4.3.8 Cross reactivity
Measuring double dilutions of a known amount of protein, the cross–reactivity
with NfM was 7.8%, with NfL 6.5% and with GFAP 0.06%. There was no
cross–reactivity with red–cells, white cells or haemolysed blood.
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Figure 4.21: Stability profile of NfHSMI35 in CSF at 4◦C (continuous line)
and at room temperature (dotted line) over 7 days.
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Figure 4.22: Stability profile of NfL in CSF at 4◦C (continuous line) and at
room temperature (dotted line) over 4 days.
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4.3.9 Reference population
Out of 561 CSF samples 463 were assayed for NfHSMI35 and 127 for NfL. In
29 patients enough CSF was available to assay for NfHSMI35 and NfLNR4 .
NfHSMI35 The distribution of the NfHSMI35 CSF levels was non–Gaussian
(Figure 4.23). In order to obtain a biological representative population the
top 10% (NfH > 1.119 ng/mL) have been removed, leaving 416 patients.
The mean age of the so determined reference population was 42.4±17.9
years, with a median of 41.9 (Range 3–80) years. There was no correla-
tion between CSF NfHSMI35 and age (R=0.065, p=0.2). Fifty–eight percent
(242/416) were female, 39.9% (166/416) male, and in 8 (1.9%) patients no
gender information was available. There was no significant difference in CSF
NfHSMI35 levels between the genders.
The relative frequency distribution of the reference–population was then
subjected to non–parametric definition of the upper reference value of the
95 percentile.369 The upper reference value corresponds to 0.73 ng/mL (Fig-
ure 4.23, reference line). The mean value of CSF NfHSMI35 was 0.25±0.23
ng/mL with a median of 0.21 ng/mL and an interquartile range of 0.07 to
0.35 ng/mL. The data were skewed towards zero by 1.33. The kurtosis was
2.15 indicating a high slim peak with more values in the tails than expected
by the Gaussian type. This was due to 18% of samples with non detectable
CSF NfHSMI35 levels.
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Figure 4.23: Frequency histogram for the reference population for CSF
NfHSMI35 (n=416). The upper reference value of 0.73 ng/mL is shown (dot-
ted line).
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NfL The distribution of the CSF NfLNR4 levels was non–Gaussian (Figure
4.24). In order to obtain a biological representative population the top 10%
(NfLNR4 > 0.24 ng/mL) have been removed, leaving 113 patients. The 95
percentile corresponds to 0.14 ng/mL (Figure 4.24, reference line). The
mean value of CSF NfLNR4 was 0.024±0.06 ng/mL with a median of 0.00
ng/mL and an interquartile range of 0.00 to 0.013 ng/mL. The data were
skewed towards zero by 2.9. The kurtosis was 7.4 indicating a high slim peak
with more values in the tails than expected by the Gaussian type. This was
due to 71% samples having no detectable NfLNR4 .
The mean age of the reference population was 46.3±18.2 years, with
a median of 44.7 (Range 1–76) years. There was no correlation between
CSF NfL and age (R=0.089, p=0.39). Fifty–two percent (59/113) were
female and 42% (47/113) male, in 7 (6%) patients no gender information
was available. There was no significant difference of CSF NfL levels between
the genders.
There was no correlation between CSF NfLNR4 and CSF NfHSMI35 (R=-
0.1, p=0.6) in those 29 samples were both proteins were measured.
4.3.10 Neurological disorders
After determination of the upper reference limit for the NfHSMI35 assay, a
second population of patients was selected according to the clinical diagnosis:
Nine patients had cluster headache (HD) with no other evidence of organic
pathology in the central nervous system. Two had a space–occupying lesion
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Figure 4.24: Frequency histogram for the reference population for CSF NfL
(n=113), the upper reference value of 0.14 ng/mL is shown (dotted line).
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(SO), one due to a cyst of the right lateral ventricle and one to a non Hodgkin
lymphoma. Three had amyotrophic lateral sclerosis (ALS), 3 a lumbar disc
prolapse (DP), 36 laboratory supported (isolated intrathecal IgG synthesis)
evidence for demyelinating disease (DM), 14 had Guillain–Barre´ syndrome
(GBS) and 5 had a subarachnoid haemorrhage (SAH). All CSF was taken
by routine lumbar puncture, except for SAH where the CSF was taken for
routine infectious screening 2 days after placement of an extra-ventricular
drain. The values for the SAH therefore represent ventricular CSF.
Because of the small patient numbers statistical significance was checked
on a categorical level by the Fisher’s exact test comparing proportions of
patients with CSF NfHSMI35 levels above the previously calculated upper
reference value (cut–off) of 0.73 ng/mL. A significantly higher number of
patients with SAH had CSF NfHSMI35 levels above cut–off when compared to
HD (p<0.001) or DM (p<0.001). A significantly higher number of patients
with SO had CSF NfHSMI35 levels above cut–off when compared to HD
(p<0.05) or DM (p<0.01) and a significantly higher number of patients
with ALS or DP had CSF NfHSMI35 levels above cut–off when compared to
DM (p<0.05, p<0.05, respectively).
4.3.11 CSF oligoclonal bands
The detection of OCB was done on time–matched CSF and serum using
standard isoelectric focusing16 on all 402 patients of the reference popula-
tion.
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Figure 4.25: Scatter plot of CSF NfHSMI35 levels in patients with cluster
headache (HD), space–occupying lesions (SO), amyotrophic lateral sclero-
sis (ALS), disc prolapse (DP, demyelinating disease (DM), Guillain–Barre´
syndrome (GBS) and subarachnoid haemorrhage (SAH). The horizontal ref-
erence line (dotted) represents the cut–off (0.73 ng/mL) derived from the
reference population, the y–axis is split at 2 ng/mL.
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Patients were classified according to their OCB pattern as described
(Chapter 6.5, page 150).
Table 4.1: Distribution of CSF NfH concentration according to the OCB
pattern
OCB Number Mean ± SD Median Range [ng/mL]
OCB -/- 214 0.21 ± 0.19 0.19 0 - 0.92
OCB +/+ 46 0.22 ± 0.16 0.23 0 - 0.67
OCB +/- 68 0.21 ± 0.19 0.19 0 - 0.64
OCB ++/+ 21 0.24 ± 0.18 0.19 0 - 0.62
OCB +++/+ 14 0.26 ± 0.21 0.26 0 - 0.62
OCB m/- 9 0.2 ± 0.24 0.16 0 - 0.67
OCB m/m 4 0.08 ± 0.09 0.07 0 - 0.18
Table 4.2: Distribution of CSF NfL concentration according to the OCB
pattern.
OCB Number Mean ± SD Median Range [ng/mL]
OCB -/- 55 0.044 ± 0.09 0.0 0.0 - 0.29
OCB +/+ 21 0.04 ± 0.08 0.008 0.0 - 0.28
OCB +/- 23 0.1 ± 0.12 0.013 0.0 - 0.35
OCB ++/+ 3 0.002 ± 0.003 0.0 0.0 - 0.007
OCB +++/+ 3 0.019 ± 0.23 0.011 0.0 - 0.045
OCB m/- 1 0.008 0.008
OCB m/m 1 0.0 0.0
There was no significant difference in the NfHSMI35 concentration in
patients separated according to the OCB pattern (F(6,369)=0.58, table
4.1). There was a trend for higher CSF NfL levels in OCB +/- patients
(F(6,100)=1.45, p=0.2), with OCB +/- having significantly higher levels
then OCB +/+ (p<0.05) only in the post–hoc analysis.
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4.4 Discussion
The novel ELISA method presented here is straightforward and based en-
tirely on commercially available antibodies. The NfHSMI35 protein was sta-
ble over a 1–week period if samples were stored at 4◦C. For longer storage
either freezing at or below -20◦C or addition of a protease inhibitor cock-
tail is recommended. The detection limit of the NfHSMI35 ELISA was 0.01
ng/mL and the sensitivity 0.02 ng/mL with a reasonable precision profile
(5.6% – 31%). In comparison the sensitivity of the NfL ELISA was 0.25
ng/mL with a relatively poor precision (CV>50%).
The upper reference value of 0.73 ng/mL NfHSMI35 has to be regarded as
conservative. It applies to a hospital population of a tertiary referral centre
biased towards neurological diseases. In a general hospital population a
more suitable upper reference value would need to be established, which is
likely to be lower.
Because this ELISA is the first one reported to measure NfH in human
CSF, no cross–validation with any other method is possible. An ELISA
for measuring NfH in brain homogenate has been reported, but the repro-
ducibility was not rigorous.142 An ELISA for quantifying the light chain
(NfL) has already been developed.335 A stability profile of NfL in CSF was
not presented by Rosengren et al. (1996), but the authors mentioned the
high susceptibility of NfL to proteolysis and refer to previous work.349,418
The instability of NfL is confirmed by the present results. The strategy
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chosen to overcome this difficulty was to snap–freeze samples directly after
lumbar puncture and store at -70◦C. Samples were only thawed directly prior
to analysis.335 No data on aggregate formation of NfL in CSF is available.
Rosengren et al. (1996) report a cross–reactivity of their assay with NfH of
15%.335 The amount of CSf–NfH contributing to the CSF–NfL levels in a
series of studies51,157,242,334,335 is not known, but could be significant if the
in–vivo half–life of NfL is significantly shorter than that of NfH as suggested
by the present results and others.349,418
In neurological diseases the highest levels of CSF NfHSMI35 were observed
in the ventricular CSF of patients with SAH, followed by lumbar CSF from
patients with amyotrophic lateral sclerosis, space–occupying lesions and disc
prolapses. The comparison of ventricular with lumbar CSF has to be done
with caution as nothing is known about the NfH concentration across the
CSF compartment. Interestingly, the distribution for CSF NfHSMI35 was
bimodal in GBS patients. This finding warrants further investigation.
There was no association between the pattern of OCB and either CSF
NfHSMI35 or NfL levels. Although similar mean CSF NfHSMI35 levels were
found for OCB -/- and OCB +/- patients a trend for higher CSF NfL levels
was observed in OCB +/- patients.
Phosphorylation is responsible for modification of epitopes recognised
by different antibodies on NfH. Because phosphorylation also modifies the
function of the protein and contributes to Nf cross–linking and axonal di-
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ameter, it is likely that the CSF contains a range of NfH phosphoforms.
The rationale for choosing SMI35 antibody as the capture antibody was
that it gave the best signal–to–noise ratio. In addition SMI35 recognises
both phosphorylated and non–phosphorylated epitopes on the NfH protein.
Importantly SMI35 stained for early neuro–axonal damage in histological
studies.124,377,378 This is relevant as the NfHSMI35 ELISA might be useful
for detecting early axonal injury in neurological disorders.
Chapter 5
Development of a GFAP
ELISA
5.1 Background
Glial fibrillary acidic protein (GFAP) is a cytoskeletal astrocytic protein
which has been found to be elevated in neurological disorders (Chapter 2.2).
In addition CSF GFAP levels have been associated with disability in MS
(Chapter 1.3). Currently there is no commercial ELISA available for the
measurement of GFAP. All previously developed assays used antibodies pro-
duced in–house6,7, 99,297,332 or resource–demanding technology.276 Although
the in–house developed antibodies are supposed to be of high specificity and
high avidity, confirmation of the results by independent groups is difficult.
This part of the study was aimed at developing a sensitive ELISA for the
detection of GFAP in the CSF based on commercially available antisera.
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5.2 Materials and methods
5.2.1 Antibodies
Capture (first) antibody
Mouse monoclonal IgG1 anti–GFAP antibodies (SMI) were purchased from
Sternberger Monoclonals (Sternberger Monoclonals Incorporated, 10 Bur-
wood Court, Utherville, MD 21093).
GFAPSMI21 SMI21 is a mouse monoclonal IgG1 raised against human brain mi-
crovessels. No cross–reactivity with other intermediate filaments or
tissues was observed. Astrocytes, Bergmann glia in human, monkeys
and dogs were GFAPSMI21 positive. In contrast rat, rabbit and mouse
GFAP was not recognised by SMI21.
GFAPSMI22 SMI22 is the mouse monoclonal cocktail of all three Bigner–Eng clones
(Mab1B4, MAb2E1 and Mab4A11) GFAP IgG2b. SMI22 reacted with
astrocytes and Bergmann glia in human, monkey and dog. The Bigner–
Eng clones are specific for astrocytes, astrocytic processes and Bergmann
glia in human, sheep, cow, dog, pig, rat, guinea pig, rat, mouse and
chicken. There was no cross–reactivity with other intermediate fila-
ments on tissue sections or Western blots.
GFAPSMI24 SMI24 is a mouse monoclonal IgG2b derived from the original Bigner–
Eng clone MAb2E1.264,302,413 SMI24 stains only for some human as-
trocytes, but the significance of this pattern has not yet been related
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to a specific pathology.
GFAPSMI26 SMI26 is a cocktail of SMI21 IgG1 and SMI24 IgG2b. SMI26 provided
the most abundant and intensive staining for astrocytes in human
brain tissue sections.
Detecting (second) antibody
Horseradish peroxidase conjugated swine polyclonal anti–rabbit Ig was pur-
chased from Dako (Copenhagen, Denmark). SDS–PAGE and immunoblot-
ting demonstrated that this antibody reacted primarily against rabbit IgG,
with no reactivity against mouse Ig1 or IgG2b (SMI 26).
5.2.2 Working reagents and buffers
All working reagents and buffers were purchased, prepared and stored as
outlined for the neurofilament ELISA (section 4.2.2 on page 81).
5.2.3 Standards
Bovine GFAP (41 kDa), was obtained from Affiniti Research Products, Ex-
eter. SDS–PAGE and immunoblotting showed six equidistant bands be-
tween 39 and 50 kDa. A range of standards from 0 to 200 pg/mL were pre-
pared by diluting human GFAP in barbitone buffer containing 0.1% serum
albumin, 6 mM EDTA and stored in aliquots at -20◦C.
Recovery and precision
Pooled CSF samples spiked with GFAP were used to calculate the within-
and between-batch precision and recovery. The within–batch precision is
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expressed as CV %, and was calculated from the mean and SD of at least 20
replicate analyses of pooled CSF spiked with GFAP, performed on a single
microtitre plate.
The between–batch precision, expressed as CV % was calculated from
the mean and SD from at least 20 replicates of pooled CSF spiked with
GFAP.
The recovery of GFAP was obtained by measuring GFAP in pooled CSF
before and after the addition of a known amount of GFAP. At least 20
replicates of unspiked and spiked pooled CSF were measured.
5.2.4 CSF samples and reference population
CSF samples from 348 neurological patients undergoing a routine diagnostic
lumbar puncture were obtained in order to define the upper reference limit.
The selection was randomised from the department’s sample library in order
to obtain a heterogeneous population. The CSF samples were centrifuged
on receipt and stored at 4◦C. Analysis was performed within 1 week.
After determination of the upper reference limit five well–defined pa-
tient cohorts were studied: 68 patients with dementia (DEM), 11 patients
with traumatic brain injury (TBI), 5 patients with subarachnoid hemorrhage
(SAH), 11 children with hydrocephalus (HC) and 29 patients with miscella-
neous disorders of the peripheral nervous system (PNS). CSF samples from
these groups were stored at -20◦C until analysis.
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5.2.5 Analytical procedure
The microtitre plates were coated overnight with the capturing antibody
diluted 1:1000 in 0.05 M carbonate buffer, 100 µL, pH 9.5. The plate was
washed with barbitone buffer containing 0.1% BSA and 0.05% Tween 20.
Fifty µL of barbitone buffer, 6 mM EDTA and 0.1% BSA were added as
sample diluent to each well. Fifty µL of standard, control or CSF sample
were then added in duplicates to the plate. The plate was incubated at
room temperature (RT) for 1 h. After washing, 100 µL of HRP labelled cow
anti GFAP diluted 1:1000 in barbitone buffer were added to each well and
the plate was incubated for 1 h at RT. After a final wash 100 µL of TMB
substrate was added. The plate was incubated for 30 to 40 minutes at RT
in the dark, the reaction was stopped by adding 50 µL 1 M HCl and the
absorbance was read at 450 nm with 750 nm as the reference wavelength on
a Wallac Victor 2.
5.2.6 Statistical evaluation
Data were managed and analysed as described (Chapter 7, page 151).
5.3 Results
5.3.1 GFAP epitopes
Standard curves The standard curves determined for the GFAP captur-
ing antibodies were expressed as the percentage optical density (OD) for
each calibrant. This normalised procedure corrects for differences arising
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Figure 5.1: Standard curve for (A) GFAPSMI21 , the quadratic regression
and the 95% confidence interval curves are shown.
from variations in incubation times, temperature and colour reagent. All
standard curves were run on the same plate to minimise the inter-assay
variation. The concentration for all antibodies was 1:1000, including the
second and third antibody. The standard curves for the antibodies bind-
ing to different epitopes on GFAP (GFAPSMI21 , GFAPSMI22 , GFAPSMI24 ,
GFAPSMI26 ) are shown in Figure 5.2 to 5.4.
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Figure 5.2: Standard curve for GFAPSMI22 . The regression line and 95%
confidence interval curves are shown.
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Figure 5.3: Standard curve for GFAPSMI24 . The regression line and 95%
confidence interval curves are shown.
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Figure 5.4: Standard curve for GFAPSMI26 . The regression line and 95%
confidence interval curves are shown.
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Detection limit and analytical range The detection limit was deter-
mined by the signal–to–noise–ratio of the lowest calibrant to the blank (Fig-
ure 5.5). An estimate for the analytical range for a particular antibody
combination is the ratio of the highest calibrant to the noise (Figure 5.6).
The signal–to–noise–ratio for SMI26 was about 3–fold and the analytical
range 1.2 to 50–fold higher than for the other antibody combinations. On
the basis of these results SMI26 was selected as the capture antibody for the
GFAP ELISA.
5.3.2 Reproducibility of the standard curve
Reproducibility of the standard curve was determined by expressing the
optical density (OD) obtained for each calibrant as a percentage of the
optical density of the top standard. This normalised procedure corrects
for differences arising from variations in incubation times, temperature and
colour reagent. Eight consecutive standard curves were normalised and the
results averaged. The resulting linear regression is shown in Figure 5.7.
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Figure 5.5: The detection limit of the GFAP assay as determined by the
signal–to–noise ratio (OD of the lowest standard divided by the blank OD)
for different capture antibodies. A signal–to–noise ratio of greater than 1
(reference line) is required in order to obtain a readable signal.
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Figure 5.6: The analytical range as determined by the signal–to–noise–ratio
for the SMI antibodies binding to different epitopes on GFAP.
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Figure 5.7: Standard–curve for the GFAPSMI26 assay. Reproducibility of
eight consecutive normalised calibration lines. The graph shows the mean
values (dots) ± standard deviation (bars), linear regression line, 5% and
95% confidence interval curves.
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5.3.3 Precision
CSF samples (neat and spiked with GFAP) were used to calculate the within-
and between-batch precision and recovery. Within–batch and between–
patch precision was determined for high and low concentrations. The within–
batch precision was 4.8% for 200 pg/mL, 7.2% for 40 pg/mL. The between–
batch precision was 10.2% for 130 pg/mL. The sensitivity was 10 pg/mL.
The recovery of GFAPSMI26 (50 pg/mL added) in CSF was 92% for pool 1
(130 pg/mL) and 96% for pool 2 (92 pg/mL), averaging to 94%.
5.3.4 Parallelism
Parallelism between calibrant and CSF was studied by quantifying recip-
rocal dilutions. Three CSF samples from SAH patients and three different
pools of HPLC–purified GFAP diluted in sample buffer were used. The OD
was normalised to the highest value of the series. The parallel relation-
ship was shown and suggested the absence of endogenous binding between
CSF–GFAPSMI26 and other CSF substrates (Figure 5.8).
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Figure 5.8: Parallelism between calibrant (dots) and CSF (circles), linear
regression.
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5.3.5 Stability of CSF samples
Stability was tested at room temperature (RT), 4◦C and -70◦C. CSF sam-
ples spiked with GFAPSMI26 were frozen in duplicates at -70◦C, thawed on
subsequent days and stored at 4◦C and RT (Figure 5.9 A). Linear regres-
sion analysis of the 7–day observation period demonstrated no significant
decrease in GFAPSMI26 at -70◦C and 4◦C. At RT there was however a sig-
nificant (p<0.05) decrease in the measured GFAPSMI26 concentration.
No problems were found with stability of antibodies. To minimise any
problems with cumulative contamination the antibodies were stored in 100
µL aliquots and each aliquot was used within 4 weeks. All buffers where
used within 1 week and stored at 4◦C.
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Figure 5.9: Stability profile of GFAPSMI26 in CSF at 4◦C (continuous line)
and at room temperature (dotted line) over 7 days.
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5.3.6 Reference population
The top 10% of the 348 analysed samples were removed in order to ob-
tain a representative reference population as discussed for the neurofilament
ELISA (section 4.3.9 on page 111).
The mean age of the reference population was 44.7±15.9 years, with a
median of 43.5 (IQR 33-56) years. The date of birth was not provided for 19
patients. There was no correlation between the age and CSF GFAPSMI26 levels
(R=0.004, p=0.93). Fifty-nine percent (182/313) were female and 39%
(122/3131) male and in 9 (3%) patients no gender was stated. There was
no significant difference of CSF GFAPSMI26 levels between the 2 genders
(Z=-0.59, p=0.27).
The distribution of the reference population for CSF GFAPSMI26 is shown
in Figure 5.10. The upper–reference value was calculated as shown for the
NfHSMI35 assay (page 111). The 97.5 percentile corresponded to 6 pg/mL
(Figure 5.10, dotted reference line).
5.3.7 Neurological disorders
The CSF levels of the patients with subarachnoid hemorrhage (SAH), trau-
matic brain injury (TBI), dementia (DEM), hydrocephalus (HC) and mis-
cellaneous disorders of the peripheral nervous system (PNS) are shown in
Figure 5.11.
The CSF GFAPSMI26 levels differed significantly between the groups
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Figure 5.10: Frequency histogram (bars) for the reference population. The
cut–off for the upper reference limit of 6 pg/mL (dotted vertical line) is
shown.
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(F(4,120)=9.88, p<0.001). The post–hoc analysis revealed that this was due
to the higher values in SAH patients when compared to DEM (p<0.001),
HC (p<0.001) and PNS (p<0.001). The levels of significance in the post–
hoc analysis for TBI patients mirrored those of the SAH group. There was
no significant difference of the GFAPSMI26 levels between SAH and TBI pa-
tients.
Table 5.1: CSF GFAPSMI26 levels (mean±SD, range) in patients in patients
with subarachnoid hemorrhage (SAH), traumatic brain injury (TBI), dementia
(DEM), hydrocephalus (HC) and disorders of the peripheral nervous system
(PNS). The number of patients with levels above the upper reference limit of
6 pg/mL is shown.
Levels of significance comparing group means (? p<0.001) or proportions (†
p<0.001) with the PNS group are indicated.
CSF GFAP [pg/mL]+SD Range Above reference
SAH 18950±16078 ? 1550–40630 100% (5/5) †
TBI 16678±15022 ? 515–43730 100% (11/11) †
DEM 1374±11098 4–91540 94% (64/68) †
HC 1197±1226 0–2970 83% (10/12) †
PNS 1.4±1.9 0–6 0% (0/29)
The one outlier in the group of dementia patients had a GFAPSMI26 level
of about 100 ng/mL (91540 pg/mL), a S100B level of 122000 pg/mL, was
positive for 14-3-3 on the Western blot and had proved Creutzfeldt–Jakob
disease on autopsy.
According to the previously defined reference limit of 6 pg/mL, 5/5 of
the SAH, 11/11 of the TBI, 61/68 of the DEM, 10/12 of the HC and 0/29
of the PNS patients had CSF GFAPSMI26 levels above the upper reference
limit. A significantly higher proportion of patients with SAH, TBI or DEM
had CSF GFAPSMI26 levels above the reference limit when compared to the
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numbers of PNS patients (p<0.001) (Table 5.1).
5.4 Discussion
The sandwich ELISA presented here is simple and based entirely on com-
mercially available antibodies. The sensitivity of the assay is 5 pg/mL, the
upper reference limit 6 pg/mL and the standard curve ranges from 0 to 200
pg/mL.
A previously described 4 to 5 layer assay6 used in–house developed mon-
oclonal antibodies8 and a standard curve derived from human brain ho-
mogenate.5,6 The GFAP range in the CSF of the control group was 2–14
ng/mL. The CSF GFAP levels in MS patients with acute relapse (10–21) or
progressive disease (10–11) where not significantly different from the control
group. The authors found significantly higher CSF GFAP levels in children
with normal pressure hydrocephalus, which has been confirmed in a subse-
quent study7 and is consistent with the results of the present study. Their
assay has also been used successfully in determining GFAP levels in amni-
otic fluid,6 but unfortunately we could not find any further studies using
this assay. This assay is similar to two radio–immune assays and had a
sensitivity of 0.5–1 ng/mL.6,99,297
A sensitivity of 16 pg/mL was achieved by using a three–layer sandwich
ELISA based on in–house produced hen and rabbit anti–GFAP antibod-
ies.332 These authors used HPLC purified GFAP333 for their standards. The
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Figure 5.11: CSF GFAPSMI26 (pg/mL; scale = log10) in patients with sub-
arachnoid hemorrhage (SAH), dementia (DEM), hydrocephalus (HC) and
a miscellaneous group of patients with disorders of the peripheral nervous
system (PNS). The horizontal reference line (dotted) represents the upper
reference limit of 6 pg/mL.
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assay was modified and a linear range for the standard–curve was obtained
for 32–4000 pg/mL337 with the sensitivity reported to be below 32 pg/mL.
Using this method the authors were able to show elevated CSF GFAP levels
in multiple sclerosis,336 encephalopathy92 and neuropsychiatric disorders.3
This assay requires two overnight incubation steps.
So far the independent confirmation of results derived by this group has
been hampered by the non–availability of their in–house developed antibod-
ies. The present assay uses well–characterised and commercially available
antibodies. In particular the capture antibody cocktail contains the orig-
inal and well–described three IgG2b Bigner–Eng clones MA1B4, MAb2E1,
MAb4A11264,302,413 and the IgG1 SMI 22. No cross–reactivity with other
intermediate filaments has been observed for the SMI26 antibody cocktail.
We and others6,99,297 have not been able to demonstrate a correlation
between CSF GFAP and age as described twice by one group.332,337 However
this group used an unique set of CSF samples from 25 healthy controls337 and
CSF GFAP levels started to rise at 48 years of age. It is of note that the other
reported correlation of CSF GFAP and age in children332 is due to 2 outliers
in a rather small sample size (n=10) and no such correlation was observed
in the larger group of children with autism (n=47). Thus the age effect
might only become important after about the age of 50. Further studies are
needed to clarify the influence of age on CSF GFAP levels. In particular one
would need to take care to avoid bias by age of onset of disease, speed of
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progression or severity of the underlying pathological process. This would
have implications for the interpretation of CSF GFAP levels in patients with
dementia.
Comparing the results for CSF GFAP levels in patients with dementia
one would need to define an upper reference limit for Rosengren’s population.
The highest value for CSF GFAP of the healthy control group of Rosengren
was 1200 pg/mL (see Figure 4 in337). The 97.5% quarantile corresponds to
about 800 pg/mL. Using 800 pg/mL as upper reference limit, 13/16 (81%)
of Rosengren’s dementia patients had pathologically elevated CSF GFAP
levels (see Figure 5 in337), which is a significantly higher proportion than
in the control group (p<0.001, post–hoc analysis, Fisher’s exact test). This
post–hoc analysis is consistent with the finding that CSF GFAPSMI26 levels
were elevated in a significant number of dementia patients (94%). The
slightly higher percentage revealed in the present study might be due to a
patient selection bias because the National Hospital of Neurology and Neu-
rosurgery is a tertiary referral centre. In a subsequent analysis the same
group subsequently reported significantly elevated CSF GFAP levels in pa-
tients with vascular dementia, senile dementia of the Alzheimer type and
’pure’ Alzheimer’s disease.416
The striking elevation of CSF GFAPSMI26 levels in patients with TBI and
SAH has to our knowledge not previously been reported. For TBI patients
high CSF GFAPSMI26 levels are likely to be related to direct parenchymal
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destruction. It is however difficult to explain why CSF GFAP should be 4
orders of magnitude above the upper reference limit. One could speculate
on a direct toxic effect of the blood released into the subarachnoid space
onto a large surface of astrocytes. On the basis that the astrocyte maintains
brain homeostasis, SAH astrocytotoxity could have a devastating impact
on patient survival. We have previously shown that rise in serum S100B,
another astrocytic marker was related to rise in ICP and mortality.308 In
this context CSF GFAPSMI26 could emerge as a second “astrocytic CSF
marker” alongside S100B and contributes to increase the diagnostic speci-
ficity in conditions where the release of S100B from extra cranial sources such
as adipose tissue, testis and skin149,268,390 are problematic.86,164 Certainly
this new finding of high CSF GFAPSMI26 levels in SAH warrants further
investigation.
In summary the present assay is reliable, reproducible and based entirely
on commercially available antibodies. Such an assay is needed in order to
clarify the issues discussed and advance the understanding of astrogliosis in
neurological disorders.
Chapter 6
Established methods
6.1 S100B ELISA
indexELISA S100B was measured in the CSF as previously described129:
Briefly, 96–well microtitre plates were coated with 200 µL 0.05 M carbonate
buffer containing monoclonal anti S100B (Affiniti Research Products, Ex-
eter, UK). The plates were washed with 0.67 M barbitone buffer containing
calcium lactate, 0.1% BSA and 0.05% tween and then blocked with 2% BSA
and washed again. Diluted serum (1:1) in 0.67 M barbitone buffer containing
1mM calcium lactate was added in duplicate. After incubation and wash-
ing HRP–conjugated polyclonal anti S100B (Dako, Copenhagen, Denmark)
was used as detecting antibody. The colour reaction was stopped with 1 M
hydrochloric acid and the absorbances read. The antigen concentration was
calculated from an internal standard curve ranging from 0 to 2.5 ng/mL.
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6.2 Ferritin ELISA
CSF ferritin was quantified using a previously described in–house ELISA
technique.185 The standards ranged from 0-20 µg/L ferritin and were pre-
pared by diluting Lyphocheck Control serum Level 1 (Bio–Rad, Hemel
Hempstead) in 0.85% W/V sodium chloride (saline) containing 0.1% BSA
and 0.01% w/v sodium azide.
96–well microtitre plates were coated overnight at 4◦C with 100 µL 0.05
M carbonate buffer (pH 9.5) containing 50 µg of polyclonal rabbit anti–
ferritin serum (Dako Ltd., No A133). The plates were blocked with 250
µL 0.85% w/v sodium chloride (saline) containing 1% BSA and 1% gela-
tine for 1 hour. After washing with 250 µL saline containing 0.1% BSA,
0.1% gelatine and 0.1% tween 100µL of undiluted CSF was added in du-
plicate. After incubation and washing HRP–conjugated polyclonal rabbit
anti–human ferritin (DAKO) was used as detecting antibody. The colour
reaction with 100µL of o–phenylenediamine in 0.02 M acetate buffer (pH
5.1) was stopped with 50µL of 1 M hydrochloric acid. The absorbances
were read at 492 nm against a reference wavelength of 405 nm. The antigen
concentration was calculated from the internal standard curve.
6.3 Albumin rockets
CSF and serum albumin were quantified by a standard Laurell “rocket”
electro immuno–assay. Briefly, 300 µL of goat anti–human albumin serum
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(Incstar Ltd., Wolkingham; No 81900) were added to 30 mL molten 1.2%
w/v medium electroendosmosis agarose (Flowgen Instruments Ltd., Sitting-
bourne; No 50013) in pH 8.6 barbitone electrophoresis buffer170 containing
3% w/v polyethylene glycol 600. The mixture was then cast on 203 mm wide
GelBond (Flowgen Instruments Ltd., Sittingbourne, product code 53760)
using a casting frame prepared from two glass plates, 195 mm × 195 mm ×
3 mm, separated by three thicknesses of Dymo tape and sealed around three
edges with Scotch electrical tape. The glass plates were partially submerged
in a water bath at 65◦C and the agarose solution was added using a Pasteur
pipette. After cooling to room temperature the gel was allowed to set at 4◦C
for a further 2 h before being used. The casting assembly was dismantled
and 80 wells punched in the gel in five ranks of 16 wells. Each well was 2 mm
in diameter and separated from its neighbour in the rank by 10 mm (centre
to centre). Ranks were separated by 30 mm. Wells in adjacent ranks were
staggered so that the rocket peak from one well would lie between two wells
of the rank in front. The gel plugs were removed by suction. Standards
were prepared from SPS01 (Protein Reference Units, Central Antiserum
Purchasing Unit, Sheffield) diluted to values of 50, 100, 200, 300, 400, 500
mg/L. Samples of 2 µL undiluted CSF (unless the total protein was greater
than 1 g/L in which case the CSF was diluted) or serum diluted 1:200 in
0.85% w/v sodium chloride (saline) were added to each well. Electrophore-
sis was carried out overnight at 150 V with cooling. After electrophoresis
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the gel was pressed, washed for 30 min in saline, pressed again, then dried
and stained using Coomassie Brilliant Blue. Albumin concentrations were
calculated from the internal standard curve.
6.4 Total protein
Total protein was measured by a modification of the Lowry method234 us-
ing the Bio–Rad DC Protein assay (Bio–Rad, Hemel Hempstead). Briefly,
standards were prepared from BSA (Sigma) diluted into values of 225, 450,
900, 1250, 1500 mg/mL in saline. Five µL of undiluted CSF or diluted
serum (1:100 in saline) were pipetted in duplicates into a 96–well microtitre
plate. Twenty–five µL of an alkaline copper tartate solution (reagent A)
were added into each well, the plate was shaken and 200 µL of a dilute folin
reagent (reagent B) were added. The plate was incubated for 15 minutes on
a plate shaker and absorbances were read at 750 nm.
6.5 Oligoclonal bands
CSF and serum immunoglobulins were separated using standard and con-
sented methods.16 Briefly, on glycerol (Sigma, No 80261), sorbitol (Sigma,
No S-0900) agarose IEF (Pharmacia, No 7-0468-01) gels. Gels were pre-
pared, cast and dismantled as described above. A sample application foil
with 20 punched holes (10mm centre to centre distance) were layered 3 cm
from the anodic edge of the gel to ensure equilined sample application. 3
µL of paired and time matched CSF (undiluted) and serum (diluted 1:400
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in water) samples were added to each application slot. A strip of Postlip
paper soaked in 0.05M sulphuric acid was placed on the outermost edge of
the anodic and a Postlip paper soaked in 1M sodium hydroxide on the ca-
thodic side of the gel. Isoelectric focusing was carried out at 1250 V, 150 mA
and 20 W for 1100 volt–hours. At 850 volt–hours the run was stopped and
IgG was passively plotted onto nitrocellulose for 30 minutes. Nitrocellulose
was blocked with 2% milk in saline for 1 hour, washed with distilled water
and incubated with polyclonal rabbit anti–goat immunoglobulin antibody
(1:1000 in saline) for 1 hour. After another washing step, amino–ethyl car-
bazol was added as colour developer. After a final wash the nitrocellulose
membrane was dried.
IgG patterns were stratified according into 7 groups. Samples without
IgG in CSF/serum were called OCB -/-, samples with equal number of
IgG bands in CSF/serum were called OCB +/+, samples with IgG bands
present only in the CSF were called OCB +/-, samples with slightly more
IgG bands in the CSF than in the serum were called OCB ++/+, samples
with considerably more IgG bands in the CSF than in the serum were called
OCB +++/+, samples with one single clone of IgG (monoclonal) in the
CSF but not in the serum were called OCB m/- and samples with the same
single clone of IgG in serum and CSF were labelled OCB m/m.
Chapter 7
Data management and
analysis
7.1 Data management
The amount of raw data of the clinical studies required a systematic ap-
proach to establish data integrity. The SAS system provides powerful data
management engines. Of particular importance is access to all major databases
such as Microsoft ACCESS, SQL, Excel, DBase, etc. Information on patients
was stored on the Sunquest system of UCLH and in the ACCESS database
of the Department of Neuroimmunology. Experimental results were stored
on Excel spread–sheets. These datasets were combined and stored within
SAS because SAS datasets are optimised to enhance database performance
and provide a close link to the statistical packages.
According to the MRC guidelines for data handling in the UK all patient
data must be stored anonymously. Therefore a unique code was assigned
to each patient. The patient names, hospital numbers and contact details
(if available) were stored locally. Access to confidential information such as
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names, addresses, etc. was protected. For collaborative studies the confiden-
tial database was stored locally in each centre. Frequent exchange of data
was necessary and performed with coded protocols on the internet. Only
datasets where anonymity of the patient was guaranteed by the unique iden-
tifier were exchanged. Statistical analysis was performed on virtual datasets
merged directly prior to analysis.
7.2 Statistical analysis
All statistical analyses and graphs were done using SAS software (SAS ver-
sion 6.12 and version 8.2, SAS Institute, Inc., Cary, North Carolina, USA).65
Descriptive statistics Descriptive statistics were performed using the
proc univariate procedure. Normal distribution was tested using the
Shapiro–Wilk test for n<2000.
All mean values were given ± the standard deviation (SD) or the stan-
dard error if n<10. Skewed data were presented as mean and 25–75% in-
terquartile range (IQR) for n>10 and the 0–100% total range when n was
smaller than 10. The presentation in tables then followed the notation:
median (range), number. The box (median and 25%–75% cumulative fre-
quency) and whisker (1%–100% cumulative frequency) were shown in the
graphs. Dots were plotted adjacent to each other (jittered) if 2 or more
observations showed the same value.
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Correlation and regression The strength of the linear relationship be-
tween 2 continuous variables was evaluated using the Pearson correlation
coefficient (α=0.05) for normally distributed and the Spearman rank cor-
relation (α=0.05) for non–Gaussian distributed observations. For multiple
comparisons a correlation matrix was calculated using the proc corr proce-
dure with the appropriate correlation coefficient. Significance of the correla-
tions was tested by analysing the scatter plot for outliers and ceiling effects.
Linear regression analysis was performed using the least–squares method
(proc reg). The 95% confidence interval for the slope was calculated by
taking approximately two standard errors above and below the mean if n
>30. When n was < 30 the number of standard errors above and below the
mean were taken from a t–table. Significance was tested by analysing the
residuals. If the root MSE (square root of the error variance or standard
deviation of the residuals) was high or the distribution of the residuals was
dubious the results were rejected.
Partial correlations were performed when a group difference could have
been biased by significant correlations of the independent variable with age
(age at onset of disease, etc.) or significant gender differences. This was
done by applying the partial option to the proc corr procedure.
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T-tests and nonparametric comparisons Means of normally distributed,
independent variables with similar variance were compared using the t–test
(proc ttest). The one–tailed t–test was applied if the alternative hypoth-
esis stated that one specific mean would be greater. If the alternative hy-
pothesis was that the two means were different, a two–tailed t–test was
performed. For dependent variables the paired t–test was used via the proc
means procedure with the options n mean stderr t prt.
For non–normally distributed, independent variables the two-sample ex-
act Wilcoxon rank-sum test was used (proc npar1way with the option
wilcoxon).
For multiple comparisons the probability of at least one significant dif-
ference by chance alone is 0.64 for an α of 0.05 and all analyses were done
by ANOVA.
Analysis of Variance For more than 2 groups and multiple comparisons
ANOVA (proc anova) was used if the groups were independent, the sam-
pling distribution were Gaussian and the groups were derived from popula-
tions with equal variances (homogeneity). If either of these assumptions was
not met or if the populations were not homogeneous and were unbalanced
(different number of subjects per group), the unbalanced two-way ANOVA
(general linear model) was applied using the proc glm procedure.
Post–hoc or multiple comparison tests were done using Duncan’s mul-
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tiple range test for ANOVA and the least–square adjusted means for main
effects for the general linear model (options lsmeans pdiff).
Categorical data analysis Proportions were compared by the χ2 test
using the proc freq procedure with the option / chisq in the table state-
ment. If the number per cell was less than 5, Fisher’s exact test was used
with α=0.05 (option / chisq FISHER). The test was one–tailed if the alter-
native hypothesis was rational and clear before the analysis. A two–tailed
test was performed if the alternative hypothesis stated only that the two
groups might be different.
Trend analysis was done using the Mantel–Haenszel (M-Hχ2) test (option
/ chisq all).
Odds ratios were calculated by applying the Cochran–Mantel–Haenszel
option / chisq CMH. The Mantel–Haenszel value and the 95% CI were
given.
Part III
Results
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Chapter 8
Experimental autoimmune
encephalomyelitis
8.1 Background
Experimental allergic encephalomyelitis (EAE) is a well established model of
a CNS autoimmune demyelinating disease. Although possibly different from
multiple sclerosis (MS) in aetiology, the underlying neurodegenerative pro-
cesses that occur in EAE allow for some comparisons with the pathological
changes that are observed in MS.
The principal advantage of studying brain–specific proteins (BSP) in
CNS tissue from mice induced with EAE is that this tissue can be snap–
frozen immediately after sacrifice of the animal. Therefore confounding vari-
ables such as variability in the post–mortem time and auto–proteolysis are
better controlled than for human post–mortem tissue.
The model chosen for this study was the EAE in ABH mice .28 In this
model the spinal cord is the primary site of demyelination. The animal
presents with clinical relapses and chronic disease progression (Figure 8.1).
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Figure 8.1: Disease progression in 11 CREAE animals followed up for 120
days with 28 relapses. The arrow indicates the time when the spinal cord
sample was taken for this study.
The chronic phase is of particular interest for understanding the relapse–
independent relationship between cumulative axonal damage and loss of
function. In addition the quantitative relations between axonal loss, glial
activation and gliosis can be evaluated. As outlined in sections 2.2–2.3 (page
59 ff.) astrocytic activation might be a double–edged sword, beneficial if
moderate, but preventing remyelination and axonal sprouting if astrocytic
transformation occurs and a gliotic scar develops. The severity of spinal
cord axonal loss and astrogliosis makes mice with chronic relapsing EAE
(CREAE)28 an ideal model to study these markers.
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Failure to halt MS disease progression with immunomodulating agents
has demonstrated that neurodegeneration is an important pathogenic com-
ponent of MS.41,438 This provides the impetus for designing and assessing
treatment paradigms in animal models. Axonal loss correlates with per-
manent neurological disability in CREAE438 and is typically assessed us-
ing time–consuming immunohistology.41,438 Therefore a simple quantitative
surrogate would be advantageous. This study examines the potential of the
ELISA–based methods presented in chapters 4–6.4 (page 73 ff.) to assess
the neurodegeneration that occurs in CREAE.
8.2 Methods
Animals Adult Biozzi ABH mice (6–8 weeks old) were supplied by the De-
partment of Neuroinflammation, University College London (David Baker,
Gareth Pryce). The mice were housed in a light- and temperature–controlled
room and matched for age in the experiment.28
Induction or CREAE Syngeneic spinal cord homogenate (1 mg lyophilised
spinal cord) was diluted in 0.15 mL PBS and Freund’s incomplete adjuvant
(Difco Laboratories) containing 60 µg killed Mycobacteria (Mycobacterium
tuberculosis H37Ra and M. butyricum (8:1)). Two subcutaneous inocula-
tions were given.28 Animals were scored clinically on a scale ranging from 0
to 6, where 0 indicated a normal animal, 1 a limp tail, 2 loss of the inverted
righting reflex, 3 partial hind limb paralysis, 4 complete hindlimb paralysis,
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5 moribund and 6 death.28 After 60–80 days post inoculation the chronic
phase of the disease had been reached (arrow in Figure 8.1) and the animals
were sacrificed by CO−2 intoxication.
Preparation of spinal cord homogenate Immediately after death in-
cisions were made in the spinal column at the level of the the lumbar and
cervical regions. A needle was inserted into the lumbar vertebral column and
the spinal cord ejected into an Eppendorf tube by a pressurised injection of
saline. The spinal cord which is the site of pathology28 was snap–frozen and
stored at -70◦C until further analysis.
Cytochemistry Frozen tissue was used for immunocytochemistry as de-
scribed using polyclonal rabbit anti–cow GFAP IgG (DAKO, Denmark) or
polyclonal rabbit anti–bovine NfH IgG (Sigma, UK) and FITC labelled
swine anti–rabbit IgG (Dako).28,29 Photographs of the fluorescin images
were digitally transformed into black–and–white slides for better visualisa-
tion.
Protein extraction The spinal cord was suspended in sample buffer 1:5
v/w containing a protease inhibitor cocktail (Sigma, No P 8340). Samples
were homogenised on ice by sonication and triturated 3 times through 19
and 21 gauge needles. In order to separate myelin protein, di–iso–propyl
ether (1:5,000) was added. After extensive mixing the sample was spun at
CHAPTER 8. CREAE 161
20,000 g. The supernatant was covered by a myelin layer. A needle was
put through the myelin layer and the supernatant drawn up into a 1 mL
syringe. The supernatant was aliquoted into triplicates of 1:1,1000, 1:5,000,
1:10,000 and 1:100,000 dilutions. The aliquots were stored at -70◦C until
further analysis.
Assays S100B (page 146), ferritin (page 147), GFAP (page 121), NfHSMI35 (page
73) and total protein (page 149) were measured as described.
Statistical analysis Data were managed and analysed as described (Chap-
ter 7, page 151). The median and 0–100% range are shown because of the
non–normal distribution and n< 10. The cutoff for categorical data analysis
was set to the 0% or 100% cumulative frequency of the control group as
appropriate.
8.3 Results
A 3–fold increase of median GFAP levels (13 ng/mg protein) in chronic EAE
animals was observed if compared to control animals (4.5 ng/mg protein,
Fig. 8.2). In addition a more intense immunocytochemical staining was
observed in CREAE mice. The white matter of CREAE animals showed
intense staining for GFAP and widespread astrogliosis. Astrocytes of the
CREAE grey matter were of larger configuration with a greater number of
extending processes (Figure 8.6 A).
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Levels of NfHSMI35 were approximately 3–fold lower in CREAE (21
ng/mg protein) than in control mice (63 ng/mg protein, Fig. 8.3). The
staining for NfH was more intense in the white matter of control animals
(Figure 8.6 B). It is of note that the continuity of axonal projections could
be followed. In CREAE animals NfH staining was less intense, axonal con-
tinuity almost disappeared and many axonal ovoids were observed (Figure
8.6 B).
Ferritin was less then 2–fold lower in CREAE (547 ng/mg protein) com-
pared to CTRL mice (858 ng/mg protein, Fig. 8.5), a median S100B levels
were about 2.6–fold lower in CREAE (786 ng/mg protein) than in CTRL
mice (2080 ng/mg protein, Fig. 8.4).
In order to compare the proportions of abnormal samples, the cut–off
was defined as the 100% cumulative frequency of the control group for GFAP
and as the 0% cumulative frequency for S100B, ferritin and NfHSMI35 . For
statistical analysis, numbers of samples were compared for values for each
group above versus below the defined cut–off (reference lines in Figure 8.2
to 8.5).
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Table 8.1: Control (CTRL) and CREAE ABH mice spinal cord ho-
mogenate. Levels of brain–specific proteins are shown in ng/mg protein.
Median (range).
Protein CTRL CREAE
ng/mg protein mice mice
GFAP 4.5 (1.4–5.2) 13 (5.0–26.4)
S100B 2080 (852–3107) 786 (219–1466)
NfHSMI35 63 (53–84) 21 (9–44)
Ferritin 858 (794–1801) 547 (355–963)
Number 7 8
Seven out of 8 (88%) of CREAE animals had GFAP levels above the
cut–off and by definition none (0%) of the control animals had GFAP levels
above the cut–off (p<0.001). For NfHSMI35 0/8 (0%) of the CREAE and 7/7
(100%) of the control animals had levels above the cut–off (p<0.001). For
ferritin 1/7 (13%) of the CREAE and 7/7 (100%) of the control mice had
levels above the cut–off (p<0.001). For S100B 3/8 (38%) of the CREAE and
0/7 (100%) of the control mice had levels above cut–off, but this did not
reach statistical significance.
As suggested by the inverse pattern shown for GFAP and NfHSMI35 (Figure
8.2) a negative correlation existed between these two proteins (R=-0.54,
p<0.05, Figure 8.7 F). Strong positive correlations (R>0.8) between levels
of NfHSMI35 , S100B and ferritin were found. Figure 8.7 shows the corre-
lations, R–values and the level of significance for each comparison. Impor-
tantly neither S100B nor ferritin correlated with GFAP.
CHAPTER 8. CREAE 164
Figure 8.2: Mice spinal cord tissue homogenates. Scatter and box and
whisker plot for GFAP (ng/mg protein) levels in control (CTRL) and chronic
EAE (CREAE) mice.
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Figure 8.3: Mice spinal cord tissue homogenates. Scatter and box and
whisker plot for NfHSMI35 (ng/mg protein) levels in control (CTRL) and
chronic EAE (CREAE) mice.
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Figure 8.4: Mice spinal cord tissue homogenate. Scatter and box and whisker
plot for S100B (ng/mg protein) levels in control (CTRL) and chronic EAE
(CREAE) mice.
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Figure 8.5: Mice spinal cord tissue homogenate. Scatter and box and whisker
plot for ferritin (ng/mg protein) levels in control (CTRL) and chronic EAE
(CREAE) mice.
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Figure 8.6: Immunocytochemistry on longitudinal fresh frozen spinal cord
sections of 3 control and 3 CREAE animals (x40). (A) GFAP staining for
white and grey matter. More intense staining is observed in the CREAE
spinal cord: in particular, the grey matter astrocytes are larger with more
and longer processes. (B) NfH staining in white matter. Axonal tracts can
be followed in control but not in CREAE animals. The staining in CREAE
animals is less intense and many axonal ovoids are seen.
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(A) (B)
(C) (D)
(E) (F)
Figure 8.7: Correlations of NfHSMI35 (ng/mg protein) with (A) ferritin
(ng/mg protein), (B) S100B (ng/mg protein), (C) GFAP (ng/mg protein)
and in (D) the correlation between Ferritin (ng/mg protein) with S100B
(ng/mg protein). GFAP did not correlate with either (E) Ferritin (ng/mg
protein) or (F) S100B. Control animals are indicated by closed and CREAE
animals by open circles.
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8.4 Discussion
The observation that GFAP levels are 3–fold elevated in the spinal cord of
mice with CREAE when compared to control animals of the same strain is
in keeping with the observation of gliosis being the histological hallmark of
the late disease stages.61 However gliosis is difficult to quantify by immuncy-
tochemical techniques and usually done by counting cells, and the number
and length of extending processes (Figure 8.6 A). The present results would
suggest that GFAP levels could be a “bulk–marker” for astrogliosis of the
CNS. The finding of grey matter astrogliosis and elevated GFAP levels is
in line with the results from human multiple sclerosis post–mortem tissue
(Chapter 9).307
Importantly the NfHSMI35 levels were significantly lower in CREAE an-
imals when compared to controls. The decrease confirms on a quantitative
biochemical basis the immunhistologically observed loss of axons.28,438 In
the light of recent data on axonal loss in MS41,398 and severe axonal loss
in the spinal cord of EAE,438 it is of particular interest that not only the
overall staining intensity for NfH decreased, but also that axonal continu-
ity almost completely disappeared. Counting axons might be particularly
difficult in these situations and would only represent an estimate at site of
section. The measurement of the total NfHSMI35 content is likely to be a
more robust overall estimate of the bulk of remaining axons.
The finding that one astrocytic protein (GFAP) was elevated whilst the
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other (S100B) was decreased could possibly be explained by S100B being a
cytokine86 (Figure 2.3 on page 63) and GFAP a structural protein95 ((Fig-
ure 2.2 on page 61). There was no correlation whatsoever between S100B
and GFAP. In contrast the correlations between S100B and ferritin with
NfHSMI35 were strong (R>0.8). All three of these BSP were decreased in the
spinal cord of CREAE animals. This suggests that at an advanced stage of
the disease astrocytes, microglia and axons appear to be affected in parallel,
i.e. severe axonal loss could be associated with a reduction of the potential
to derive neurotrophic factors from glia which have been transformed into a
gliotic scar.
8.5 Conclusion
Spinal cord tissue from EAE mice provide an important model for studying
brain–specific proteins, particularly because confounding variables such as
the post–mortem interval and autoproteolysis can be better controlled than
in humans. In summary, this study demonstrates that axonal loss and gliosis
can be measured biochemically by quantifying NfHSMI35 and GFAP levels in
the spinal cord tissue of animals with CREAE. These findings support the
concept of CSF BSP as putative surrogate markers and secondary outcome
measures in patients with MS and also be used in animal models.
Chapter 9
Post–mortem study
9.1 Background
General introduction Despite the fact that GFAP was initially discov-
ered in MS plaques96,288 no systematic study of a quantitative profile of BSP
in histologically classified MS 289 lesions has yet been reported. In order to
extend the animal study (Chapter 8) and to prepare for the human CSF
studies (Chapters 10 to 12), this chapter presents BSP levels in human MS
brain tissue. It was hypothesised that BSP levels differed between lesion
types, normal–appearing MS and control brain tissue. The second aim was
to find those proteins which are associated with acute lesions, because they
would be of particular importance in a human CSF study.
Axonal damage and NfH phosphoforms Chapter 2.1 introduced the
general relation of Nf to axonal damage. Since the use of specific mono-
clonal antibodies permits us to detect distinct Nf epitopes, the distribution
of different NfH phosphoforms was studied in axonal pathology and in neu-
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rodegeneration. It is on the background of this research that Sternberger
et al. (1985) proposed the classification of the antibodies recognising these
NfH phosphoforms according to their cellular distribution into 4 groups:
1. Group I antibodies stain cells and structures in the grey matter (GM).
2. Group II antibodies stain for projecting axons, but not for neuronal
perikarya, dendrites or proximal axons.
3. Group III antibodies stain for perikarya, dendrites and proximal axons.
Only little overlap with group II antibodies.
4. Group IV antibodies stain for all structures revealed by group II and
group III antibodies.
These properties of the SMI antibodies have been discussed into detail
in Chapter 4.
Attempts to relate NfH phosphoforms to axonal pathology have revealed
everything but a unifying theory. It appears that there is considerable het-
erogeneity of axonal pathology in different diseases:
MS: In multiple sclerosis (MS) axonal injury has been related to increased
staining by NfHSMI32 [398, Figure 8B, page 282]. NfHSMI32 was par-
ticularly abundant in axonal ovoids which indicate the site of axonal
transection.
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MND: In motor–neuron (MND) disease increased staining for phosphory-
lated NfH (i.e. NfHSMI34 , NfHSMI35 ) has been shown in axons and
the neuronal cell bodies. There is evidence for accumulation of phos-
phorylated NfH in the degenerating motor neurons.282,339 However
Nf dephosphorylation has been reported to precede excitotoxicity in
a spinal cord cell culture model of MND.396,410 Extending their work,
this group has recently reported an increase of staining for NfHSMI32 in
cultured spinal cord neurons after exposure to CSF from patients with
MND.397 Interestingly 3 of the 6 control CSF samples were from pa-
tients with MS, but the individual breakdown of the data has not been
published.397
AD: In Alzheimer’s disease (AD) increased staining for phosphorylated NfH
is evident in the proximal axon and the perikaryon.379,386,387,446 The
staining for phosphorylated NfH has been shown in the proximal axon
elongating from AD plaques.378,386,387 This has been interpreted as ev-
idence for early axonal injury remote (neuron proximal) to the plaque
which exhibits toxic properties .386,387 In addition there is evidence
that NfHSMI32 positive neurons are selectively lost in AD .126,151,280
In cell culture experiments this has been related to selective hypervul-
nerability of these NfHSMI32 positive neurons to kainate.126
A common methodological approach to reveal the phosphorylation state
of Nf was to incubate the tissue with alkaline phosphatase (ALP) .246,246,376–379,386,387,446
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These experiments have been summarised for the non–phosphorylated NfH
SMI epitopes in Table 9.1, and for the phosphorylated NfH epitopes in Ta-
ble 9.2. In order to allow for comparison with experiments using antibodies
distinct from the Sternberger archive, Table 9.3 summarises some represen-
tative studies. For each NfH phosphoform the antibody source and main
effects as observed by immunocytochemistry were summarised with regard
to ALP–treated versus non–treated tissue sections. Because the applied
method of dephosphorylation varied considerably (e.g. incubation times
from 2.5 to 18 hours), the exact protocol is referred to in the footnotes of
Tables 9.1 and 9.3.
The common finding in MS, MND and AD is that NfHSMI32 seems
to indicate vulnerable or pre–damaged axons/neurons.126,151,280,396–398,410
The finding of NfHSMI34 or NfHSMI35 positive axons in AD is either related to
plaques or neurofibrillary tangles (NFT)73,379,386,387,446 or an entire axon–
proximal finding.246,282,339,379,386,387,446
Three NfH phosphoforms∗ emerge from Table 9.1 and 9.2 as the most
interesting to be studied in MS brain tissue: NfHSMI32 , NfHSMI34 and
NfHSMI35 .
∗The labelling of the commercially available SMI antibodies has changed since the
earlier publications. SMI31 was 02–135, SMI33 was 02–40, SMI34 was 07–5, SMI35 was
03–4, SMI36 was 06–68, SMI 37 was 06–32, SMI38 was 10–1. For reasons of consistent
nomenclature (see section 2.1.1 on page 54) the currently used names are shown in Table
9.1 and 9.2.
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Table 9.1: Non–phosphorylated Nf stained in immunocytochemistry by the SMI
clones. Characterisation of the antibody staining pattern in untreated and ALP,
N.D. = not determined, N/A = not available/ data was not shown, GM = grey
matter, WM = white matter, + = positive, - = negative, ↓ less intense after ALP
treatment.
Antibody Model Not treated Treated
NfHSMI32 ctrl thick axons (+)376–378 thick axons (+)†
ctrl neuron/dendrites (++)376–378 neuron/dendrites (++)
NfHSMI32 cell culture vulnerable GABAergic axons (+++) 126 N.D.
NfHSMI32 MS demyelinated axons (+++)398 N/A
NfHSMI32 MS axonal ovoids (+++)398 N/A
NfHSMI32 AD plaques (+)387 plaques +++
NfHSMI32 AD dystrophic neurons (+)386 ++ ‡ §
NfHSMI33 AD data not shown386 N/A
NfHSMI33 MND Spine: ctrl > ALS246 staining ↓↓¶
NfHSMI33 AD GM ++: AD = CTRL73 N.D.
NfHSMI33 AD WM +: AD = CTRL73 N.D.
NfHSMI33 AD pyramidal neurons, no NFT +++: AD <<< CTRL73 N.D.
NfHSMI33 AD pyramidal neurons, with NFT +: AD = CTRL73 N.D.
†Alkaline phosphatase treatment: 43µL calf intestinal alkaline phosphatase (type VII,
Sigma) per mL in 0.1 M Tris–HCl, pH 8.0, 0.01 M phenylmethylsulfonyl fluoride, at 32◦C
for 18 hours.
‡NfH was also detectable in plaques which did not stain for tau/PHF.
§Alkaline phosphatase treatment: 400 µg/mL calf intestinal alkaline phosphatase (type
VII, Sigma) in 0.1 M Tris–HCl, pH 8.0, at 37◦C for 1.5–2 hours.
¶Alkaline phosphatase treatment: 400 µg/mL calf intestinal alkaline phosphatase (type
VII, Sigma) in 0.1 M Tris–HCl,0.01 M phenylmethylsulfonylfluoride, pH 8.0, at 32◦C for
2.5 hours. Similar results were found for pretreatment with trypsin (GIBCO), 400 µg/mL
in 0.05 M Tris–HCL, 0.3 M sodium chloride, 0.02 M CaCl, pH 7.6, 37◦C for 10 minutes.
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Table 9.2: Phosphorylated Nf stained in immunocytochemistry by SMI clones. Char-
acterisation of the antibody staining pattern in untreated and ALP treated samples.
Antibody Model Not treated Treated
NfHSMI31 MND Brain: ctrl > ALS246 staining ↓↓
NfHSMI31 AD GM +: AD = CTRL73 N.D.
NfHSMI31 AD WM +++: AD = CTRL73 N.D.
NfHSMI31 AD pyramidal neurons, no NFT —: AD = CTRL73 N.D.
NfHSMI31 AD pyramidal neurons, with NFT —: AD = CTRL73 N.D.
NfHSMI31 AD data not shown387 N/A
NfHSMI31 AD (+)386 N/A
NfHSMI34 ctrl thick axons (+++)376–378 staining abolished
thin axons (++)376–378 staining abolished
basket cell dendrites (+) staining abolished
NfHSMI34 AD GM ±: AD = CTRL73 N.D.
NfHSMI34 AD WM ±: AD = CTRL73 N.D.
NfHSMI34 AD pyramidal neurons, no NFT —: AD = CTRL73 N.D.
NfHSMI34 AD pyramidal neurons, with NFT +++: AD >>> CTRL73 N.D.
NfHSMI34 MND Spine: ctrl = ALS246 staining ↓↓
NfHSMI34 MND Brain: ctrl >> ALS246 staining ↓↓
NfHSMI35 MND Brain: ALS >>> CTRL246 staining ↓↓
NfHSMI35 ctrl thick axons (++)376–378 staining reduced
NfHSMI35 ctrl thin axons (+++)376–378 staining reduced
NfHSMI35 ctrl neuron/dendrites (+/—) staining abolished
NfHSMI35 AD GM +: AD = CTRL73 N.D.
NfHSMI35 AD WM ++: AD << CTRL73 N.D.
NfHSMI35 AD pyramidal neurons, no NFT —: AD = CTRL73 N.D.
NfHSMI35 AD pyramidal neurons, with NFT ++: AD >> CTRL73 N.D.
NfHSMI310 ALS inconsistent results246 staining ↓↓
AD intraneuronal tangles (++)379,446 staining abolished
NfH–P∗ stroke early neuronal damage ++145 N.D.
∗The antibodies NfHSMI35 , NfHSMI34 , NfHSMI31 were used, but the authors did not
specify in the results section which antibody stained for which condition.
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Table 9.3: Neurofilament antibodies other than then the SMI clones used for immuno-
cytochemistry.
Antibody Model Not treated Treated
NfHN4142 ∗ AD data not shown387 N/A
NfHRT97 17 nerve injury +++: neurons with crushed nerves >>> CTRL neurons281 N.D.
NfHRT97 17 AD Cerebellum +144 staining ↓ †
NfHRT97 17 AD Hippocampus +144 staining ↓↓
NfHRT97 17 AD Hippocampus NFT +144 staining ↓
NfHBF10 17 AD Cerebellum +144 staining ↓
NfHBF10 17 AD Hippocampus +144 staining ↓
NfHBF10 17 AD Hippocampus NFT +144 +
NfHBF147 17 AD Cerebellum +144 staining ↓
NfHBF147 17 AD Hippocampus +144 staining ↓↓
NfHBF147 17 AD Hippocampus NFT —144 staining —
NfH1D285 CJD swollen neurons: +284 — ‡
NfH–P § WHD early damage in LMN ++226 N.D.
NfHmab1 .1 .1 23 AD AD +, CTRL: —389 N.D.
NfHMAB147 17 tractotomy affected neurons: +248 N.D.
Glial axonal interactions There is emerging evidence of overlap between
axonal and glial pathology. The secondary aim of this study was to investi-
gate the relation of axonal and glial markers. This was done within different
types of lesions. On basis of the results on CREAE model (chapter 8) it
was hypothesised that in chronic plaques, correlations similar to that found
for the atrophic CREAE spinal cord should be found, i.e. low NfH and
high GFAP levels. However in acute lesions the relation between glial and
∗Sigma, rabbit polyclonal anti NfH.
†Alkaline phosphatase treatment: 100µL calf intestinal alkaline phosphatase (Supplier
not given) in 0.1 M Tris–HCl, pH 8.0, at 37◦C for 2.5 hours.
‡Alkaline phosphatase treatment: 20 IU/mL alkaline phosphatase (Supplier not given)
in 0.1 M Tris–HCl, 5 mM phenylmethylsulfonyl fluoride pH 8.0, at room temperature for
24 hours.
§The author did not specify which one of the SMI anti–phosphoneurofilament antibod-
ies he used.
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axonal markers might be very different. Trapp et al. (1988) found about
an 660–fold increase of axonal transections in active lesions (11236±2775)
versus normal–appearing white matter (17±28). Because the axonal ovoids
indicates the site of transection it was hypothesised for the present study
that there is at least one NfH phosphoform which should be increased in ac-
tive lesions. In addition one would expect that in active lesions the relation
of NfH phosphoforms to glial markers would be different to the relation in
chronic lesions or NAWM.
9.2 Methods
9.2.1 Brain tissue preparation
Unfixed post–mortem brain tissue was obtained from 12 clinically and histo-
logically definite MS patients and 8 controls. These specimens were kindly
provided by the MS Society Tissue Bank at the Institute of Neurology. All
MS cases where classified as secondary progressive MS with significant dis-
ability (EDSS 9–10).138 The mean age of the MS patients was 48.6 (29–65)
years, with a mean disease duration of 19.5 (7–43) years and a post-mortem
interval of 30.2 (9–52) hours. The mean age in the control group was 56.7
(37–71) years and the mean post-mortem interval 26.9 (1–40) hours. The
brain tissue was histologically classified into normal appearing white matter
(NAWM), acute lesions (AL), subacute lesions (SAL), chronic lesions (CL)
and normal appearing grey matter (NAGM) from MS patients using previ-
ously published criteria.289 Normal control grey (NCGM) and white matter
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Homogenate
Protein extraction
Myelin extraction
block
Tissue−
CNS Immunohistology / Classification
Biochemistry / Quantification
AL
SAL
CL
NAWM
NAGM
GFAP
S100B
Ferritin
NfH−SMI32
NfH−SMI34
NfH−SMI35
total protein
NCGM
NCWM
Figure 9.1: Sample preparation: the top layer of a frozen CNS tissue block
was analysed immunohistologically in order to classify the MS lesion. The
adjacent tissue was homogenised and analysed biochemically.
(NCWM) were obtained from control subjects without neurological diseases.
Adjacent pieces of each type of tissue were excised and homogenised for BSP
analysis as outlined in Figure 9.1.
Immunocytochemistry: For immunocytochemistry, sections were im-
munoperoxidase stained with antibodies directed against GFAP,288 14E for
oligodendrocytes and reactive astrocytes.290 Cryostat sections were fixed
in methanol (-20◦C, 10 min), incubated with primary antibody overnight
(4◦C) and stained using a three-step peroxidase method.
CHAPTER 9. POST–MORTEM STUDY 181
Protein extraction Snap-frozen blocks of brain tissue from MS and con-
trol cases of between 0.5 and 1g wet weight, were cut and re-suspended at
1:5 g/mL in Tris-HCl buffer (100mM Tris, pH 8.1 with 1% Triton X-100).
Samples were homogenised on ice by sonication, triturated 3 times through
19 and 21 gauge needles and spun at 20,000g. In order to separate myelin
protein, di–iso–propyl ether (1:5,000) was added. After extensive mixing
the sample was spun at 20,000 g. The supernatant was covered by a myelin
layer. A needle was put through the myelin layer and the supernatant drawn
up into a 1 mL syringe. A protease inhibitor cocktail containing AEBSF for
inhibition of trypsin and chymotrypsin, aprotinine for inhibition of trypsin,
chymotrypsin, plasmin, trypsinogen, urokinase and kallikrein, leupeptin for
inhibition of calpain, trypsin, papain and cathepsin B, bstatin for inhibition
of aminopeptidases, pepstatin A for inhibition of acid proteases and E–64
for inhibition of cysteine proteases (Sigma, P 8340) was added in a dilu-
tion 1:100 to supernatant. After dilution into aliquots of 1:1,1000, 1:5,000,
1:10,000 and 1:100,000 the samples were stored at -70 ◦C.
Assays S100B (page 146), ferritin (page 147), GFAP (page 121) and total
protein (page 149) were measured as described.
The NfH phosphoforms NfHSMI32 , NfHSMI35 and NfHSMI34 were mea-
sured as described (Figures 4.1 to 4.9 on page 85–93).
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Statistical analysis Data were managed and analysed as described (Chap-
ter 7, page 151). Because of the small sample size no Gaussian curve with
valid 95%CI could be calculated. Therefor the cut–off for categorical data
analysis (Fisher’s exact test) was set to the 100% cumulative frequency of
the group with the lowest values.
9.3 Results
9.3.1 White matter
Axonal markers The median NfHSMI34 and NfHSMI35 levels were about
2–4 fold elevated in AL when compared to NCWM and NAWM (Table 9.4).
For NfHSMI34 the lowest values for all NfH phosphoforms were found in CL
(Table 9.4, see top–range). Therefore the 100% cumulative frequency of for
NfHSMI34 was taken as the cut–off (Figure 9.2 A, dotted line). Significantly
more samples taken from AL had NfHSMI34 levels above the cut–off (Figure
9.2 A) if compared to CL (p<0.001) or NAWM (p<0.05). Although me-
dian NfHSMI34 levels appeared to be about 3–fold higher in NCWM when
compared to NAWM, this did not reach statistical significance on a rigorous
categorical level.
NfHSMI35 levels were 3–fold higher in AL if compared to CL, NAWM or
NCWM. The cut–off was determined as above. Significantly more samples
taken from AL had NfHSMI35 levels above the cut–off (Figure 9.2 B) when
compared to CL (p<0.001), NAWM (p<0.001) or NCWM (p<0.001). The
median NfHSMI35 levels were about 2–fold higher in SAL if compared to CL.
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A significantly higher number of SAL samples had NfHSMI35 levels above
the cut–off when compared to CL (p<0.05). There was no difference in
NfHSMI35 levels between NCWM and NAWM (Table 9.4).
Levels of NfHSMI32 were generally low and no statistically significant
difference was found between the lesion types.
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Glial markers Each glial marker had about 2 to 3–fold higher median
levels in MS lesion if compared to control brain tissue. For S100B and ferritin
this was also true comparing NAWM and NCWM (Table 9.5). Note that
all values are given as µg/mg protein as opposed to the NfH phosphoforms
which were in ng/mg protein. The top range for S100B was lowest in SAL
and for ferritin in NCWM, which have therefore been taken as the cut–off
for subsequent categorical data analysis.
S100B levels were approximately 2–fold higher in acute plaques than in
SAL (Table 9.5). Significantly more AL than SAL had S100B levels above
the cut–off (p<0.001, Figure 9.4A).
Ferritin levels were higher in all MS lesions types compared to con-
trols (Table 9.5). A significantly higher proportion of samples from NAWM
had ferritin levels above the cut–off when compared to control WM tissue
(p<0.05, Figure 9.4 B).
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Table 9.5: Levels of S100B, GFAP and ferritin in µg/mg protein in homogenised
brain tissue. The median (range, number) values for normal control white matter
(NCWM), normal–appearing white matter (NAWM), acute lesions (AL), subacute
lesions (SAL), chronic lesions (CL) and values for grey matter from control and MS
tissue are shown. Level of significance are indicated as revealed by Fisher’s exact test
comparing proportions of samples.
µg/mg White matter
protein NCWM NAWM AL SAL CL
S100B 2.4(1.5-5.6), 5 4.8(2.6-7.1), 5 5.2(4.0-6.4), 6 3.4(2.4-4.1), 4 3.9(2.0-8.0), 7
|—— p < 0.001 ——|
GFAP 1.7(1.1-5.9), 5 1.4(0-6.0), 5 5.3(2.6-6.7), 6 3.9(2.5-5.4), 4 4.0(0.4-11.4), 7
Ferritin 3.6(2.5-4.7), 5 7.0(4.8-9.4), 5 5.2(3.7-11.2), 6 5.1(3.9-7.0), 4 5.7(4.0-13.2), 7
|—— p < 0.05 ——|
µg/mg Grey matter
protein CTRL MS
S100B 1.1(0.9-1.5, 4) 2.2(1.6-3.5, 6)
|—— p < 0.001 —————————|
GFAP 0.8(0.5-1.2), 4 2.4(0.2-5.0), 6
|—— p < 0.05 ——————————|
Ferritin 3.1(1.3-4.1), 4 4.8(2.5-12.3), 6
9.3.2 Grey matter
GFAP and S100B were elevated 2- to 3–fold in NAGM compared to NCGM
(Figure 9.6, Table 9.5). Significantly more NAGM samples had S100B and
GFAP levels above the cut–off when compared to NCGM (p<0.001, p<0.05,
respectively). Ferritin levels were higher in NAGM than in control GM.
There were however no differences between NAGM versus NAWM or NCGM
versus NCWM ferritin levels.
NfHSMI34 levels appeared slightly elevated in NCGM if compared to
NAGM, whilst the NfHSMI35 levels were lower in NCGM (Table 9.4). How-
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Figure 9.2: White matter NfHSMI34 levels. Significantly more samples from
AL had NfHSMI34 levels above the cut–off (79.9 ng/mg protein, dotted line)
when compared to NAWM or CL.
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Figure 9.3: White matter NfHSMI35 levels. Significantly more samples from
AL had NfHSMI35 levels above the cut–off (75.5 ng/mg protein, dotted line)
when compared to NCWM, NAWM or CL.
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Figure 9.4: White matter S100B levels. Significantly more samples from
acute plaques have S100B levels above the cut–off (4.1 µg/mg protein, dotted
line) than subacute plaques (p<0.001). (B) White matter ferritin levels.
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Figure 9.5: White matter ferritin levels. Significantly more samples from
NAWM had ferritin levels above the cut–off (4.7 µg/mg protein, dotted line)
compared to control white matter (p<0.001).
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ever this did not reach statistical significance. There were no differences in
NfHSMI32 levels between NAGM and NCGM. One sample had to be excluded
from the analysis of NfHSMI32 because of contamination.
9.3.3 Relation of BSP
The correlation anaylsis was motivated by the results of Chapter 8. As
suggested by the correlations found in CREAE (Figure 8.7 on page 169)
S100B correlated with both phosphorylated NfH phosphoforms (Figure 9.8
and 9.9). For the correlation of S100B with NfHSMI35 (R=0.55, p<0.001)
two outliers with NfHSMI35 levels above 200 ng/mg protein were observed.
Removal of these outliers did improve the correlation to R=0.62, p<0.001
(dotted line in Figure 9.9).
The same outliers affected 3 further correlations: NfHSMI35 with NfHSMI34
(Figure 9.12 R=0.64, p<0.001) which was reduced to R=0.6, p<0.001 af-
ter removal (dotted line in Figure 9.12). The correlation of NfHSMI35 with
GFAP (R=0.43, p<0.05, Figure 9.14), which improved to R=0.45, p<0.01
after removal (dotted line in Figure 9.14). The correlation of NfHSMI35 with
ferritin (R=0.39, p<0.05, Figure 9.16), which was reduced to R=0.36, p<0.05
after removal (dotted line in Figure 9.16).
The strong correlation between ferritin and phosphorylated NfH (R=0.92,
Figure 8.7 A) observed in the CREAE model was weaker in this human
study, with R=0.39, p<0.05 for ferritin with NfHSMI35 and R=0.33, p<0.05
for ferritin with NfHSMI34 .
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Figure 9.6: Grey matter S100B: comparing levels of S100B in cortical MS
versus controls a 2-fold increase was observed. Significantly more cortical
samples from MS than controls had S100B levels above the cut–off (1.5
µg/mg protein, dotted line, p<0.001).
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Figure 9.7: Grey matter GFAP: comparing levels of GFAP in cortical MS
versus controls a 3-fold increase is observed. Significantly more cortical
samples from MS than controls had GFAP levels above the cut–off (1.2
µg/mg protein, dotted line, p<0.05).
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Figure 9.8: Correlation of S100B (µg/mg protein) with NfHSMI34 (ng/mg
protein). NCWM = •, NCGM = ◦, NAWM = 4, NAGM = 2, AL = ∗,
SAL = +, CL = ×.
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Figure 9.9: Correlation of S100B (µg/mg protein) with NfHSMI35 (ng/mg
protein). NCWM = •, NCGM = ◦, NAWM = 4, NAGM = 2, AL = ∗,
SAL = +, CL = ×. The straight line shows the regression over all data.
The dotted line represents the correlation after removal of the outliers (see
text).
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Figure 9.10: Correlation of S100B (µg/mg protein) with Ferritin (µg/mg
protein). NCWM = •, NCGM = ◦, NAWM = 4, NAGM = 2, AL = ∗,
SAL = +, CL = ×.
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Figure 9.11: Correlation of S100B (µg/mg protein) with GFAP (µg/mg
protein). NCWM = •, NCGM = ◦, NAWM = 4, NAGM = 2, AL = ∗,
SAL = +, CL = ×.
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Figure 9.12: Correlation of NfHSMI34 (ng/mg protein) with
NfHSMI35 (ng/mg protein). NCWM = •, NCGM = ◦, NAWM = 4,
NAGM = 2, AL = ∗, SAL = +, CL = ×. The straight line shows the
regression over all data. The dotted line represents the correlation after
removal of the outliers (see text).
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Figure 9.13: Correlation of GFAP (µg/mg protein) with NfHSMI34 (ng/mg
protein). NCWM = •, NCGM = ◦, NAWM = 4, NAGM = 2, AL = ∗,
SAL = +, CL = ×.
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Figure 9.14: Correlation of GFAP (µg/mg protein) with NfHSMI35 (ng/mg
protein). NCWM = •, NCGM = ◦, NAWM = 4, NAGM = 2, AL = ∗,
SAL = +, CL = ×. The straight line shows the regression over all data.
The dotted line represents the correlation after removal of the outliers (see
text).
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Figure 9.15: Correlation of Ferritin (µg/mg protein) with NfHSMI34 (ng/mg
protein). NCWM = •, NCGM = ◦, NAWM = 4, NAGM = 2, AL = ∗,
SAL = +, CL = ×.
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Figure 9.16: Correlation of Ferritin (µg/mg protein) with NfHSMI35 (ng/mg
protein). NCWM = •, NCGM = ◦, NAWM = 4, NAGM = 2, AL = ∗,
SAL = +, CL = ×. The straight line shows the regression over all data.
The dotted line represents the correlation after removal of the outliers (see
text).
CHAPTER 9. POST–MORTEM STUDY 203
From the CREAE study no correlation between GFAP and S100B was
expected (Figure 8.7 F). However, for the post–mortem study a good corre-
lation between these proteins was found (Figure 9.11, R=0.56, p<0.001).
The positive correlation of S100B with ferritin (R=0.52, p<0.001) was
consistent with the finding in CREAE (R=0.81, Figure 8.7 D). Also con-
sistent with the CREAE study, no correlations were found between ferritin
and GFAP.
9.4 Discussion
White matter The finding that two axonal markers (NfHSMI35 , NfHSMI34 )
and one glial marker (S100B) were significantly increased in AL has to be
regarded as the most important finding of this study because in patients
this type of lesion is the most closely related to an “acute” clinical relapse.
The relevance of these results is heightened by the significant correlation
of S100B with both NfH phosphoforms (NfHSMI34 , NfHSMI35 ) and of the
latter two with each other.
The finding that S100B levels in SAL decreased to the range found for
NCWM supports the notion that S100B is an “acute phase” protein. The
decrease could partly be explained by the small molecular size (12 kDa),
high solubility and rapid wash–out of the protein as suggested by studies
from cardiovascular operations .10,11,15,45,165,188,202,228,319,327,417,428,429
In contrast NfHSMI34 and NfHSMI35 remained high in SAL. The longer per-
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sistence in the tissue could also be due to the higher molecular weight (above
190 kDa) and the lower solubility of the protein. Therefore NfHSMI35 and
NfHSMI34 could emerge as potential markers for acute to subacute axonal
damage. It is of note that immunocytochemistry did not show an increase
of either NfHSMI34 or NfHSMI35 staining in the core of AL, but at the lesion
border. The high levels measured biochemically could thus represent either
a high concentration of NfHSMI34 /NfHSMI35 from the AL borders and/or a
higher concentration in the extracellular matrix. Certainly disintegration
of the axonal membrane would cause release of axonal proteins into the ex-
tracellular space. The presence of damage–related extracellular NfHSMI35 or
NfHSMI34 is a sine qua non for any attempt to measure either phosphoform
in the CSF. Consistent with the findings that NfHSMI32 is highly susceptible
to proteolysis, NfHSMI32 were substantially lower in all lesions. It is conceiv-
able that for this reason no differences were found for NfHSMI32 between the
lesion types.
Ferritin is consistently higher in MS than in control brain tissue and
was significantly higher in MS NAWM compared to control WM. This sug-
gests that ferritin is a sensitive but non–specific marker for microglial ac-
tivity in NAWM. The correlation of ferritin with NfHSMI34 and NfHSMI35 is
consistent with the model of Wallerian degeneration (Figure 1.2 on page
33). The bulk of axonal protein release occurs during the early and mature
glial/macrophage response (Figure 1.2 C, D).
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Grey matter The levels of all glial markers appear to be increased in
NAGM. This was significant for S100B and GFAP. The involvement of
GM in MS has been recognised for a long time.30,247 One paper describes
seven distinct lesion patterns,189 which has been reduced to 3 major types
by others.305 Importantly Peterson et al. (2001) using immunocytochem-
istry, detected a significant activation of cortical astrocytes and microglia
305 which is consistent with the present results of a 2- to 3–fold increase in
GFAP and S100B levels in NAGM.
Relation of BSP With 2 exceptions the findings of the post–mortem
study were consistent with the findings for the CREAE model. In order to
facilitate the comparsion between these two studies the Spearman correla-
tion coeffiencents have been summarised in Table 9.6.
The positive correlation found for GFAP with NfHSMI35 (Figure 9.16
on page 202) was at first glance contradictory to the finding of a negative
correlation for the same proteins in the CREAE study (Figure 8.7 C, on page
169). It appears however from Figure 8.7 C that the negative correlation
is really due to the CREAE animals having lower NfHSMI35 levels then the
control animals. For the CREAE animals alone a positive correlation is
suggested by the scatter of the points. The post–hoc analysis revealed that
this was significant (R=0.79, p<0.05). Whereas for the animal study the
number of the CREAE to control mice was relative balanced, in the post–
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mortem study 27 samples from MS patients outweighted the 9 samples from
control brain tissue.
Table 9.6: Correlations between BSP in the CREAE and human post–
mortem study.
BSP CREAE Post-mortem Consistent
NfHSMI35 with S100B 0.83 0.55 yes
NfHSMI35 with GFAP -0.54 0.43 no
NfHSMI35 with Ferritin 0.92 0.39 yes
Ferritin with S100B 0.81 0.52 yes
Ferritin with GFAP N.S. N.S. yes
GFAP with S100B N.S. 0.56 no
The situation is more complex for the comparison of S100B with GFAP.
The post–hoc analysis for CREAE animals alone is not significant (R=0.55,
p=0.16). Whilst the values for GFAP were spread out relatively wide in
the CREAE mice (5.0–26.4 µg/mg protein) the scatter was narrower for the
control mice (1.4–5.2 µg/mg protein, Table 8.1 on page 163). In the post–
mortem study the correlation between S100B and GFAP was due to low
values for GFAP and S100B in NAGM and NCWM which are contrasted
by higher values in AL, SAL and NAGM (Figure 9.10 and 9.11). Again the
distribution for GFAP in MS brain tissue is broad (0.1–11.4). In contrast,
if one disregards one outlier for the NCWM with a GFAP level of about 5.9
µg/mg protein the distribution for GFAP in the control tissue is narrower,
ranging from (0.9–2.8 µg/mg protein).
Taking all this together it appears that the findings for BSP in an animal
study and in a human post–mortem study are highly consistent. However,
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the strength of the correlations is weaker in the post-mortem study. This
could possibly be due to the heterogeneity of the lesions, or to autoproteol-
ysis during the variable post–mortem interval.
9.5 Conclusion
The results of this postmortem study provide evidence for NfHSMI35 and
NfHSMI34 being practical markers for axonal damage in the acute and sub-
acute phase of the disease. The probable accumulation in the extracellular
matrix would allow for diffusion into the CSF, therefore providing a testable
hypothesis for any CSF study.
The relation of the different NfH phosphoforms to NAWM versus AL
and SAL suggests heterogeneity of axonal pathology in MS.
S100B could be associated with AL, whilst ferritin is generally elevated
in MS white matter.
Chapter 10
Disease heterogeneity:
Cross–sectional
10.1 Background
The concept of disease heterogeneity in MS has important prognostic and
therapeutic implications. The clinical heterogeneity originates in the wide
spectrum of disorders presenting with symptoms consistent with demyelina-
tion. This has been discussed in Chapter 1.1 and is briefly recapitulated in
Table 10.1. Careful examination of MS plaques revealed distinct immunohis-
tological patterns of demyelination (Table 1.1 on page 28).112,238 The profile
of glial and axonal markers in different MS lesions (Chapter 9) further sup-
ported this notion. Heterogeneity of lesions was also apparent in magnetic
resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) stud-
ies.50,217 Furthermore, treatment response is not homogeneous.91,298 It is
probable that the pathological features associated with demyelination are
not exclusive, but occur simultaneously at different phases of the disease.
These include inflammation, glial reaction and axonal injury. The balance of
208
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pathological processes might partly account for the clinical phenotype and
influence treatment response.
Quantification of CSF levels of biomarkers for reactive astrocytosis (Sec-
tion 2.3, page 62), microglial activation (Section 2.4, page 66), astrogliosis
(Section 2.2, page 59) and axonal injury (Section 2.1, page 50) could poten-
tially be relevant for understanding in vivo factors contributing to disease
heterogeneity in MS.
However the design of previous studies did not allow sufficiently detailed
analysis of both disease subtype and disability in relation to CSF levels of
glial171,172,222,251,270,336 and axonal markers.172,212,242,278,353 Consequently
most authors had not shown any statistically significant difference between
clinical subgroups . A detailed summary has been presented in Tables 1.2 to
1.4. The post–hoc analyses for two studies251,270 showed (Table 1.2 on page
45) that there is evidence that S100B is elevated in acute disease. Another
study used a sophisticated composite score in order to distinguish clinical
subtypes of MS .172
Table 10.1: Idiopathic inflammatory demyelinating diseases of the CNS.
Adapted † from Weinshenker and Miller (1997).427
Acute Intermediate Chronic
ADEM RR MS Chronic myelopathy
Marburg’s SP MS Balo’s
Optic neuritis Benign MS Relapsing myelitis
Transverse myelopathy Cerebellar syndrome
Devic’s
In this study CSF levels of S100B, GFAPSMI26 and ferritin were quanti-
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fied for the first time in all three principal clinical subgroups of MS (Figure
1.1 on page 23), which were not heavily biased by patients having acute
relapses. This is important because release of biomarkers during the acute
phase of disease are slanted towards relapse–related tissue destruction. As
a result regression to the mean might be the main effect seen.
The purpose of this cross–sectional study was to determine levels of CSF
BSP in MS patients and to evaluate their relation to the clinical subtype.
The relation of the same BSP to disability was also investigated, but for
reasons of clarity this will be presented separately in Chapter 11.
10.2 Methods
Patients One-hundred and two patients with neurological disease were
included in the study. In response to an article in the journal of the Dutch
Society of MS, 65 MS patients volunteered to undergo lumbar puncture.
Fifty-one patients in whom a diagnosis of clinically definite MS could be
made were included in the study. MS patients were classified as having
relapsing remitting (RR), secondary progressive (SP) or primary progressive
(PP) disease according to previously published criteria.236
Due to restricted sample size glial markers (S100B, GFAPSMI26 and fer-
ritin) and neurofilament phosphoforms were measured in two different con-
trol groups. The control group for glial markers consisted of 51 patients
with other neurological disorders: One patient had aphasia, 1 ataxia, 1 back
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pain, 1 benign intracranial hypertension (BIH), 1 chorea, 2 cerebral infarc-
tion, 2 dementia, 1 dysphagia, 12 headache, 4 motor symptoms, 2 peripheral
neuropathies, 1 sarcoid, 1 transient ischaemic attack and 21 non–specific
sensory symptoms presumably of a functional basis. The control group for
neurofilament phosphoforms consisted of 9 patients with cluster headache
syndrome in whom no other pathology could be revealed. All these samples
were obtained from a library of CSF from patients undergoing diagnostic
lumbar punctures at the National Hospital for Neurology and Neurosurgery,
London.The CSF samples were coded and anonymised in accordance with
the MRC guidelines on the ethical use of biological specimen collections in
clinical research.
Patient demographics are shown in Table 10.2. The demographics of the
control patients are shown in Table 10.3.
Table 10.2: Demographic data from MS patients: median (range). MS
patients are classified into clinical subgroups : PP = primary progres-
sive, SP = secondary progressive, RR = relapsing remitting disease.
Clinical classification
MS RR SP PP
Age (years) 46(27–65) 40(27–55) 46(28–65) 51(43-55)
Gender (f, m) 28, 23 11, 9 10, 11 7, 3
Age at onset (years) 29(17–45) 28(22–45) 28(17–42) 38(24–44)
Disease duration (years) 13(0–35) 8(0–27) 18(6–35) 15(6–27)
Time from last relapse (months) 37(1–228) 15(1–79) 77(4–228) N/A
Number 51 20 21 10
CHAPTER 10. DISEASE HETEROGENEITY 212
Table 10.3: Demographic data from control patients: median (range.
OND represents a heterogeneous group with other neurological diseases
and headache a well defined group of patients with cluster headache
syndrome.
OND Headache
Age (years) 41(27–63) 37 (25–44)
Gender (f, m) 37, 14 8, 1
Number 51 9
Samples Samples of CSF were obtained by routine lumbar puncture. CSF
was centrifuged and aliquots of the supernatant were stored at -70◦C until
assayed. Approval for the study was obtained from the local Ethics Com-
mittees. Written informed consent was obtained from all MS patients.
Assays S100B (page 146), ferritin (page 147), GFAPSMI26 (page 121), NfH
(page 73), albumin (page 147) and oligoclonal bands (page 149) were mea-
sured as described.
Statistical analysis Data were managed and analysed as described (Chap-
ter 7, page 151). Because of the small sample size a Gaussian curve with
valid 95%CI could not be calculated. Therefore the cut–off for categorical
data analysis (Fisher’s exact test) was set to the 100% cumulative frequency
of the indicated control group.
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10.3 Results
Oligoclonal bands The CSF and serum IEF patterns were classified ac-
cording to whether the patients had evidence of intrathecal IgG synthesis
(OCB+), evidence of a systemic oligoclonal response with matched bands
in the serum and CSF (OCB*), i.e. a “mirror pattern” or no evidence of an
intrathecal or systemic oligoclonal response (OCB-). Forty–six out of 51 MS
patients (90%) had intrathecal oligoclonal IgG synthesis. Four (8%) of the
MS patients had a mirror pattern OCB(*) and one (2%) had no evidence of
a local or systemic oligoclonal IgG response. None of the control patients
had evidence of intrathecal IgG synthesis.
Brain–specific proteins CSF levels of BSP did not correlate with age,
age at onset of disease, disease duration or time from last relapse in the MS
patients. In the subgroup analysis CSF ferritin levels in SP MS patients
correlated with disease duration (R=0.46, p<0.05). There was a pseudo–
correlation between S100B and NfHSMI35 (R=-0.3, p<0.05) due to two out-
liers. Removal of the outliers abolished the correlation. There was no other
correlation between the different BSP. The CSF to serum albumin ratio was
normal.
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Table 10.4: CSF levels of S100B, ferritin, GFAPSMI26 , NfHSMI34 and
NfHSMI35 in RR, SP and PP MS patients: median (range), number.
Clinical classification
OND MS RR SP PP
S100B 0.25(0–0.4),51 0.3(0.1–2),51 0.3(0.1–2),20 0.27(0.2–1.4),21 0.25(0.1–0.4),10
ng/mL |—— p<0.05 ———|
|—— p<0.01 ————————————|
Ferritin 5(3–7), 51 5(1–20),51 4.5(1–20),20 6(1–19),21 5.5(3–13),10
ng/mL |—— p<0.01 ————————————————————|
GFAPSMI26
pg/mL 1(0–13),51 3(0–16),51 3(0–11),20 2(0–16),21 0.5(0–11),10
Headache MS RR SP PP
NfHSMI34 684(0–964),9 11(0–47),51 8.5(0–37),20 11(5–44),21 11(5–47),10
pg/mL |—— p<0.001 ———|
NfHSMI35 0(0–151),9 53(0–1386),51 74.5(0–1386),20 42(11–240),21 95(7–155),10
pg/mL |—— p<0.001 ———|
10.3.1 Controls
CSF S100B was significantly higher in MS compared to OND patients (p<0.05,
Table 10.4). CSF GFAPSMI26 levels did not distinguish significantly be-
tween OND and MS patients. CSF ferritin levels tended to be higher in MS
compared to control patients, but this was not significant. MS patients
had significantly higher CSF Nf-SMI35 levels than patients with cluster
headache (p<0.01). Conversely cluster headache patients had significantly
higher NfHSMI34 levels than MS patients (p<0.001).
10.3.2 Relapsing disease
RRMS patients had higher median CSF S100B and GFAPSMI26 levels com-
pared to the other clinical subgroups (Table 10.4).
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Figure 10.1: Scatter and box-whisker plot for CSF S100B. The trend for
stepwise increase of S100B levels in proportions of patients from PP to SP
to RR MS is significant (p<0.05).
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Figure 10.2: Scatter and box-whisker plot for CSF GFAPSMI26 . There
was no significant difference for GFAPSMI26 levels between the clinical sub-
groups.
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S100B levels were significantly different between the clinical subgroups
and controls
(F(3,105)=2.77, p<0.05). The post–hoc analysis showed that this signifi-
cance originated from higher levels present in RR MS when compared to
control patients (p<0.01). Mean S100B levels in RR patients were nearly
2–fold higher compared to PP and 1.5–fold compared to SP MS patients,
but these differences did not reach statistical significance. There was how-
ever a trend for a stepwise increase of S100B levels from PP to SP to RR
MS patients (Figure 10.1). None (0/10) of the PP, 14% (3/21) of the SP
and 35% (7/20) of the RR MS patients had S100B levels above the cut–off
of 0.39 ng/mL. This trend for linear increase was significant (M-Hχ2=5.633,
p<0.05). Importantly S100B did not correlate with time from last relapse
in either of the clinical subgroups.
GFAPSMI26 levels were not significantly different between the clinical
subgroups (Figure 10.2). A bimodal distribution for GFAPSMI26 was ob-
served in PP MS patients. PP MS patients with high GFAPSMI26 levels
were however not clinically more disabled when compared to those with low
GFAPSMI26 levels (see Section 11.3.1, page 231). In particular there was
no statistical significant difference regarding age, age at onset of disease,
EDSS, 9HPT or AI. PP MS patients with high GFAPSMI26 levels had a
slightly longer disease duration (17.6±8.6 years) when compared to PP MS
patients with lower GFAPSMI26 levels (11.8±3.3 years), but this failed to
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reach statistical significance.
10.3.3 Progressive disease
SP patients had the highest median CSF ferritin levels of the clinical sub-
types (Figure 10.3). Ferritin levels in progressive MS patients (SP and PP)
were higher than in RRMS patients, which was inverse to the levels observed
for S100B (Table 10.4). Consequently a ratio of S100Bferritin distinguished signif-
icantly between clinical subgroups (F(3,98)=6.45, p<0.001). The S100Bferritin
ratio was significantly higher in RR (1.0±0.8) than in SP (0.7±0.6) or in
PP (0.5±0.3) and control (0.5±0.2) patients (p<0.05, p<0.01 and p<0.001,
respectively, Figure 10.6). None (0/10) of the PP, 19% (4/21) of the SP and
45% (9/20) of the RR MS patients had a S100Bferritin ratio above the cut-off.
The trend analysis revealed a significant linear increase of the S100Bferritin ratio
from PP to SP to RR MS patients (M-Hχ2=7.7, p<0.01).
In PP patients ferritin and GFAPSMI26 were slightly elevated, but the
difference from the control patients did not reach statistical significance.
S100B in PP MS patients was similar to the control group.
No overall statistically significant difference was observed for the three
clinical subgroups regarding CSF levels of either NfHSMI34 or NfHSMI35 .
One outlier of 1386 ng/mL was observed for NfHSMI35 (Figure 10.4). Re-
moval of this outlier decreased the median CSF NfHSMI35 level in the RR
MS group to 53 (0–196) ng/mL without altering the statistics.
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Figure 10.3: Scatter and box and whisker plot for CSF ferritin. The median
ferritin levels are slightly higher in progressive than in relapsing MS patients.
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Figure 10.4: Scatter and box and whisker plot for CSF NfHSMI35 . No
statistically significant difference is observed for the three clinical subgroups.
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Figure 10.5: Scatter and box and whisker plot for CSF NfHSMI34 . No
statistically significant difference is observed for the three clinical subgroups.
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Figure 10.6: Scatter and box and whisker plot for the CSF S100Bferritin [×103]
ratio. The S100Bferritin ratio was significantly higher in RR than in SP (p<0.05)
or in PP MS (p<0.01) patients. 0% of PP, 19% of SP and 45% of RR MS
patients have S100B levels above the cut-off of 0.97. The trend for linear
stepwise increase (PPMS to RRMS) is significant (p<0.01).
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10.4 Discussion
The results provide evidence that biomarkers for astrocytic and microglial
activation have the potential to distinguish between patients with relapsing
remitting (RR) and progressive MS (PP and SP). There was a significant
trend for increasing S100B levels from PP to SP to RRMS patients, with RR
MS patients having significantly higher S100B levels than control patients.
Ferritin levels were significantly higher in SP MS patients than in control
patients (Table 10.4). Consequently a S100Bferritin ratio was capable of distin-
guishing RR from SP MS patients. This suggests that astrocytic activation
predominates in relapsing disease and microglial activation in progressive
disease.
MS patients had significantly elevated CSF S100B levels compared to
control patients, which was principally due to the high S100B levels in
RRMS patients. This result confirms most previous studies.211,250,251,270
The median relapse–free interval in our study was 15 months in the RR and
77 months in the SP MS patients. Therefore the CSF S100B levels repre-
sent relapse–independent astrocytic activity. In vitro astrocytes have been
shown to increase their expression of S100B after exposure to adrenocorti-
cotropic hormone (ACTH),388 which has shown to be an effective drug in
MS .107 The results of Chapter 9 (page 172) where high S100B levels have
been shown in NAWM (Figure 9.4) are in keeping with this argument.
The dynamics of clearance of all investigated markers from the extracel-
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lular space via the CSF are unknown, but one would assume that because of
dilution the extracellular concentration at the site of release is much higher
than that in the CSF. Nanomolar levels S100B have neurotrophic activity
whilst micromolar S100B levels have cytotoxic properties.86 This could be
of pathological and therapeutic relevance.
It is of note that elevated levels of S100B due to head injury or rapid
parenchymal destruction have been reported in epilepsy,212,373 Creutzfeldt–
Jakob disease,127,301 stroke 22,439 and acute brain injury148 (Chapter 2.3
on page 62). These levels should however be distinguished from those in
slowly progressive diseases where S100B might play a different pathogenic
role i.e. by modulating the inflammatory response through stimulation of
inducible nitric oxide synthetase (iNOS) 2,86 or modify disease progression
by yet unknown mechanisms, e.g. in Down’s syndrome or Alzheimer’s dis-
ease.86,128,132 Although extra–cranial sources of S100B such as adipose tis-
sue, testis and skin are known149,268,390 and are potential confounding fac-
tors in the interpretation of serum S100B levels,86,164 these are unlikely to
be a problem for CSF levels in this study because the BBB (as determined
by CSF/serum albumin ratio) was intact and all of the MS patients were
outside acute relapse.
In the present study CSF ferritin was significantly higher in SP MS
patients than in the control group. Medline, Embase and reference research
revealed only one other study where ferritin levels have been measured in
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MS patients and found them to be elevated in progressive patients.222 This
result is in keeping with the findings in MS brain homogenate where NAWM
ferritin concentrations were significantly increased when compared to control
WM (Figure 9.4 B, page 189). As NAWM contributes the bulk of brain
tissue equilibrating with the CSF the result in CSF of MS patients is not
surprising. Interestingly Hulet (1999) found decreased binding of ferritin to
white matter within the MS lesion.160 The oligodendrocyte requires iron for
the synthesis of myelin ,71 therefore upregulated ferritin levels in MS brain
could reflect a physiological reaction to decreased binding and metabolic
needs.
In contrast to one study336 using the CSF of 5 healthy volunteers as
controls, this study together with others7,296 did not find any significant
difference between CSF GFAPSMI26 levels in MS and the control group con-
sisting of patients with other neurological disorders. GFAPSMI26 has also
been found to be elevated in dementia,97 normal pressure hydrocephalus
,7 asphyxiated newborns,44 post head injury ,276 brain infarction22 Lyme–
borreliosis,87 trypanosomiasis220 and MS .336 GFAPSMI26 should therefore
be regarded as a non–specific biomarker of CNS tissue injury, probably as-
trocytic activation 199,383 and astrogliosis (Chapters 8 and 9).
The poor discriminatory power of NfH phosphoforms for the clinical sub-
groups of MS suggests that axonal injury is a uniform phenomenon in MS.
The only other study measuring Nf, albeit the light chain in CSF of different
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clinical types, by Semra et al. (2002) also did not reveal a statistical signifi-
cant difference between RR and SP/PP MS patients.353 However in Semra’s
and the present study the median/mean NfL/ NfH levels were slightly higher
in progressive compared to relapsing MS patients. An important question
to ask is how axonal damage develops during progression of the disease, i.e.
if the dynamics of axonal injury in SP/PP MS are distinct from those in RR
MS. This will be possible in the longitudinal study presented in Chapter 12.
10.5 Conclusion
This study investigated the relationship between biomarkers for different
glial cell responses and the clinical subgroups of MS.
There was a significant trend for increasing S100B levels from PP to SP
to RR MS (p<0.05). S100B was significantly higher in RR MS than in
control patients (p<0.01), whilst ferritin levels were significantly higher in
SP MS than in control patients (p<0.01). The S100Bferritin ratio discriminated
between patients with RR MS and those with SP, PP or control patients
(p<0.05, p<0.01 and p<0.01, respectively).
S100B was a good marker for the relapsing phase of the disease (con-
firmed by post–mortem observation in chapter 9) as opposed to ferritin
which is elevated throughout the entire course. The results of this study
might be considered in future classifications of MS subgroups.
Chapter 11
Disability: Cross–sectional
11.1 Background
In his remarkable 1868 papers Charcot distinguished three steps in the
pathology of his disease, la scle´rose en plaques (multiple sclerosis): (1) ini-
tial astrocytic and microglial activation: “la multiplication des noyaux et
l’hyperplasie concomitante des fibres re´ticule´es de la ne´vroglie sont le fait
initial”, (2) secondary neuro–axonal degeneration: “l’atrophie de´ge´nerative
des e´le´ments nerveux est secondaire” and (3) astrogliosis: “la ne´vroglie fait
place au tissu fibrillaire” (Figure 11.1), which he considered to represent
the anatomical substrates of progressively impaired locomotor activity: “est
conside´re´e a` juste titre comme le substratum anatomique de l’ataxie loco-
motrice progressive.”61
Out of these, axonal damage has become one of the most intensely stud-
ied aspects of recent MS research and will be investigated in Chapter 12.
Moreover the clinical relevance of the glial response has received less at-
tention despite recent evidence that glial pathology can precede secondary
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Fig. 11.1 – Elle repre´sente une pre´paration fraˆıche, provenant du centre
d’une plaque scle´reuse, colorie´e par le carmin et traite´e par delace´ration. Au
centre, vaisseau capillaire portant plusieurs noyaux. A droite et a` gauche,
cylindres d’axe, les uns volumineux, les autres d’un tre`s–petit diame`tre, tous
de´pouille´s de leur mye´line. Le vaisseau capillaire et les cylindres d’axe e´taient
fortement colore´s par le carmin. Les cylindres d’axe ont des bords parfaite-
ment lisses, ne presentant aucune ramification. Dans l’intervalle des cylindres
d’axe, membranes fibrilles de formation re´cente, a` peu pre`s paralle`les les unes
aux autres dans la partie droite de la pre´paration, formant a` gauche et au
centre, une sorte de re´seau re´sultant, soit de l’encheveˆment, soit de l’ana-
stomose des fibrilles. Celles–ci se distinguent des cylindres d’axe, 1◦ par leur
diame`tre qui est beaucoup moindre ; 2◦ par les ramifications qu’elles offrent
dans leur trajet ; 3◦ parce qu’elles ne se colorent pas par le carmin. — C¸a´ et
et la`, noyaux disse´mine´s. Quelques–uns paraissant en connexion avec les fi-
brilles conjonctives ; d’autres ayant pris une forme irre´gulie`re, due a` l’action
de la solution ammoniacale du carmin.60
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axonal degeneration.111
Previously only one attempt has been made to relate a glial marker to
disability (Table 1.2 on page 45). Confirmation of this result was hampered
by the use of tests which were only available to the original laboratory.332,336
In this chapter the CSF levels of S100B, GFAPSMI26 and ferritin quanti-
fied in the clinical MS subtypes described in Chapter 11 were related to the
degree of disability as quantified by different clinical scales. The hypothe-
ses underlying the study were that CSF BSP levels relate to the degree of
disability.
11.2 Methods
Patients As described in Chapter 10.2 (page 208). Patient demographics
and baseline characteristics are shown in Table 11.1.
Clinical assessment The Amsterdam group assessed all the MS patients.
An ambulation index (AI),14 an expanded Disability Status Scale score
(EDSS)206 and a 9–hole PEG test (9HPT) for both hands14,177 were per-
formed on all patients within one week of the lumbar puncture. The AI
classified the gait on a scale ranging from 0 (no impairment) to 9 (restricted
to wheelchair without independent transfer). The 9HPT is a measure of up-
per limb motor function. The 9HPT was performed twice with each hand.
The quickest performance for each hand was taken to calculate an average
value.177
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CSF analysis As described in Chapter 10.2.
Statistical analysis Data were managed and analysed as described (Chap-
ter 7, page 151). Because of the small sample size a Gaussian curve with
valid 95%CI could not be calculated. The cut–off for categorical data analy-
sis (Fisher’s exact test) was therefore set to the 100% cumulative frequency
of the indicated control group.
Table 11.1: Demographic and clinical data: median (range, number). MS
patients are classified into clinical subtypes: PP = primary progressive, SP
= secondary progressive, RR = relapsing remitting disease. AI = ambulation
index, EDSS = Kurtzke’s extended disability status score, 9HPT = 9–hole
PEG test (see text).
Clinical classification
CTRL MS RR SP PP
Age (yrs) 41(27-63),51 46(27-65),51 40(27-55),20 46(28-65),21 51(43-55),10
Gender (f, m) 37, 14 28, 23 11, 9 10, 11 7, 3
AI N/A 4.5 (0–10),44 1.5 (0–10),18 6.5 (1–9),18 4 (1–9),8
EDSS N/A 3.5 (0–8),51 1.75 (0–6.5),2) 6 (1–8),21 6 (1.5–8),10
|— p<0.001 ——————————–|
|— p<0.001 ————|
9HPT N/A 25 (17–84),49 20 (18–29),18 29 (17–84),21 26 (17–36),10
|— p<0.01 ———|
11.3 Results
Patients were categorised according to the frequency distribution on the
clinical scales (Figure 11.2). The distribution of the AI and EDSS was
trimodal. Patients were therefore classified into those with good (AI ≤2),
moderate (3-6) and poor (≥7) ambulation. The EDSS was classified as
indicating mild (0–3), moderate (3.5–6.5) and severe disability (7–10).
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Figure 11.2: Frequency plot of the clinical scales: (A) EDSS, no patient had
an EDSS above 8.5, (B) Ambulation index and (C) 9HPT. The number of
patients is indicated on the ordinate.
11.3.1 Ambulation index
There was a significant difference in CSF GFAPSMI26 levels between MS
patients classified according to the AI and control patients (F(3,64)=5.49,
p<0.001, Table 11.2). In the post–hoc analysis MS patients with poor ambu-
lation had significantly higher CSF GFAPSMI26 levels than control patients
(p<0.001) or MS patients with good ambulation (p<0.05). The subgroup
analysis revealed that this significance was due to the 9 SP MS patients with
poor ambulation, which had nearly 6-fold elevated median GFAPSMI26 levels
when compared to control patients (p<0.05, Table 11.2). Significantly el-
evated GFAPSMI26 levels were also present in poorly ambulating RR MS
patients compared to control patients (p<0.01), but not in poorly ambulat-
ing PP MS patients.
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Figure 11.3: CSF GFAPSMI26 levels correlated significantly with the AI in
SP MS patients (R=0.57, p<0.01). Data points are horizontally adjacent if
observations overlapped. The linear regression line, the 5% lower and 95%
upper confidence curves are shown.
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In SPMS patients disability measured by the AI correlated with levels of
GFAPSMI26 (R=0.57, p<0.01, Figure 11.3). The 100% cumulative frequency
(2 pg/mL) of the CSF GFAPSMI26 levels of patients with good ambulation
was taken as cut–off for the trend–analysis. None (0/4) of patients with
good, 40% (2/5) of patients with moderate and 78% (7/9) of patients with
poor ambulation had CSF GFAPSMI26 levels above this cut–off. The trend
analysis revealed a significant linear increase within these 3 AI categories
(M-Hχ2=6.6, p<0.01).
11.3.2 EDSS
There was a significant difference in CSF GFAPSMI26 levels between MS pa-
tients classified according to the EDSS and control patients (F(2,57)=5.06,
p<0.01, Table 11.2). Severely disabled MS patients had significantly higher
GFAPSMI26 levels than control patients (p<0.01). The post–hoc analysis
revealed that this was caused by the approximate 6-fold elevation in median
GFAPSMI26 levels in severely disabled SP MS patients when compared to
control patients (p<0.01). The post–hoc analysis also revealed significantly
elevated GFAPSMI26 levels in severely disabled compared to moderately dis-
abled MS patients (p=0.05). There was no linear correlation between the
EDSS and GFAPSMI26 levels and the trend analysis was not significant.
In SP MS patients ferritin correlated with the EDSS (R=0.45, p<0.05).
Because of the previously indicated correlation between disease duration
and ferritin levels, a partial correlation correcting for disease duration was
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Figure 11.4: CSF S100B levels correlated significantly with the 9HPT of the
dominant hand in PP MS patients (R=-0.85, p<0.01). The linear regression
line, the 5% lower and 95% upper confidence curves are shown.
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performed which abolished the correlation between EDSS and ferritin.
11.3.3 9–hole PEG test
CSF ferritin levels were about 2-fold higher in patients with a test perfor-
mance > 55 seconds (12.3±5.1 ng/mL) than in “quick” (6.2±4.8 ng/mL)
patients (p<0.05, Wilcoxon rank sum test). Because there were only 4
“slow” patients the results were checked by the Fisher’s exact test and no
significance could be demonstrated. CSF S100 correlated negatively with
the 9HPT in PP MS patients (R=-0.85, p<0.01, Figure 11.4).
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Table 11.2: CSF GFAPSMI26 levels in control, MS patients and clinical sub-
types: median (range), number. GFAPSMI26 distinguishes significantly the
grades of disability in clinical subtypes (post–hoc analysis) from those in con-
trol patients (AI: F(3,64)=5.49, p<0.001; EDSS: F(2,57)=5.06, p<0.01).
GFAPSMI26 [pg/mL] Ambulation index
CTRL < 2 2–6 > 6
MS 1(0–13),51 2(0–11),19 0(0–11),8 6(0–16),17
|——————————————— p<0.001 ——|
|————————– p<0.05 ——|
SP 0(0–2),4 0(0–11),5 6(0–16),9
|——————————————— p<0.001 ——|
|————————– p<0.05 ——|
PP 0(0–11),3 4.5(0–9),2 1(0–10),3
RR 3(0–10),12 0(0),1 6(3–11),5
|——————————————— p<0.01 ——|
EDSS
< 3.5 3.5-6.5 > 6.5
MS 3(0–11),27 0(0–11),15 6(0–16),9
|——————————————— p<0.01 ——|
|——— p=0.05 ——|
SP 2(0–10),5 0(0–11),9 6(0–16),7
|——————————————— p<0.01 ——|
PP 0(0–11),4 4.5(0–10),4 5.5(1–10),2
RR 3.5(0–11),18 0(0),2 N/A
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11.4 Discussion
Patients with poor ambulation had significantly higher CSF GFAPSMI26 levels
than patients with good ambulation and control patients (Table 11.2). Also
severely disabled patients had significantly higher CSF GFAPSMI26 levels
compared to mildly disabled patients. This is suggestive of increased as-
trogliosis within the spinal cord of poorly ambulating or disabled patients.
Compared to the control group these were the only patients with signifi-
cantly higher GFAPSMI26 levels. The subgroup analysis revealed that this
was most marked in patients with SP MS. This study revealed a significant
correlation between GFAPSMI26 and individual scoring on the AI for SP MS
patients (R=0.57, Figure 11.3). The lack of correlation in PP MS may relate
to the small number of cases studied. We interpret the results as showing a
direct relationship between GFAPSMI26 and astrogliosis, which is expressed
clinically as disability.
The reason why a direct correlation was found between GFAPSMI26 and
individual points on the AI but not with the EDSS may be explained by the
physiological basis of these clinical scales. The AI essentially measures gait.
The EDSS in contrast includes other neurological functions which are outside
(rostral) the anatomical parts of the CNS which equilibrate with the CSF
in the lumbar sac. This “CSF analytical brain” consists of the inner half of
the telencephalon, the basal cortex, the cerebellum, the brain stem and the
spinal cord.104 Each lost axon innervating the lower limb could potentially
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be replaced by a gliotic scar about 1 meter long.198 Therefore a considerable
amount of gliotic tissue would form the source of GFAPSMI26 release and
would hence parallel the decline in ambulation. Thus almost all changes
measured by the AI, but only some assessed by the EDSS, would be reflected
in a change of lumbar CSF GFAPSMI26 levels.
This was also demonstrated by the study of Rosengren (1995) who stud-
ied serial CSF samples in 10 RRMS patients.336 The scale applied to as-
sessing disability, the regional functional score system (RFSS) includes vi-
sual and mental functions. Contradictory changes in the RFSS and lumbar
CSF GFAPSMI26 levels can be observed in 8 out of the 10 patients stud-
ied. Importantly this study on serial CSF samples (7 lumbar punctures per
patient over a 2 year period) did not reveal any relationship between CSF
GFAPSMI26 levels and the time from relapse.
The strong negative correlation between S100B and the 9HPT in PP
MS patients which has not previously been observed and is difficult to ex-
plain. None of the previous studies investigated the relation of CSF S100B
with disability (see Table 1.2 on page 45). The neurotrophic role of S100B
in nanomolar concentrations is well described.86,139 One might speculate
whether there is an association between the treatment response to ACTH in
MS107 which upregulates of S100B excretion in vitro.388 In this context high
levels would have to be associated with relapse and possible toxic effects,
whilst low levels would be related to failure of initiating an adequate cellular
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response (Chapter 8). These results need to be confirmed by other groups
to assess whether the correlation of S100B with disability is a consistent
finding.
11.5 Conclusion
Disease progression in MS occurs within the interface of glial activation and
gliosis. This study aimed to investigate the relationship between biomarkers
of different glial cell responses to disability.
MS patients with poor ambulation (AI≥7) or severe disability (EDSS >
6.5) had significantly higher CSF GFAPSMI26 levels than less disabled MS
patients or controls (p<0.01, p<0.001, respectively). There was a correlation
between GFAPSMI26 levels and ambulation in SP MS (R=0.57, p<0.01) and
S100B and the 9HPT in PP MS patients (R=-0.85, p<0.01).
CSF GFAPSMI26 may therefore be a marker for irreversible damage due
to a gliotic scar as already suggested by Charcot in 1868. The results of this
study have broader implications for finding new and sensitive outcome mea-
sures for treatment trials which aim to delay the development of disability.
Chapter 12
Axonal pathology:
Longitudinal
12.1 Background
The new insight from recent studies into axonal pathology in multiple scle-
rosis (MS) is that a high number of transected axons was already present in
acute lesions ,106,398 in patients with a short clinical course 42,398 and inde-
pendently from demyelination.40 Axonal damage/loss results in atrophy of
the spinal cord,231 cerebellum230 and cortex,113 all of which correlate with
disability.113,230,231
The neuron relies on the axonal compartment to maintain function over
long distances in an ever–changing environment. It does so by exploiting
functional properties of proteins, which can be modulated locally in the
axon, e.g. by phosphorylation and dephosphorylation of proteins such as Nf
(Chapter 2.1 on page 50). Of the three Nf subunit proteins NfH is highly
phosphorylated and its KSP (Lys-Ser-Pro) repeat–enriched tail domain con-
stitutes a target for a range of protein kinases .27,34,119,136,169,223,293,411 In
240
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the healthy axonal compartment NfHSMI35 dominates.214,294,404 After ax-
onal injury the relative amount of NfHSMI32 increases in the proximal axon
and intense staining for hypophosphorylated NfH isoforms is observed at the
site of injury398,404 (Table 9.1 on page 176). Disintegration of the axonal
membrane results in release of Nf (Chapter 9). CSF Nf levels are therefore
putative markers for axonal damage.131,242,353 Using two discrete mono-
clonal antibodies we have monitored phosphorylated (NfHSMI35 ) and ex-
tensively phosphorylated (NfHSMI34 ) NfH not just in relation to each other
(as a ratio) but also the changes in levels over time (∆ NfH).377,378
This prospective study presents the 3–year follow–up data of the cross–
sectional study in Chapters 10 and 11. The longitudinal study was stim-
ulated by 3 questions256,424: (1) Can clinical subgroups of MS be distin-
guished on the basis of axonal damage? (2) Does disability correlate with
markers of axonal pathology? And (3) Can we predict loss of function by
using biomarkers for axonal injury as prognostic indicators?
12.2 Methods
Patients Twenty–eight patients from the cohort presented in Chapters
10 and 11. A second CSF sample was available from those patients who
agreed to another lumbar puncture at 3–years follow–up. To avoid measur-
ing regression to the mean CSF was analysed only in those patients who
had a relapse–free interval of at least 2 months prior to lumbar puncture, by
CHAPTER 12. AXONAL PATHOLOGY: LONGITUDINAL 242
which time CSF NfL is known to return to baseline levels.242 MS patients
were classified as having relapsing remitting (RR), or progressive (SP/PP)
disease.236 Approval for the study was obtained from the local Ethics
Committees. Written informed consent was obtained from all patients. In
8 of the MS patients (5 RR, 3 SP) treatment with interferon beta (IFN)
had been started since 1996. The control group consisted of the 9 patients
with cluster headache presented in Chapter 10. The demographic data of
the patients are shown in Table 12.1.
Table 12.1: Baseline characteristics of the patients. The median (IQR) is shown.
CTRL MS SP/PP RR
Female:Male 8:1 13:15 9:9 4:6
Age 37 46.3 48.5 39.8
(years) (25–44) (39.7–51) (42.5–51.5) (38.3–47.7)
Disease duration N/A 14 18.1 8.8
(years) (8.0–19.9) (12.6–27.6) (7.4–13)
Relapse–free interval N/A 38 96 11.5
(months) (8–96) (47.5–150.5) (6–38)
No of patients N=9 N=28 N=18 N=10
Clinical assessment The patients were reassessed as described in Chap-
ter 11 at the 3–year follow–up visit. All clinical evaluations were performed
on all patients within one week of each lumbar puncture. Patients were
classified as clinically advancing if the EDSS had increased by at least 1
point166 over the 3 years.
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Assays The NfH phosphoforms NfHSMI34 and NfHSMI35 were analysed as
described in Chapter (page 73). Albumin (page 147) and oligoclonal bands
(page 149) were measured as described.
Data analysis Data were managed and analysed as described (Chapter
7, page 151). Because of the small sample size a Gaussian curve with valid
95%CI could not be calculated. The cut–off for categorical data analysis
(Fisher’s exact test) was therefore set to the 100% cumulative frequency of
the indicated control group. Independent variables were compared using
the non-parametric two-sample exact Wilcoxon rank-sum test or the unbal-
anced two-way ANOVA (general linear model) for more than two groups65
which were done in the following order (1) controls, RR, SP/PP MS; (2) con-
trol, RR (stable), RR (advancing), SP MS; (3) control, RR (disease course
maintained), RR (RR to SP conversion).
The change of NfH levels between baseline and follow–up was expressed
as the difference:
∆NfH = NfH follow−up −NfH baseline
A positive number indicated an increase in NfH follow–up levels. The
phosphoform ratio is a measure of the degree of phosphorylation and was
expressed as a cross–sectional measure:
RATIO =
NfH SMI34
NfH SMI35
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A ratio <1 indicates an overall decrease in the level of phosphorylation.
Values with zero deliminator (or NfH at baseline and follow–up below assay
sensitivity) could not be calculated and were excluded from this analysis.
For each variable the numbers of valid observations were therefore shown in
the table.
12.3 Results
At baseline the CSF levels of NfHSMI35baseline were higher in all MS patients when
compared to controls (p<0.01, Table 12.2). Comparing clinical subgroups
(F(3,33)=3.38, p<0.05) and progression (F(3,33)=3.38, p<0.05) this was
due to higher NfHSMI35baseline levels in SP/PP MS patients (p<0.05, Table 12.2)
and in patients with clinically advancing RR MS (p<0.05, Table 12.3).
At baseline the CSF levels of NfHSMI34 were higher in control subjects
compared to MS patients (p<0.001). Comparing MS clinical subgroups
(F(3,33) = 3.38, p<0.05) with the control patients the same levels of signif-
icance were revealed for each subtype (p<0.001, Table 12.2).
Three RR patients converted to SP disease, accounting for 7 RR and 21
SP/PP MS patients at follow–up. Treatment with IFN had no significant
effect on either NfH phosphoform levels, the ratio or the change of levels
over time. No correlations were found between any Nf phosphoform or the
ratio, with age, age at onset, disease duration or time from last relapse.
CHAPTER 12. AXONAL PATHOLOGY: LONGITUDINAL 245
Table 12.2: CSF levels and ratio of NfH phosphoforms (median, IQR, number). RR
MS patients which showed a decrease of at least 1 point on the EDSS between baseline
and follow–up were classified as advancing RR. Three of the RRMS patients converted
to SP MS, explaining the change of patient numbers in the clinical subgroups at
follow–up. At follow–up the change of NfH over time (∆NfH) was also calculated.
Clinical subgroup
CTRL MS (all) SP/PP RR
Baseline
NfHSMI35 pg/mL 0 78 80.5 78
(0-47) 9 (19.5-167) 28 (22-179) 18 (11-139) 10
—— p<0.001 ——
—— p<0.05 ——————————
NfHSMI34 pg/mL 684 9 11 7
(230-795) 9 (6.0-13) 28 (7.0-13) 18 (5-9) 10
—— p<0.001 ——
—— p<0.001 ——————————
—— p<0.001 ————————————————
Ratio 55.9 1.8 2.4 1
(24.6-145.5) 4 (0.6-5.8) 27 (0.6-6.1) 18 (0.42-3.5) 9
——— p<0.05 ———
Follow–Up
NfHSMI35 pg/mL N/A 116.5 132 0
——— p<0.05 ———
(0-178) 28 (96-209) 21 (0-120) 7
NfHSMI34 pg/mL N/A 49.6 48 51
(8.5-129.1) 28 (10-139) 21 (3-120) 7
Ratio N/A 3.3 3.3 5
(0.9-10.1) 18 (0.90-139) 16 (0.2-10) 2
∆ NfHSMI35 pg/mL N/A 11.5 82 -49
(-59-98) 28 (-11-104) 21 (-107-0) 7
∆ NfHSMI34 pg/mL N/A 42.5 35 51
(-1-123) 28 (-3-134) 21 (1-112) 7
12.3.1 Accumulation of axonal damage in progressive disease
An increase of NfHSMI35 from baseline to follow–up was observed in more
cases with SP/PP MS (14/19, 74 percent, Figure 12.1, closed lines) when
compared to RR patients (1/5, 20 percent), which was statistically signifi-
cant (p<0.05). Two RR and 2 SP/MS patients were excluded from analysis
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baseline follow–up baseline follow–up
Figure 12.1: CSF NfHSMI35 levels in patients RR (open circles) and SP/PP
(diamonds) forms of MS. Three of the RR patients converted to SP MS
at follow–up (superimposed diamonds). RR MS patients who experienced
clinically advancing disease are indicated (grey circles). Increasing levels of
NfHSMI35 between baseline and follow–up are indicated by closed lines and
decreasing levels by dotted lines. The control group consists of patients with
cluster headache (triangles). The sensitivity of the NfH–assay is 20 pg/mL
(horizontal reference line).
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because NfH levels were below assay sensitivity for both measurements (hor-
izontal reference line, Figure 12.1).
The distribution of NfHSMI35 was bimodal for RR and SP/PP MS pa-
tients both at baseline and follow–up with no levels observed between 50–100
pg/mL (Figure 12.1). No statistical significant difference could be revealed
for any demographic or clinical data explaining this bimodal distribution.
There was no correlation between either of the NfH phosphoform concen-
tration and blood–brain barrier dysfunction as measured by the ratio of
CSFalbumin
Serumalbumin (data not shown).
Table 12.3: CSF levels and ratio of NfH phosphoforms (median, IQR, number) at
baseline. RR MS patients are classified according to progression on the EDSS scale
or the clinical classification.
Disability Clinical subtype
Stable Advancing Maintaining RR Converting to SP
NfHSMI35 pg/mL 5 23 49 123
(0-11) 3 (49-190) 7 (5-190) 7 (37-139) 3
—— p<0.001 ——
NfHSMI34 2 8 7 9
(0-7) 3 (5.0-13) 7 (2-8) 7 (5.0-13) 3
Ratio 5.1 0.7 2.3 0.73
(4.0-6.4) 2 (0.6-3.5) 7 (0.4-4) 6 (0.4-3.5) 3
—— p<0.001 ——
12.3.2 Axonal injury: correlation with disability
NfHSMI35 levels correlated with all clinical scales at follow–up (Figure 12.2
to 12.4). The correlation was strongest for the 9HPT (R=0.59, p=0.001),
followed by the EDSS (R=0.54, p<0.01) and the AI (R=0.42, p<0.05). One
outlier was observed for the 9HPT, exclusion of which did not change the
significance of the analysis (R=0.55, p<0.01). No correlations were found
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between NfHSMI34baseline and any of the disability scales. The ratio of the NfH
phosphoforms at follow–up correlated with the EDSS (R=0.52, p<0.05).
At baseline no such correlation was demonstrated. The ratio could not
be calculated in one patient at baseline (zero denominator). At follow–up
the denominator was zero in 10 patients. By definition correlations with
the change of NfH phosphoforms could only be calculated for the follow–
up assessment. The (∆NfHSMI35 ) correlated with the 9HPT at follow–up
(R=0.39, p<0.05) but not with the EDSS (R=0.36, p=0.06) or AI (R=0.23,
N.S.). No correlations were found for ∆NfHSMI34 and any of the disability
scales.
Table 12.4: Disability as measured on the EDSS, AI and 9HPT at baseline and
follow–up. As expected advancing RR patients were more disabled at follow–up then
at baseline (p<0.01). There was no significant difference for AI and 9HPT between
baseline and follow–up in the subgroups. Three of the RR patients converted to SP
MS between baseline and follow–up, explaining the change of numbers of the groups.
The data for the advancing versus stable RR MS patients are shown according to the
baseline classification only.
MS Clinical subtype RR (baseline cohort)
all SP/PP RR stable advancing
Baseline
EDSS 4.3 6 1.75 2 1
(2–6.5) 28 (4.5–7) 18 (1–2) 10 (1.5–4) 3 (1–2) 7
AI 2 6 1 1 1
(1–7) 25 (2–8) 15 (1) 10 (1) 3 (0–2) 7
9HPT 24.3 26.5 20 20.5 20
(20–28.3) 28 (24–30) 18 (18–22) 10 (18–23) 3 (18–22) 7
Follow–up
EDSS 4.5 6 3 3 3.5
(3.4–6.3) 28 (4–7) 21 (2.5–4) 7 (1.5–4) 3 (3–4) 7
AI 2 4 1 1 2
(2–6) 28 (2–7) 21 (1–2) 7 (0–2) 3 (1–2) 7
9HPT 23.5 24.5 20 21 20
(20–29.3) 28 (21.5–31) 21 (18–22) 7 (16–21) 3 (18–25) 7
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Figure 12.2: Correlation between the NfHSMI35 and the EDSS at follow–up.
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Figure 12.3: Correlation between the NfHSMI35 and the AI at follow–up.
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Figure 12.4: Correlation between the NfHSMI35 and the 9HPT at follow–up.
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12.3.3 Early axonal injury: indicator of poor prognosis in
RR MS
A significantly higher proportion 7/10 (70 percent) of RR MS versus 3/18
(17 percent) SP/PP patients progressed on the EDSS during the study
(p<0.001). The median EDSS at 3–year follow–up was over 3-fold higher
than at baseline for the advancing RR MS patients (p<0.01, Table 12.4).
No significant change in the EDSS was observed for the SP/PP MS patients.
At follow–up all RR MS patients (7/7, 100 percent) who progressed had
NfHSMI35baseline levels above the assay sensitivity level (20 pg/mL, Figure 12.1,
grey circles). None (0/3, 0 percent) of the clinically stable RR MS patients
had NfHSMI35baseline levels above this cut–off (p<0.001, Figure 12.1, open circles).
RR patients who converted to SPMS had higher baseline median NfHSMI35
levels when compared to non–converting RR patients, but this did not reach
statistical significance (Table 12.3; Figure 12.1, circles with superimposed
diamond).
Pooling RR and SP/PP MS patients in order to test for a general pro-
gression on the EDSS did not reveal any statistical significance for either
NfH phosphoform, the ratio or change over time.
12.4 Discussion
The observation that NfHSMI35 levels were higher in SP/PP patients, who
were more disabled compared to patients with RR MS, suggests that ax-
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onal damage predominates in SP/PP MS. Additionally the significant higher
proportion of SP/PP MS patients in whom NfHSMI35 levels increased from
baseline when compared to RR patients suggests the accumulation of axonal
injury during the 3–year observation period.
These findings provide further evidence that loss of neurological function
is a consequence of axonal injury .256,398,424 McDonald et al. (1992) hy-
pothesised that axonal damage is a gradual cumulative process as the disease
progresses.258 However, uncertainty about this concept exists in the histo-
logical literature because some authors found little106 whilst others found
compelling evidence398 for axonal damage in chronic lesions. This discrep-
ancy may be due to the staining methods applied399 and the dynamics of
amyloid precursor protein which was used as a marker for axonal injury.194
Our results would be in favour of cumulative axonal injury during SP/PP
disease. A hypothesis supported by recent brain imaging studies.31
Interestingly, high CSF NfHSMI35 levels at the baseline were associated
with the development of disability in RR MS patients 3 years later. Axonal
staining for NfHSMI35 using the well–characterised Sternberger monoclonal
antibodies377,378 is an early sign of axonal injury145 (Table 9.2 on page 177).
This result confirms on a biochemical level the histological observation of
axonal damage in acute lesions42,106,398 and is consistent with the findings of
Chapter 9. Those RR MS patients with elevated NfHSMI35baseline levels advanced
by a median of 2.5 points on the EDSS. Evidence of axonal damage early
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in the disease course of RR MS should therefore be interpreted as a poor
prognostic sign.
The correlation between NfHSMI35follow−up and the EDSS extends this argu-
ment and confirms two previous reports on a different neurofilament subunit
(the 68 kDa light chain, NfL) .242,353 In the study of Lycke et al. CSF NfL
correlated with the EDSS at baseline (R=0.27) and follow–up (R=0.34)
in RR MS patients.242 In the study by Semra et al. CSF NfL corre-
lated with the EDSS (R=0.41) in progressive MS patients. Interestingly
Trapp et. al (1998) described increased staining for hypophosphorylated
NfH (SMI32 antibody) in demyelinated and transected axons as opposed
to healthy axons.398 Hypophosphorylated Nf are, however, prone to pro-
tease digestion349,418 whilst the phosphorylated forms are relatively pro-
tected from proteolysis.124,378 Phosphorylated NfH is reported to be more
soluble then hypophosphorylated NfH or NfL.403 Consequently the phos-
phorylated (NfHSMI35 ) and extensively phosphorylated (NfHSMI34 ) NfH
phosphoforms have been measured.
The interpretation of the present data needs to take into account the fact
that the patient group is population based (Chapter 10). Clinically there was
no significant change in the EDSS of the SP/PP MS patients over 3 years.
This represents a benign course compared to the more rapid progression
observed in other cohorts of patients selected from hospital populations.
The results must therefore be interpreted with caution and will need to be
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cross–validated in other longitudinal studies. This would be particularly
important for advancing the argument that axonal damage may accumulate
despite a stable EDSS.
In contrast to RR MS patients no definite conclusion can yet be drawn
regarding the prognostic value of high NfHSMI35baseline levels in SP/PP MS pa-
tients. This might however be a consequence of the sensitivity of the clinical
scales applied. The functional consequences of loss of axons on a clinical
level will not necessarily be captured using the EDSS (as well as the AI or
the 9HPT), particularly after an EDSS of 4–5 has been reached.70,399 The
EDSS in the SP/PP patients in this study was above this limit (median
EDSS of 6 at baseline). The epidemiological observation that the disease
course in MS progresses from EDSS 4 to 6 and from 6 to 7 with similar speed
in SP/PP and RR patients70 could thus be interpreted in 2 ways: Firstly the
concept of inexorable axonal loss above a certain threshold399 leads to SP
disease, which is reflected by uniform progressing clinical disability.70 Sec-
ondly these observations are biased by the method of quantification (EDSS),
and the dynamics from axonal injury to axonal loss might provide a win-
dow for therapeutic intervention. The latter interpretation would be more
in keeping with the binomial distribution observed for NfHSMI35baseline in SP/PP
MS patients in this study. However treatment with IFN in a small number
of patients did not give rise to a significant change of CSF NfH phosphoform
levels, but it is impossible to draw conclusions from this data.
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Taking all these observations together, the results of this study are nev-
ertheless in accordance with the current concept of progressive axonal de-
generation in MS which is based on evidence from animal,195 human post–
mortem,42,106,398 magnetic resonance spectroscopy,409 magnetic resonance
imaging113,230,231,402 and epidemiological studies.70,341
The results of this prospective 3–year study further suggest that NfHSMI35
might be a valuable surrogate marker and has the potential to be used as
a new secondary outcome measure in MS treatment trials. In addition CSF
Nf levels may be used to select patients with a poor prognosis to improve the
power of studies to detect a therapeutic effect in progressive MS. CSF lev-
els of NfH phosphoforms could be exploited for evaluating neuroprotective
treatment strategies in MS and potentially other neurodegenerative diseases.
12.5 Conclusion
This study aimed to investigate the relation of neurofilament phosphoforms
as biomarkers for axonal injury to (1) disease heterogeneity, (2) disability
and (3) as prognostic indicators.
A significantly higher proportion of patients with SP/PP disease expe-
rienced an increase in NfHSMI35 levels between baseline and follow–up com-
pared to those who remained with RR disease. SP/PP patients at baseline
and follow–up were found to have higher NfHSMI35 levels than stable RR MS
patients at baseline or RRMS patients at follow–up. Median NfHSMI35 levels
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at baseline were significantly higher in clinically advancing RR MS ver-
sus stable RR MS patients. NfHSMI35 correlated with the EDSS (R=0.54,
p<0.01), the AI (R=0.42, p<0.05) and the 9HPT (R=0.59, p<0.01) at
follow–up. The degree of phosphorylation (ratio) correlated with the EDSS
(R=0.52, p<0.05) and ∆NfHSMI35 with the 9HPT (R=0.39, p<0.05).
The increase of Nf during the progressive phase of the disease together
with the correlation of NfHSMI35 with all clinical scales at follow–up sug-
gests that cumulative axonal loss is responsible for sustained disability. The
results also suggest that early axonal injury is a poor prognostic sign. Mea-
surement of NfH phosphoforms could be exploited for evaluating neuropro-
tective treatment strategies in those neurological disorders where axonal
degeneration is of pathological relevance.
Part IV
Discussion
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Chapter 13
General discussion
The diagnosis of MS is made on the basis of the appearance of demyelinat-
ing lesions separated by time and space.257,311 The term multiple sclerosis
provides most probably an umbrella for a heterogeneous group of CNS de-
myelinating diseases sharing certain pathological (Figure 1.4 on page 38)
and phenotypical (Table 10.1 on page 209) features. The clinical course of
MS is variable and classified into different patterns of progression of disabil-
ity (Figure 1.1 on page 23).236 The clinical course and prognosis remain
difficult to predict.
This Ph.D. aimed to investigate whether the analysis of brain–specific
proteins could contribute to a better understanding of two issues: disease
heterogeneity and disability.
The purpose of the general discussion is to put the results obtained in the
different chapters into a broader context. This will be accomplished by firstly
comparing the consistency of the models studied, secondly by evaluating the
value of BSP as biomarkers to describe disease heterogeneity and thirdly by
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discussing the concept of BSP as surrogate markers for disability. Finally
the advantages and disadvantages for each BSP as a surrogate marker will
be summarised.
13.1 Consistency of the models studied
The basic idea followed in this subsection is, that for each BSP investigated
the CV provides an estimate of the accuracy of the method upon the model
studied. Three different models have been used in this Ph.D. project. Table
13.1 and Table 13.2 summarise the CVs found for each experiment. The
lowest CVs were found for the mouse model with a range from 18.5–56.3. In
the post–mortem study the CV ranged from 16.2–139.9 and in the human
CSF study from 26.6–206.9. The methodological advantage of the mouse
model was that tissue could be snap frozen directly after the animal was
killed. For the post–mortem study a considerable variation of the post–
mortem interval had to be taken into account. During the post–mortem
interval auto–proteolysis of the brain poses a serious problem in particular
for the analysis of proteins more susceptible to proteolysis. What are the
implications for the results of Chapter 8 to 10?
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Table 13.1: The coefficient of variation (CV) of the results for the BSP studied in
Chapter 8 to 10. The sample size (n) for each CV is given in brackets. P.M. =
post–mortem, N.D. = not determined.
Model Type S100B GFAP Ferritin NfHSMI35 NfHSMI34
Mouse CTRL 40.1 (7) 35.9 (7) 37.0 (7) 18.5 (7) N.D.
Mouse CREAE 45.4 (8) 56.3 (8) 34.0 (8) 53.9 (8) N.D.
P.M. NCWM 53.0 (5) 77.7 (5) 27.3 (5) 62.8 (6) 88.0 (6)
P.M. MS (all) 41.0 (23) 64.5 (23) 44.3 (23) 136.8 (30) 136.0 (30)
P.M. NAWM 42.5 (5) 100.0 (5) 30.0 (5) 71.4 (6) 75.1 (6)
P.M. AL 16.2 (6) 35.7 (6) 48.0 (6) 94.8 (6) 51.3 (6)
P.M. SAL 21.8 (4) 32.9 (4) 26.8 (4) 94.4 (6) 109.1 (6)
P.M. CL 45.0 (7) 71.3 (7) 54.2 (7) 39.5 (6) 85.7 (6)
Table 13.2: The coefficient of variation (CV) of the results for the different methods
used to characterise MS patients. The sample size (n) for each CV is given in brackets.
Method MS (all) RR MS SP MS PP MS
S100B 87.8 (51) 101.4 (20) 71.1 (21) 33.4 (10)
GFAP 105.6 (51) 90.0 (20) 119.7 (21) 114.1 (10)
Ferritin 75.3 (51) 85.6 (20) 74.6 (21) 52.0 (10)
NfHSMI34 177.7 (51) 206.9 (20) 87.7 (21) 71.5 (10)
NfHSMI35 78.3 (51) 84.8 (20) 67.0 (21) 91.4 (10)
Statistically the variation of the range of the CVs was reflected by the
strength of the correlations found between the BSP. Although overall con-
sistency was found for the investigation of tissue homogenate (Table 9.6 on
page 206), the strengths of the correlations varied. For the mouse model the
Spearman correlation coefficient ranged from R=0.81 to R=0.92 and there
was one negative correlation with an R=-0.54 (Figure 8.7 on page 169). For
the post–mortem study the Spearman correlation coefficient ranged from
R=0.45 to R=0.64 (Figure 9.8–9.16 on page 194–202). Apart from a pseu-
docorrelation between NfHSMI35 and S100B with R=-0.3 (Chapter 10.3 on
page 213) no such correlations were found in the CSF study. What conclu-
sions can be drawn from the comparison of these data?
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The CSF represents an overall average of proteins released from differ-
ent lesion types. Furthermore the metabolism and the dynamics of these
proteins through the CSF are different. The highly soluble S100B diffuses
within minutes into the systemic circulation,11 whilst less soluble proteins
of higher molecular weight such as GFAP and NfH have different physio-
logical dynamics.104 The conclusion for future studies aiming to investigate
the the relations between different BSP to each other is that a mouse model
and possibly cell–cultures have to be regarded as a more reproducible model
than human post–mortem material or CSF.
13.2 Disease heterogeneity
Disease heterogeneity in MS is observed by almost all clinical and paraclini-
cal methods. From the review of the literature (Chapter 1.1 on page 24 ff.) it
appeared that heterogeneity is greater in early MS.12,30,78,84,184,187,247,310,330,342,344,427,427,444
In later disease stages heterogeneity seems to decrease. Epidemiological
studies are in line with this concept and provided evidence that with the
increase of disability a common final (degenerative ?) pathway might be
present68–70 (Figure 1.4 on page 38). This hypothesis is supported by patho-
logical studies.41,201,237,398 Schuller (1973) coined the term “MS a two–
phase disease” .351 Steinman (2001) recently reintroduced this terminology
as “MS a two–stage disease”.375
The results from the animal study are consistent with this concept. The
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atrophied CREAE spinal cord could be distinguished from the control ani-
mals (Table 8.1 on page 163). GFAP was higher in the atrophied and gliotic
spinal cord then in control animals. S100B, ferritin and NfHSMI35 were lower
in the atrophic spinal cord.
In the post–mortem study AL, SAL, NCWM and MSGM could be dis-
tinguished with the aid of BSP (Table 9.4 on page 184 and Table 9.5 on page
186). In brief, the findings were that S100B, NfHSMI34 and NfHSMI35 were
elevated in AL. Ferritin was generally higher in all MS lesions when com-
pared to control tissue. GFAP and S100B were higher in MSGM when
compared to control tissue. However, as suggested in the discussion of the
consistency of the model (section 13.1) the distinction was less clear than
for the animal experiment.
In MS patients there was a trend for increasing S100B levels from PP to
SP to RR MS patients (Table 10.4 on page 214). This trend became more
evident using a ratio of S100Bferritin (Figure 10.6 on page 222). However, the
underlying pathology in MS patients when estimated by the measurement
of CSF BSP does not permits us to distinguish the between subgroups as
proposed by Lublin et al. (1996).236 The measurement of BSP is more likely
to be of value as a surrogate marker for disability as summarised in the next
section.
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13.3 Disability
Disability (i.e. “a restriction or lack. . . of ability to perform an activity in
the manner of within the range considered normal for a human being”)300 is
probably the most devastating result of MS in the life of a patient. Where
cure is not possible, treatment should aim at holding or slowing down the
progression of disability. The main caveat of surrogate markers currently
used is that the most accurate relation is found between MRI measurements
of atrophy and disability as estimated by clinical scales.31,274 Correlation
of other MRI measures with disability have been rather weak .183 Con-
sequently the value of MRI as a secondary outcome measure of MS trial
has been discussed.260 The conclusion was drawn that at present no single
MRI measurement has been validated as a tool for distinguishing clinical
subgroups of MS with acceptable speceficity. However, the use of multiple,
new scanning sequences was put up higher on the research agenda.260
The problem using MRI measurements of CNS atrophy is that atrophy
is non–reversible. The concept of biological surrogate markers tries to close
this gap by enabling to monitor subclinical but relevant damage to the CNS.
The hypotheses behind employing BSP as surrogate markers in MS
(Chapter 3 on page 69) were, in brief:
• Nf is a marker for axonal damage and should relate to disability
• GFAP is a measure for astrogliosis and should relate to the “total
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lesion load” and relate indirectly to disability
• S100B is a measure of astrocytic activation and should be higher in
patients with active disease
• Ferritin is a measure of microglial activation and should be higher in
patients with active disease
The data presented in this study and the literature (see Tables 1.2 to
1.4 on pages 45–48, Table 11.2 on page 236, Table 12.3 on page 247 and
Table 12.4 on page 248) show considerable variability in the strength of the
assumed correlations between BSP and disability as estimated by clinical
scales. The explanation that this was due to the different methods ap-
plied, would only be valid for the comparisons of studies between different
groups.241,307,353 It would however not explain the variability found for the
present longitudinal data (Chapter 12). The present data suggest that ax-
onal pathology might be a dynamic process. Degenerative and regenerative
processes could be balanced, at least for a certain time. It was noted that
once a critical threshold is reached, the inexorable loss of axons and neurons
which had been integrated into the functional CNS network would surpass
the potential for plasticity. It was hypothesised that this phase could possi-
bly be reflected by the epidemiological finding that above an EDSS of about
4 the disease progress is uniform and inexorable.70
Taking these together the current concept of surrogate markers has an
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important shortcoming: it does not allow for improvement. In other words
the hypothesis that elevated levels of certain substances inevitable demon-
strates damage which leads to irreversible disability might only be partly
valid. In theory elevated levels of Nf could result from either release from
a disintegrating axon or the growth cone of a regenerating axon. Simi-
larly one could hypothesise that S100B could indicate astrocytic activation
in response to damage, but also a physiological response necessary to for
supplying regenerating axons with growth factors.86 Neuroprotective prop-
erties are now attributed to a range of substances and mechanisms which
have previously been related only to CNS tissue damage.108,161,186,291
In order to allow for these possibilities a concept of a surrogate which
is expected to correlate more consistently with clinical measurements of
disability should include a combination of markers for degeneration and
regeneration. Two theoretical models for the interpretation of surrogate
markers are postulated:
1. A one–factor model: Tissue damage leads to release of substances
such as BSP. Therefore the quantification of BSP allows us to esti-
mate the extent of CNS tissue damage. One would expect to find a
relationship of baseline damage with disability at future time points
as demonstrated for MRI measurements.49 BSP could potentially be
included as a secondary outcome measure in MS treatment trials. The
hypothesis would be that an effective treatment reduces the levels of
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BSP into the range found in normal control subjects.
2. A two–factor model: In the CNS, both tissue damage and regenera-
tion lead to release of substances such as BSP. In order to maintain the
plasticity of the CNS a permanent remodelling of the axon–dendritic
tree can be expected.4,63,178,180 The use of at least 2 functionally dis-
tinct isoforms of one protein could provide a way around the shortcom-
ings of a linear model. One isoform would need to be predominantly
released during tissue damage, whilst the other isoform would increase
during regeneration. The advantage of quantifying different isoforms
of one protein as opposed to different proteins is that molecular size,
solubility, metabolism and therefore the physiological dynamics are
likely to be similar, even though both protein isoforms would originate
from the same cellular source. A ratio of the “degenerative isoform A”
to the “regenerative isoform B” would then indicate the predominant
pathological feature. Furthermore the measurement of these 2 iso-
forms at 2 time–points would allow to estimate the dynamics of these
proteins over time. For the evaluation of treatment trials the dynamic
model would allow us to define secondary outcome measures for halt-
ing disease progression and enhancement of neuroprotective features.
In conclusion a simple one–factor approach seems to be feasible in acute
conditions (e.g. frequently relapsing MS) and can expected to be of great
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value for neurological intensive care (e.g. subarachnoid–hemorrhage, trau-
matic brain injury and stroke). A more sophisticated two–factor approach,
allowing for the dynamics of degeneration and regeneration would be of
value for assessing more chronic conditions, such as present in the relapse
independent progression of disability in MS.
13.4 The value of BSP as surrogate markers
13.4.1 Neurofilament proteins
CSF levels of NfHSMI35 correlated with disability in MS. This finding is con-
sistent with two previous studies.242,353 Additionally NfHSMI35 predicted
development of disability in RR MS patients. NfH phosphoforms did not
distinguish between MS subgroups on a cross–sectional basis, which is in
keeping with one previous report.353 However, there was evidence for in-
creasing NfHSMI35 levels over time in progressive MS patients suggesting
accumulation of axonal damage.
CSF NfHSMI35 should be regarded as a sensitive marker for axonal dam-
age. The clinical value is likely to be the long–term prediction of disability.
Correlations with disability should be regarded with caution as they might
be a spurious finding. There is no evidence that NfHSMI35 could be a disease
specific or diagnostic marker.
In this respect the finding of markedly elevated levels in SAH and in
some GBS patients (Figure 4.23 on page 112) is of particular interest.
NfHSMI35 might be an early indicator of axonal variant of GBS.103
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13.4.2 Glial fibrillary acidic protein
CSF GFAP levels correlated with disability in progressive patients. The
correlation with disability is consistent with the finding of the only other
published study investigating this relationship.336 GFAP did not distinguish
between MS subgroups which is consistent with the only published study
allowing for such a comparison.5
It is therefore of note that elevated CSF GFAP levels were found in
another chronic progressive CNS disease, dementia (Figure 5.11 on page
142). However as the same Figure showed high CSF GFAP levels were also
found in acute disorders such as SAH or TBI. Therefore CSF GFAP levels
cannot be regarded as a “pure” marker for astrogliosis and the interpretation
of the levels needs to be done in the light of any other acute CNS insult.
In MS particular attention needs to be paid to the presence of relapses as
revealed by either MRI or clinical observation.
CSF GFAP levels could be a marker for disability in relapse–free MS
patients who have reached the progressive phase of the disease. However,
the relation between CSF GFAP and disability is likely to reflect the “burnt–
out” phase of the disease. Therefore the prognostic value of measuring CSF
GFAP levels remains questionable.
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13.4.3 S100B protein
CSF S100B levels were higher in MS patients than in controls, which is
consistent with most211,250,251,270 but not all363 previous studies. This
difference was explained by the higher S100B levels in RR MS patients.
Although there was no clinical evidence for recent relapses in the present
RR MS patient, the post–hoc analysis of the data from the literature indi-
cated that elevated CSF S100B were associated to acute disease.251,270,278
This notion is largely supported by studies into acute neurological disor-
ders.37,147,148,163,314,338,354,421
CSF S100B should be regarded as a sensitive marker for acute impair-
ment of CNS homeostasis. This can be caused by a wide range of conditions
and CSF S100B is not a disease specific marker. In MS CSF S100B and
possibly serum S100B might however prove a valuable indicator of relapses.
There might also be a potential for identifying those patients with a higher
disease activity, which might escape MRI or clinical observations, but who
would profit and respond to early treatment. CSF S100B might become the
“CRP of the brain”. The biochemical advantages are high solubility, small
molecular size and stability. The investigation of S100B levels in various
body fluids and various diseases will become increasingly important.
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13.4.4 Ferritin
CSF ferritin levels were higher in SP MS patients then in control patients
which is consistent with the finding of elevated CSF ferritin levels in pro-
gressive MS patients.222
Because ferritin is primarily involved in iron metabolism, CSF ferritin
has been shown to be elevated in patients with evidence for intracerebral
bleed. Ferritin is of particular importance for diagnosing occult bleed-
ing, such as present in CNS siderosis. Secondly ferritin is involved in the
metabolism of myelin proteins by distributing iron as an essential cofactor
and increased endocytotic ferritin uptake could be demonstrated in oligoden-
drocyte progenitor cells .71,159 As outlined in the introduction (on page 66)
oligodendrocytes contain the ferritin heavy chain (FTH), whilst microglia
also express the light chain (FTL).
The role for measuring CSF ferritin in MS is not yet clarified, but it
would be worthwhile to investigate if measurement of FTL and FTH would
permit to identify MS patients with different potential to remyelinate. FTL
and FTH are two candidates which should be investigated in a two–factor
model model for surrogate markers as proposed above.
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